Caracterização de novos complexos da LAP1 e a sua relevância na distonia DYT1 by Graça, Mariana Santos Moreda
 Universidade de Aveiro 
2014  
Secção Autónoma de Ciências da Saúde 
Mariana Santos  
Moreda Graça 
Caracterização de novos complexos da LAP1 e a 
sua relevância na distonia DYT1 
 
Characterization of novel LAP1 complexes and their 
relevance in DYT1 dystonia 
 
 
 
   
  
Universidade de Aveiro 
2014  
Secção Autónoma de Ciências da Saúde 
Mariana Santos  
Moreda Graça  
 
Caracterização de novos complexos da LAP1 e a sua 
relevância na distonia DYT1 
 
Characterization of novel LAP1 complexes and their 
relevance in DYT1 dystonia 
 
 Tese apresentada à Universidade de Aveiro para cumprimento dos requisitos 
necessários à obtenção do grau de Doutor em Ciências Biomédicas, realizada 
sob a orientação científica da Professora Doutora Odete Abreu Beirão da Cruz 
e Silva, Professora Auxiliar com Agregação da Secção Autónoma de Ciências 
da Saúde da Universidade de Aveiro, e coorientação científica da Professora 
Doutora Sandra Maria Tavares da Costa Rebelo, Professora Auxiliar 
Convidada da Secção Autónoma de Ciências da Saúde da Universidade de 
Aveiro. 
 
  Apoio financeiro da FCT e do FSE no 
âmbito do III Quadro Comunitário de 
Apoio (Bolsa de Doutoramento SFRH/ 
BD/65353/2009). 
 
   
 
 
 
 
 
 
o júri   
 
presidente Professor Doutor António Carlos Mendes de Sousa 
Professor Catedrático do Departamento de Engenharia Mecânica da Universidade de Aveiro 
  
 
 Professora Doutora Maria João Gameiro de Mascarenhas Saraiva 
Professora Catedrática do Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto 
  
 
 Professor Doutor Carlos Jorge Alves Miranda Bandeira Duarte 
Professor Associado com Agregação da Faculdade de Ciências e Tecnologia da Universidade de 
Coimbra 
  
 
 Professor Doutor João Carlos Cruz de Sousa 
Professor Auxiliar da Escola de Ciências da Saúde da Universidade do Minho 
  
 
 Doutora Sónia Cristina das Neves Ferreira 
Investigadora de Pós-Doutoramento da Universidade de Coimbra 
  
 
 Professora Doutora Ana Gabriela Henriques 
Professora Auxiliar Convidada da Secção Autónoma de Ciências da Saúde da Universidade de 
Aveiro 
  
 
 Professora Doutora Odete Abreu Beirão da Cruz e Silva 
Professora Auxiliar com Agregação da Secção Autónoma de Ciências da Saúde da Universidade 
de Aveiro 
 
 
 Professora Doutora Sandra Maria Tavares da Costa Rebelo 
Professora Auxiliar Convidada da Secção Autónoma de Ciências da Saúde da Universidade de 
Aveiro 
 
  
  
 
agradecimentos 
 
Ao Prof. Edgar da Cruz e Silva pela orientação na fase inicial do meu 
doutoramento, por todo o conhecimento partilhado e pela oportunidade de 
trabalhar neste projeto. 
 
À Prof. Odete pela orientação e oportunidade de trabalhar no Laboratório de 
Neurociências. À Sandra Rebelo pela orientação, e por me encorajar e 
acompanhar durante este trabalho. 
 
A todos os colegas do CBC pela ajuda e apoio. Em particular, às minhas 
“companheiras de bancada” Filipa e Pati, e à Joana Rocha, à Joana Oliveira, à 
Lili, à Regina, ao Roberto e à Sara Soares por todo o apoio, companheirismo e 
por animarem os meus dias no laboratório. À Patrícia Costa por me ter 
acompanhado neste trabalho. Ao Luís Godinho pela ajuda e conhecimentos 
partilhados. À Sara Domingues, à Sara Esteves, ao Korrodi, à Sandra Vieira, à 
Margarida Fardilha, à Fátima e ao Miguel por estarem sempre disponíveis a 
ajudar. 
À Mónica Ferreira, que me acompanha desde que cheguei ao CBC, e à 
Mónica Almeida. Obrigado pelos bons momentos partilhados ao longo destes 
anos e pela vossa amizade. 
E ainda aos nossos colaboradores Dr. William Dauer e Dr. Thorsten Muller por 
terem contribuído para a realização de alguns objetivos deste trabalho.  
 
Aos amigos de sempre pela vossa amizade. À Tatiana, ao Daniel, ao Avelino, 
ao Pedro, ao Álvaro, à Ângela, à Inês e ao Chico.  
Ao Eurico por todo o apoio, carinho e paciência. 
 
Aos meus pais e à minha irmã por me terem sempre apoiado. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
palavras-chave 
 
Proteína 1B associada com a lâmina (LAP1B), invólucro nuclear, fosforilação 
de proteínas, proteína fosfatase 1 (PP1), torsinaA, distonia. 
resumo 
 
 
A distonia é a terceira doença de movimento mais comum depois do tremor 
essencial e da doença de Parkinson e abrange um variado número de 
síndromes clínicos. A distonia DYT1 é a forma mais comum de distonia isolada 
de início precoce e é causada por uma mutação no gene DYT1, a qual resulta 
na perda de um ácido glutâmico na proteína torsinaA (ΔE-torsinaA). A torsinaA 
localiza-se no retículo endoplasmático e no invólucro nuclear (IN), enquanto 
que a ΔE-torsinaA é anormalmente distribuída para o IN. No IN, a torsinaA 
interage com a proteína 1 associada com a lâmina (LAP1), cuja função ainda 
não é totalmente conhecida. A LAP1 é uma proteína da membrana interna do 
núcleo e três isoformas (LAP1A, B e C) desta proteína já foram descritas na 
literatura. 
As interações proteína-proteína têm vindo a ser determinantes no estudo de 
doenças humanas e de sinalização celular. Neste trabalho, foi identificada uma 
nova interação entre a LAP1B humana e a proteína fosfatase 1 (PP1). A PP1 é 
uma fosfatase serina/treonina que é responsável pela desfosforilação de cerca 
de um terço de todas as proteínas em células eucarióticas. A versatilidade da 
PP1 é possível através da sua ligação a diferentes proteínas reguladoras 
responsáveis pela sua especificidade e atividade. A LAP1B é desfosforilada 
pela PP1 e liga-se a esta através de um motivo semelhante ao RVxF que se 
encontra no seu domínio nucleoplasmático. No decorrer deste trabalho, 
identificamos também uma nova isoforma da LAP1 humana – LAP1C, que 
nunca tinha sido descrita em células humanas. A expressão da LAP1B e 
LAP1C humanas parece ser regulada durante a diferenciação celular e 
neuronal e são ambas desfosforiladas pela PP1. Além disso, estas proteínas 
são provavelmente crucias para a manutenção do IN e regulação da mitose. 
Dado que a PP1 interage com a LAP1 no nucleoplasma e esta interage com a 
torsinaA no espaço perinuclear, a existência do tricomplexo 
PP1/LAP1/torsinaA foi validada em cérebro de rato e linhas celulares. A 
torsinA é desfosforilada pela PP1 mas liga-se a esta, provavelmente, através 
da LAP1. Dada a localização aberrante da ΔE-torsinaA no IN, é possível que o 
papel dos complexos formados pela LAP1 no IN e a sua regulação por 
fosforilação esteja na base da patologia da distonia DYT1. Além disso, a 
distonia DYT1 tem sido relacionada com uma disfunção nos circuitos dos 
gânglios de base e da sinalização dopaminérgica. Curiosamente as proteínas 
PP1 e DARPP-32 desempenham um papel fundamental na sinalização 
dopaminérgica. Assim, os nossos resultados podem ajudar a compreender os 
mecanismos moleculares e celulares inerentes à distonia DYT1, onde a 
fosforilação de proteínas pode desempenhar um papel crucial. 
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abstract 
 
Dystonia is the third most common movement disorder, following essential 
tremor and Parkinson’s disease, and comprises a large number of clinical 
syndromes. DYT1 dystonia is recognized as the most common form of early 
onset isolated dystonia and is caused by a mutation in the DYT1 gene, 
resulting in the loss of a single glutamic acid within the torsinA protein (ΔE-
torsinA). TorsinA resides in the endoplasmic reticulum and nuclear envelope 
(NE), but the mutant form is abnormally relocated to the NE. At the NE, torsinA 
interacts with lamina associated polypeptide 1 (LAP1), whose function is poorly 
understood. LAP1 is a transmembrane protein of the inner nuclear membrane 
that was described to exist as three alternatively spliced isoforms (LAP1A, B 
and C) in rat. 
Protein-protein interactions are becoming increasingly important in the study of 
human diseases and signaling pathways. In this work, human LAP1B was 
identified as a novel protein phosphatase 1 (PP1) binding protein. PP1 is a 
major Ser/Thr phosphatase that is estimated to dephosphorylate about one 
third of all proteins in eukaryotic cells. The versatility of PP1 is only possible by 
complexing with different binding proteins that play regulatory and targeting 
roles. We found that LAP1B is a substrate of PP1 and binds to the latter 
through an RVxF-like motif located in the nucleoplasmic domain. In the course 
of this work, we also identified a novel human LAP1 isoform - LAP1C that is N-
terminally truncated. Human LAP1B and LAP1C isoforms seem to be 
developmentally regulated and are both dephosphorylated by PP1. Moreover, 
LAP1 proteins seem to be important for NE integrity and mitosis regulation. 
Given that PP1 interacts with LAP1 in the nucleoplasm, which in turn interacts 
with torsinA in the perinuclear space, the existence of the tricomplex 
PP1/LAP1/torsinA was validated in rat brain and cultured cells. Moreover, 
torsinA was dephosphorylated by PP1 but probably binds to the latter via LAP1. 
The aberrant behavior of ΔE-torsinA in the NE implicates nuclear dysfunction in 
DYT1 dystonia pathogenesis. Thereby, the role of LAP1 complexes in the NE 
and its regulation by protein phosphorylation may underlie the pathology of 
DYT1 dystonia and other NE-related diseases. Moreover, DYT1 dystonia has 
been related with a dysfunction in the basal ganglia circuit, including dopamine 
signaling disturbance. Interestingly, PP1/DARPP-32 cascade plays a key role 
in mediating the actions of dopamine and modulating the phosphorylation and 
activity of effectors in dopaminoceptors neurons. Thus, our results may lead to 
novel insights into the molecular and cellular mechanisms of DYT1 dystonia, 
where protein phosphorylation cascades represent a regulatory mechanism.   
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I.1. PROTEIN PHOSPHORYLATION 
 
Reversible protein phosphorylation is the most common type of pos-translational 
modification in eukaryotic organisms. It involves either the addition of phosphate 
groups via the transference of the terminal phosphate from ATP to an amino acid 
residue by protein kinases or its removal by protein phosphatases (Fig. I.1). Protein 
phosphorylation is a crucial mechanism for signal transduction that regulates the 
biological activity of diverse proteins. For example, protein phosphorylation allows for 
the regulation of enzymatic activities and is important for modulation of protein-protein 
interactions (Barford et al., 1998). About one third of all eukaryotic proteins can be 
phosphorylated, mainly at serine (Ser), threonine (Thr) and tyrosine (Tyr) amino acids. 
Proteomic analysis of more than 2000 human proteins revealed that phosphorylation at 
Ser, Thr and Tyr accounts for 86.4%, 11.8% and 1.8%, respectively, of the 
phosphorylated amino acids (Olsen et al., 2006). Analysis of the human genome 
revealed that it contains about 518 kinases that are classified as Tyr kinases or Ser/thr 
kinases (Johnson and Hunter, 2005). Whereas the number of Tyr kinases is 
approximately the same as that for Tyr phosphatases, the number of Ser/Thr kinases is 
much higher when compared to Ser/Thr phosphatases. The discrepancy of this number 
can be explained by the unique manner by which Ser/Thr phosphatases are regulated. 
These enzymes have additional interacting and regulatory proteins that bind to the 
phosphatase catalytic subunits and control their activity and/or subcellular location 
(Bollen et al., 2010; Cohen, 2002b; Moorhead et al., 2007). 
 
 
Figure I.1.  Schematic representation of reversible protein phosphorylation. Protein kinases transfer 
a phosphate group from ATP to the target protein (protein phosphorylation), while protein phosphatases 
catalyze the hydrolysis of the phosphate group from the target protein (protein dephosphorylation). 
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Protein phosphorylation is a major mechanism for controlling several intracellular 
events in eukaryotic cells, such as, metabolism, contractility, membrane transport and 
secretion, transcription and translation, cell division, fertilization and memory (reviewed 
in Cohen, 1989). Additionally, aberrant protein phosphorylation of key proteins has 
been linked to many diseases and dysfunctional states, such as, cancer, metabolic 
disorders and inflammatory and neurological diseases. In neurodegenerative diseases, 
such as Alzheimer’s disease, there is evidence for abnormal regulation of protein 
phosphorylation. Alzheimer’s disease is primarily characterized by the presence of 
neuritic plaques and neurofibrillary tangles in the brains of affected individuals. 
Neurofibrillary tangles result from the aggregation of hyperphosphorylated tau protein 
into paired helical filaments. Glycogen synthase kinase 3β (GSK3β) and protein kinase 
A (PKA) may be key kinases involved in tau phosphorylation (Delobel et al., 2002a), 
while inhibition of protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1) 
lead to tau hyperphosphorylation (Bennecib et al., 2000; Planel et al., 2001). Moreover, 
the inactivation of PP1 leads to a relative increase in Alzheimer’s amyloid precursor 
protein processing by the non-amyloidogenic pathway (da Cruz e Silva et al., 1995a). 
Other neurodegenerative diseases associated with abnormal protein phosphorylation are 
Parkinson’s disease and Huntington’s disease. Parkinson’s disease is characterized by 
the presence of Lewy bodies (proteinaceous inclusions) that contain phosphorylated and 
aggregated α-synuclein. It was demonstrated that α-synuclein is constitutively 
phosphorylated, predominantly on serine residues (Okochi et al., 2000), and the levels 
of phosphorylated α-synuclein were found to be higher in Parkinson’s disease patients 
compared to the control cases (Foulds et al., 2011). Synapsin I, a major phosphoprotein 
important in regulating neurotransmitter release, is abnormally phosphorylated in mice 
expressing the Huntington’s disease mutation. It has been suggested that an imbalance 
between kinase and phosphatase activities also occurs in Huntington’s disease (Lievens 
et al., 2002). Therefore, protein phosphorylation systems represent attractive targets for 
diagnostics and therapeutics in several diseases. Indeed, kinases are the second most 
important group of drug targets in the pharmaceutical industry’s (Cohen, 2002a). In 
contrast, protein phosphatases were recognized later as potential therapeutic targets. 
Further, the therapeutic value of protein phosphatases interacting proteins as targets is 
only currently being addressed (da Cruz e Silva et al., 2004; Fardilha et al., 2010). 
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I.1.1. Protein phosphatases 
 
Based on substrate specificity, eukaryotic protein phosphatases can be classified 
into two families: ser/thr protein phosphatases, that catalyze the dephosphorylation of 
ser and thr amino acids, and tyr phosphatases, which catalyze the dephosphorylation of 
tyr amino acids. Ser/thr protein phosphatases can be categorized into three families: 
phosphoproteins phosphatases (PPPs), metal-dependent protein phosphatases (PPMs) 
and the aspartate-based phosphatases represented by FCP/SCP (TFIIF-associating 
component of RNA polymerase II CTD phosphatase/small CTD phosphatase). 
Members of the PPPs family include: PP1, PP2A, PP2B (also known as calcineurin), 
PP4, PP5, PP6 and PP7. PP1 and PP2A are some of the most well conserved enzymes 
with a variety of cellular functions attributed to the interaction with a large number of 
regulatory subunits (reviewed in Honkanen and Golden, 2002; Moorhead et al., 2009; 
Shi, 2009). PP2B alone is inactive, acquiring phosphatase activity after binding with 
Ca
2+
-calmodulin. In contrast, PP1 and PP2A are mainly active in the absence of divalent 
cations, despite dephosphorylation of some substrates being strongly stimulated by 
Mn
2+ 
(Cohen, 1989; Wang et al., 2008a). PP4, PP5 and PP6, like PP1, PP2A and PP2B, 
were identified in all mammalian tissues examined. At the structural level, PP4 and PP6 
are closely related to the catalytic subunit of PP2A. PP5 contains an N-terminus 
tetratricopeptide repeat domain that is a protein-protein interaction motif (Cohen, 1997; 
Shi, 2009). In contrast with other PPPs, human PP7 is not ubiquitous and was primarily 
found in retina. PP7 contains multiple Ca
2+
 binding sites and its activity is dependent of 
Mg
2+
 (Kutuzov et al., 2002). These PPPs contain a common catalytic core domain that 
is conserved among species. The remarkable degree of evolutionary conservation of 
these enzymes (Fig. I.2) is related to their essential role in the regulation of fundamental 
cellular processes (Honkanen and Golden, 2002). PP1, PP2A, and PP2B together with 
PP2C of the PPM family, account for the majority of the protein ser/thr phosphatase 
activity in vivo (Barford et al., 1998). The PPM family includes PP2C and pyruvate 
dehydrogenase phosphatase, which are Mn
2+
/Mg
2+ 
dependent enzymes. Unlike most 
PPP family members, PPMs do not have additional regulatory subunits but contain 
additional domains and conserved motifs that may determine substrate specify. 
Members of the FCP/SCP family use an aspartate-based catalysis mechanism (reviewed 
in Moorhead et al., 2009; Shi, 2009).  
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Figure I.2. Phylogenic tree representing the homology between members of the phosphoprotein 
phosphatase (PPP) family based on their primary amino acid sequence. PP1-PP7 belongs to the PPP 
family that is structurally different from PP2C (metal-dependent protein phosphatase family, PPM) 
(adapted from Honkanen and Golden, 2002). 
 
 
I.1.2. Protein phosphatase 1  
 
PP1 and PP2A together are responsible for more than 90% of the protein 
phosphatase activity in eukaryotic cells. However, in terms of substrate diversity, PP1 is 
predicted to catalyze the majority of protein dephosphorylation events (Bollen et al., 
2010; Heroes et al., 2013). As a major phosphatase, PP1 is present in various eukaryotic 
organisms. Eukaryotic genomes contain multiple genes encoding PP1 isoforms with the 
exception of yeast Saccharomyces cerevisiae which only contains one PP1 gene. PP1 
isoforms are about 70% identical in the central region and mainly differ at the N- and C-
terminal sequences. Moreover, PP1 was shown to be one of the most conserved 
eukaryotic proteins. PP1 sequences are highly conserved between different species, as is 
the case for Giardia lamblia which expresses a PP1 isoform very similar to the 
mammalian form. This suggests that PP1 may have similar functions in different 
organisms (reviewed in Ceulemans and Bollen, 2004; Lin et al., 1999). In mammals, 
PP1 isoforms are encoded by three genes: PPP1CA, PPP1CB and PPP1CC that encode 
for PP1alpha (PP1α), PP1beta/delta (PP1β/δ) and PP1gamma (PP1γ), respectively 
(Barker et al., 1994; Barker et al., 1993; Sasaki et al., 1990). These isoforms are about 
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90% identical in amino acid sequence; most of the differences are located at the N- and 
C-terminals (Fig. I.3). The gene encoding PP1γ undergoes alternative splicing to 
originate an ubiquitous PP1gamma1 (PP1γ1) variant and a PP1gamma2 (PP1γ2) variant 
enriched in testis (da Cruz e Silva et al., 1995b). 
 
 
PP1gamma1       MADLDKLNIDSIIQRLLEVRGSKPGKNVQLQENEIRGLCLKSREIFLSQPILLELEAPLK 60 
PP1gamma2       MADLDKLNIDSIIQRLLEVRGSKPGKNVQLQENEIRGLCLKSREIFLSQPILLELEAPLK 60 
PP1alpha        MSDSEKLNLDSIIGRLLEVQGSRPGKNVQLTENEIRGLCLKSREIFLSQPILLELEAPLK 60 
PP1beta         MADG-ELNVDSLITRLLEVRGCRPGKIVQMTEAEVRGLCIKSREIFLSQPILLELEAPLK 59 
                *:*  :**:**:* *****:*.:*** **: * *:****:******************** 
 
PP1gamma1       ICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 120 
PP1gamma2       ICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 120 
PP1alpha        ICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 120 
PP1beta         ICGDIHGQYTDLLRLFEYGGFPPEANYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 119 
                ********* **************:*********************************** 
 
PP1gamma1       LRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 180 
PP1gamma2       LRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 180 
PP1alpha        LRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 180 
PP1beta         LRGNHECASINRIYGFYDECKRRFNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 179 
                ***********************:************************************ 
 
PP1gamma1       QSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVLGWGENDRGVSFTFGAEVVAKFLHKHD 240 
PP1gamma2       QSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVLGWGENDRGVSFTFGAEVVAKFLHKHD 240 
PP1alpha        QSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVQGWGENDRGVSFTFGAEVVAKFLHKHD 240 
PP1beta         QSMEQIRRIMRPTDVPDTGLLCDLLWSDPDKDVQGWGENDRGVSFTFGADVVSKFLNRHD 239 
                ***************** *************** ***************:**:***::** 
 
PP1gamma1       LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPAE 300 
PP1gamma2       LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPAE 300 
PP1alpha        LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPAD 300 
PP1beta         LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGGMMSVDETLMCSFQILKPSE 299 
                ****************************************.*****************:: 
 
PP1gamma1       KKK---------PNATRPVTPPRG------MITKQAKK-------- 323 
PP1gamma2       KKK---------PNATRPVTPPRVGSGLNPSIQKASNYRNNTVLYE 337 
PP1alpha        KNKGKYGQFSGLNPGGRPITPPRN-------SAKAKK--------- 330 
PP1beta         KKAKYQYG---GLNSGRPVTPPRT--------ANPPKKR------- 327 
                *:            . **:****          :  :          
 
Figure I.3. Analysis of homology of PP1 isoforms using CLUSTALW algorithm. Identical (*); 
conservative (:); similar (.). 
 
 
PP1 holoenzymes are composed by a highly conserved catalytic subunit called 
protein phosphatase 1 catalytic subunit (PP1c) complexed with one or two variable 
regulatory subunits. The crystal structure of mammalian PP1c revealed that PP1 is a 
metalloenzyme with two divalent metal ions (Mn
2+
 and Fe
2+
) at the center of the 
catalytic site (Egloff et al., 1995; Goldberg et al., 1995). The catalytic site of PP1 is 
located at the intersection of three potential substrate-binding grooves (Fig. I.4): the 
hydrophobic, the acidic and the C-terminal grooves (Peti et al., 2013). Most PP1 
regulatory subunits interact with the PP1 catalytic subunit through a conserved PP1 
binding motif termed the RVxF motif. The RVxF motif binds to a hydrophobic groove 
of PP1c that is distant from the catalytic site (Egloff et al., 1997). The residues of PP1c 
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responsible for binding of the RVxF motif are conserved in all isoforms of different 
species (Barford et al., 1998; Egloff et al., 1997). Initially, the RVxF motif was defined 
as a five-residue motif with the consensus sequence [R/K] XA(0-1) [V/I] XB [F/W], where 
XA is any amino acid and XB is any amino acid except proline (Wakula et al., 2003). 
Later on, a more specific consensus sequence for the RVxF motif was proposed: 
[HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-[FW] (Meiselbach et al., 2006). The 
latter definition has only 40% of sensitivity but is more specific compared to the first 
one (Ceulemans and Bollen, 2006; Meiselbach et al., 2006). A remarkable aspect is that 
the RVxF motif is often N-terminally flanked by basic residues and C-terminal flanked 
by acidic residues and this affects the binding affinity for the RVxF motif (Meiselbach 
et al., 2006; Wakula et al., 2003). Based on the two proposed definitions for the RVxF 
motif, Hendrickx and colleagues (Hendrickx et al., 2009) performed an in silico 
screening for novel PP1 interactors in combination with  biochemical validation, and 
proposed a novel consensus sequence: [KRL][KRSTAMVHNQ][VI]{FIMYDP}[FW]. 
The binding of PP1 to regulatory proteins through the RVxF motif does not cause major 
effects on the conformation and activity of PP1 (Egloff et al., 1997; Meiselbach et al., 
2006; Wakula et al., 2003). However, the RVxF motif mediates the initial anchoring of 
regulatory subunits to PP1 and thereby promotes the occupation of secondary binding 
sites, and this often does affect the activity and/or substrate specificity of PP1 (Bollen, 
2001). Additional PP1 binding motifs were identified, the SILK and MyPhone motifs. 
The SILK motif has the consensus sequence [GS]IL[RK] (Hendrickx et al., 2009) and it 
was first described for inhibitor-2. The SILK motif was shown to be essential for PP1 
inhibiton by inhibitor-2 (Huang et al., 1999) and can functionally replace the RVxF 
motif in nuclear inhibitor of PP1 (NIPP1) (Wakula et al., 2003). The SILK motif is 
always positioned N-terminal to the RVxF sequence and binds in a hydrophobic groove 
on the opposite face of the PP1 active site (Bollen et al., 2010). The myosin phosphatase 
targeting subunit 1 (Mypt1) has a N-terminal PP1 binding motif (MyPhone motif) with 
the consensus sequence RxxQ[VIL][KR]x[YW], where x can be any residue (Terrak et 
al., 2004). The MyPhone motif is present in other PP1 regulatory proteins and is also N-
terminal to the RVxF sequence (Bollen et al., 2010). Some members of the anti-
apoptotic Bcl-2 family have, in addition to the RVxF motif, another PP1 binding motif 
with the consensus sequence F-X-X-[KR]-X-[KR] (Ayllon et al., 2001; Godet et al., 
2010). This motif, termed apoptotic signature, was also found in other PP1 binding 
proteins (Esteves et al., 2012b).  
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Figure I.4. Representation of the PP1α structure. A- PP1α contains two divalent metal ions (pink 
spheres) at the center of the catalytic site (green), which is located at the intersection of three potential 
substrate-binding grooves: the hydrophobic (blue), the acidic (orange) and the C-terminal (red). B- 130º 
rotation of A to show the binding sites for the RVxF (purple), SILK (cyan) and MyPhone (wheat) motifs 
(Bollen et al., 2010). 
 
 
Close to 200 PP1 interacting proteins have been identified and many more are 
expected to be found (Esteves et al., 2012a; Esteves et al., 2012b; Fardilha et al., 2010; 
Fardilha et al., 2011; Hendrickx et al., 2009; Heroes et al., 2013). As explained, the 
versatility of PP1 is largely determined by the binding of its catalytic subunit to 
different specific regulatory subunits. These PP1 binding proteins can function as 
inhibitors of the catalytic activity, substrate-specifying subunits, targeting subunits or 
substrates (Fig. I.5) (Bollen et al., 2009; Bollen et al., 2010). Many substrates that 
directly associate with PP1c are enzymes that are activated by dephosphorylation, as is 
the case for focal adhesion kinase, E3 ubiquitin ligase and caspase 2 (Bollen et al., 
2010). In contrast, PP1α dephosphorylates NEK2, Aurora-A and C-Nap1 and keeps 
these proteins in an inactive state (Mi et al., 2007). Some substrates are 
dephosphorylated specifically on a single residue, whereas others are dephosphorylated 
on multiple residues (Bollen et al., 2010). Many PP1 binding proteins mediate the 
targeting of PP1 to specific subcellular compartments or protein complexes. This brings 
PP1 in close proximity to specific substrates (Bollen et al., 2010; Ceulemans et al., 
2002a). For example, spinophilin directs PP1 to dendritic spines in brain, near to 
potential substrates, which mediate the regulation of PP1 synaptic function (Allen et al., 
1997). NIPP1 was initially identified as a nuclear inhibitor of PP1c but it also targets 
PP1 to dephosphorylate spliceosome-associated protein 155 (SAP155), not as an 
inhibitor of PP1 (Tanuma et al., 2008). Some PP1 binding proteins selectively inhibit 
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PP1 dephosphorylation of only a subset of substrates such as glycogen phosphorylase. 
Thus, these proteins are defined as substrate specifiers rather than as inhibitors. In 
addition, some substrate specifiers enhance PP1 activity toward PP1 substrates, as is the 
case of the MYPT1. Interaction of MYPT1 with PP1 not only promotes the 
dephosphorylation of the myosin regulatory light chain but also decreases PP1 activity 
towards other substrates. PP1 true inhibitors are capable of blocking the PP1 active site 
and inhibit the dephosphorylation of all substrates. Innibitor-1 and DARPP-32 
(dopamine and cAMP-regulated phosphoprotein, Mr 32 kDa) potently inhibit PP1c 
when phosphorylated on a thr residue, while inhibitor-2 and -3 activity does not require 
prior phosphorylation (Bollen, 2001; Bollen et al., 2010; Ceulemans and Bollen, 2004). 
Targeting and inhibitor proteins were also found to associate simultaneously with PP1 
forming a trimeric complex (Lesage et al., 2007; Terry-Lorenzo et al., 2002).  
 
 
 
Figure I.5. Schematic representation of the PP1 holoenzyme structure.  The protein phosphatase 1 
catalytic subunit (PP1c) interacts with regulatory subunits that can be substrates, targeting proteins, 
inhibitors of the catalytic activity or substrate-specifiers. 
 
 
PP1 is the most widely expressed ser/thr phosphatase and regulates a variety of 
cellular functions. It is involved in glycogen metabolism, transcription, protein 
synthesis, cellular division and meiosis, and apoptosis. When nutrients are abundant 
PP1 stimulates the synthesis of glycogen and also enables the return to the basal state of 
protein synthesis and the recycling of transcription and splicing factors. PP1 is required 
for anaphase progression, exit from mitosis and is also responsible for maintenance of 
the cells in G1 or G2 cell cycle phases. In addition, PP1 can also promote apoptosis 
when cells are damaged. PP1 in combination with its regulatory proteins is also 
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involved in neurotransmission, neurite outgrowth and synapse formation (reviewed in 
Ceulemans and Bollen, 2004; Cohen, 2002b). Most PP1 binding proteins identified so 
far have an annotated function. In accordance with the broad action of PP1, its binding 
proteins are also linked to diverse cellular functions. However, they function 
predominantly in signal transduction events, including regulation of nucleic acid, cell 
cycle, protein synthesis, stress response, metabolism and transport (Esteves et al., 
2012b; Heroes et al., 2013). Some PP1 binding proteins do not show cell or tissue-
specific expression, while others are selectively expressed in brain, testis or white blood 
cells (Heroes et al., 2013), accordingly with the high expression levels of PP1 in those 
tissues (da Cruz e Silva et al., 1995b; Fardilha et al., 2011; Heroes et al., 2013). 
Regarding the subcellular localization, PP1 binding proteins are mainly found in the 
nucleus, cytoplasm and plasma membrane (Esteves et al., 2012b; Heroes et al., 2013). 
This is consistent with the fact that all PP1 isoforms can be found in the nucleus and 
cytoplasm (Andreassen et al., 1998).  
 
 
I.1.2.1. PP1 functions in the nucleus 
 
The nucleus is a highly dynamic subcellular compartment where reversible 
protein phosphorylation is a crucial regulatory mechanism (Moorhead et al., 2007; 
Olsen et al., 2006). The activity of protein phosphatases that regulate nuclear events are 
often enriched in the nucleus, as is the case for PP1 (Kuret et al., 1986). All PP1 
isoforms can be found in the nucleus and cytoplasm with PP1γ and PP1β/δ showing 
additional accumulation in the nucleoli. The localization of PP1 isoforms is dynamic 
and changes throughout mitosis. Moreover, each PP1 isoform shows different 
localization patterns during cell cycle, suggesting isoform-specific roles. During mitosis 
PP1α was found in centrosomes, PP1β/δ was located in chromosomes, and PP1γ was 
differentially found at kinetochores, chromosomes, cleavage furrow and midbody 
throughout mitosis progression (Andreassen et al., 1998; Trinkle-Mulcahy et al., 2003; 
Trinkle-Mulcahy et al., 2001). The specific locations of PP1 isoforms can be due to 
different affinities for regulatory subunits which have distinct subcellular distribution 
themselves (Moorhead et al., 2007; Trinkle-Mulcahy and Lamond, 2006).  
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I.1.2.1.1. mRNA processing and transcription  
 
The two most abundant nuclear PP1 binding proteins are phosphatase 1 nuclear 
targeting subunit (PNUTS) and NIPP1 (Tran et al., 2004), both bind to RNA and are 
thought to play a role in pre-mRNA splicing. PNUTS may anchor PP1 to specific RNA 
complexes in the nucleus (Kim et al., 2003). Moreover PNUTS can inhibit the 
phosphatase activity of PP1γ and PP1α towards exogenous substrates in vitro (Allen et 
al., 1998; Kreivi et al., 1997). NIPP1 is a potent inhibitor of PP1 that has a 
nucleoplasmic distribution, but also accumulates in nuclear speckles where it binds to 
pre-mRNA splicing factors (Trinkle-Mulcahy et al., 1999). When overexpressed in 
cells, NIPP1 is capable of redirecting PP1γ and PP1α to nuclear speckles (Trinkle-
Mulcahy et al., 2001). NIPP1 was also found to mediate the interaction of PP1 with a 
regulator of pre-mRNA splicing (CDC5L). It was suggested that CDC5L and PP1-
NIPP1 complex may be involved in the splicing reaction and in the spliceosome 
disassembly (Boudrez et al., 2000). NIPP1 also associates with the spliceosomal 
component SAP155 and recruits PP1 to dephosphorylate the latter (Tanuma et al., 
2008). Indeed, previous reports showed that activity of ser/thr phosphatases, including 
PP1, is required for pre-mRNA splicing (Mermoud et al., 1992; Mermoud et al., 1994). 
PP1 may also be involved in alternative 5’ splice site selection, possibly by 
dephosphorylating splicing factors of the SR family (Cardinali et al., 1994). 
Furthermore, PP1 was found to associate with splicing factors regulating its activity, 
including PTB-associated RNA splicing factor and non-POU-domain-containing, 
octamer binding protein (Liu et al., 2011) and transformer2-beta1 (Novoyatleva et al., 
2008). 
 
In the nucleus, PP1 has been linked to other processes, such as, regulation of 
transcription. The transcription by RNA polymerase II relies on the reversible 
phosphorylation of the C-terminal domain of the largest subunit of the polymerase. PP1 
was found to associate with RNA polymerase II in nuclear extracts and to 
dephosphorylate, the C-terminal domain of the polymerase, at least in vitro (Ceulemans 
and Bollen, 2004; Washington et al., 2002). The transcription factor cAMP-responsive 
element-binding protein (CREB) was initially identified as a mediator of cAMP-
induced gene expression. CREB has several phosphorylation sites that differentially 
regulate its activity (reviewed in Carlezon et al., 2005). PP1 dephosphorylates CREB 
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and inhibits c-AMP dependent transcription, thus regulating CREB activity (Hagiwara 
et al., 1992). It was also reported that histone deacetylase associates with CREB and 
PP1, and promotes CREB Ser133 dephosphorylation via interaction with PP1 
(Canettieri et al., 2003). Furthermore, PP1 was found in association with several 
transcription factors in the nucleus, namely Hox11 (Kawabe et al., 1997; Riz and 
Hawley, 2005), human factor C1 (Ajuh et al., 2000) and myocyte enhancer factor-2 
(MEF2) (Perry et al., 2009). Hox11 is a homeobox proto-oncogene that may function as 
a transcription factor for G1/S cell cycle progression. The interaction with PP1 and 
PP2A are important effectors of Hox11 transcriptional activity (Riz and Hawley, 2005). 
Human factor C1 is involved in regulation of G0/G1 phase of the cell cycle and can 
inhibit the phosphatase activity of PP1 toward phosphorylase a (Ajuh et al., 2000). 
MEF2 interaction with PP1α blocks MEF2-dependent transcription and MEF2 mediated 
neuronal survival (Perry et al., 2009). 
 
 
I.1.2.1.2. Cell Cycle 
 
PP1 has different localization patterns during the cell cycle suggesting an 
association with different regulatory subunits. The PP1 complexes are capable of 
controlling cell cycle progression in diverse aspects (Fig. I.6). Protein phosphatases are 
important regulators of G1/S transition by maintaining retinoblastoma proteins 
dephosphorylated, which enables the latter proteins to recruit stimulators of G1/S 
transition (e.g. E2F transcription factor) (Bollen and Beullens, 2002). The 
retinoblastoma protein pRB is dephosphorylated at the end of mitosis by PP1, but at the 
G1/S transition PP1 is inactivated by a cyclin-dependent kinase (CDK) phosphorylation, 
allowing S phase entry (Liu et al., 1999; Rubin et al., 2001). PP1, like other protein 
phosphatases, controls the entry into mitosis by regulating the activity of mitotic 
kinases. Activation of CDK1 in association with cyclins is crucial for entry into mitosis 
and requires dephosphorylation by Cdc25B and Cdc25C phosphatases at the 
centrosomes and nucleus. Dephosphorylation of Cdc25C on Ser287 partially activates 
Cdc25C and it is mediated by PP1, resulting in the activation of a pool of CDK1 at the 
G2/M transition (reviewed in Bollen et al., 2009).  
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Figure I.6. Activity of PP1 and its regulatory proteins during cell cycle progression. The upper panel 
shows a timeline of cell cycle stages, the middle panel underlines the major events known to be regulated 
by PP1 and the lower panel shows the activity stage of PP1 regulatory proteins. PP1 regulates G1/S 
transition by dephosphorylation of the retinoblastoma protein pRB. BRCA prevents centrosome 
maturation in a PP1-dependent manner. PP1 keeps Aurora A, Nek2 and c-Nap1 dephosphorylated to 
prevent centrosome splitting. The inhibitor-2 (I2) restrain PP1 activity and promotes Nek2 activation and 
centrosome splitting. PP1-Mars complex stabilize microtubules. PP1 dehosphorylates KNL1 and CENP-E 
and stabilizes microtubule-kinetochore attachments. PP1 and its binding proteins Repo-man and PNUTS 
are required for chromatin decondensation at the end of mitosis. AKAP-149 recruits PP1 to the nuclear 
envelope to dephosphorylate lamin B, promoting nuclear envelope reassembly. Inhibitor 1 (I1) is 
inactivated by PP1 allowing PP1 to dephosphorylate proteins required for mitotic exit. 
 
 
When cells enter mitosis, one of the first steps for mitotic spindle formation is 
the separation of duplicated centrosomes (duplication occurs at S phase), the main 
microtubule organizing centers that form the two spindle poles. Formation of a stable 
mitotic spindle is crucial for accurate separation of chromosomes during mitosis. PP1 
may prevent the premature splitting of the duplicated centrosomes at the beginning of 
mitosis by inactivating the kinases involved in this process (Fig. I.6). One of these 
kinases is Aurora A, which is required for centrosome separation. Aurora A and PP1 
antagonize each other and inhibitor-2 additionally regulates this complex by inhibiting 
PP1 and activating Aurora A. Centrosome separation also depends on Nek2a activity 
and its substrates C-Nap1 and Rootletin. PP1, Nek2 and C-Nap1 form a trimeric 
complex. During interphase, PP1 dephosphorylates Nek2 leading to its inhibition and 
also dephosphorylates c-Nap1 maintaining centrosome cohesion. Additionally, 
inhibitor-2 associates with the Nek2/PP1 complex, where it inhibits PP1, and thereby 
promotes Nek2 activation and centrosome splitting. In turns, Nek2 phosphorylates PP1, 
reducing its phosphatase activity (Bollen et al., 2009; Ceulemans and Bollen, 2004). 
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Recently, it was reported that a leucine rich repeat protein that binds to PP1 termed 
PPP1R42 also regulates centrosome separation. PPP1R42 is a positive regulator of PP1 
and its depletion reduces PP1 activity and consequently leads to Nek2 activation 
(Devaul et al., 2013). It seems that separation of centrosomes at early mitosis requires 
inactivation of PP1 and that PP1 maintains centrosomes together during interphase 
(reviewed in Bollen et al., 2009; Ceulemans and Bollen, 2004). Indeed, PP1 was shown 
to be involved in centrosome maturation (G2 phase), a process characterized by the 
accumulation of γ-tubulin and other proteins. The BRCA protein promotes 
ubiquitination and further degradation of γ-tubulin, and thus inhibits centrosome 
maturation. During interphase PP1α activates BRCA by dephosphorylation, suggesting 
an additional role for PP1 in centrosome maturation (reviewed in Bollen et al., 2009). 
Furthermore, PP1 also binds to the centrosomal proteins SFI1, CEP192, CEP170 and 
inhibitor-3 (Esteves et al., 2012a; Hendrickx et al., 2009; Huang et al., 2005).  
 
Furthermore, mitotic spindle assembly that begins with microtubule outgrowth 
at the centrosomes, is regulated by different phosphatases, including PP1 (Fig. I.6) 
(Bollen et al., 2009). It was proposed that the PP1 binding protein Mars targets the 
centrosomal microtubule stabilizer dTACC to be dephosphorylated by PP1, thus 
contributing to mitotic spindle stability (Tan et al., 2008). Others functions that have 
been attributed to PP1 are the maintenance of microtubules-kinetochores attachment and 
spindle assembly checkpoint (SAC) silencing. Stable attachment of kinetochores to 
spindle microtubules is crucial for accurate chromosome separation. Aurora B 
phosphorylates diverse proteins to destabilize the binding of microtubules to 
kinetochores, thus preventing erroneous attachments. Conversely, PP1 stabilizes correct 
microtubule-kinetochore attachments during metaphase by opposing Aurora B-mediated 
phosphorylation (reviewed in Bollen et al., 2009; Funabiki and Wynne, 2013). It was 
demonstrated that the kinetochore protein KNL1 targets PP1γ to kinetochores and this 
recruitment is required for PP1γ dephosphorylation of other Aurora B substrates at 
kinetochores (Liu et al., 2010). PP1γ is also directed to kinetochores through binding to 
the centromere-associated protein E (CENP-E). Binding and dephosphorylation of 
CENP-E by PP1 is required for stable attachment of kinetochores to microtubules (Kim 
et al., 2010b). On the other hand, Aurora B inhibits targeting of PP1 to kinetochores by 
phosphorylation of the PP1 binding motif in KNL1 and CENP-E (Kim et al., 2010b; Liu 
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et al., 2010). In addition, polo-like kinase 1 (PLK1) was reported to promote 
kinetochore-microtubule attachment and SAC silecing. The SAC signaling pathway is 
activated on unattached kinetochores to block the metaphase-anaphase transition, until 
chromosomes are properly attached to the mitotic spindle. When the chromosomes align 
at methaphase, the levels of the PLK1 at kinetochore decrease and this seems to be 
dependent on PP1 recruitment. Like Aurora B, PLK1 substrates are likely to be 
dephosphorylated in a PP1-dependent manner (Liu et al., 2012). Moreover, PLK1 
directly binds to the PP1 interactor MYPT1. Depletion of MYPT1 increases PLK1 
phosphorylation on Thr210 and thus increases its kinase activity, suggesting that 
MYPT1/PP1 antagonizes PLK1 activity (Yamashiro et al., 2008). It was also shown 
that, in yeast, PP1 localization at the kinetochores is necessary for SAC silencing, 
indicating that dephosphorylation of kinetochore-associated proteins is required for 
SAC silencing. In yeast the association of PP1 with Spc7 (KLN1 in human) and 
kinesins Klp5/6 is needed for SAC silencing and kinetochore-microtubule attachment. 
IF18A, the vertebrate orthologue of Klp5/6, also interacts with PP1 (Meadows et al., 
2011).  
 
Protein phosphatases, including PP1, are required for mitotic exit (Bollen et al., 
2009). Mitotic exit is characterized by mitotic spindle breakdown, chromosome 
decondensation and reassembly of interphase structures, particularly the NE. PP1 was 
shown to be required for kinetochore disassembly, possibly by dephosphorylation of a 
chromatin or kinetochore-bound substrate (Emanuele et al., 2008). Moreover, it was 
demonstrated that inhibitor-2 is required for accurate chromosome segregation and 
cytokinesis by regulating the Aurora B and PP1 activity (Wang et al., 2008b). PP1 and 
its regulatory subunits Repo-man (recruits PP1 onto mitotic chromatin at anaphase) and 
PNUTS are required for chromatin decondensation. Repo-man was initially found to 
recruit PP1γ to chromatin at anaphase and when overexpressed also recruits PP1α to 
chromatin (Trinkle-Mulcahy et al., 2006). The PP1γ/Repo-man complex, in particular, 
mediates the dephosphorylation of histone H3 at the end of mitosis and regulates 
chromosomal targeting of Aurora B (Qian et al., 2011). Dephosphorylation of histone 
H3 by PP1 seems to be correlated with chromosome decondensation in budding yeast 
and nematodes (Hsu et al., 2000). PNUTS is targeted to the reforming nucleus in 
telophase concomitantly with chromatin decondensation and promotes chromatin 
decondensation in a PP1-dependent manner (Landsverk et al., 2005). Furthermore, it 
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was reported that PP1 is involved in the first step of nuclear envelope (NE) reassembly 
by stimulating the targeting of membrane vesicles to chromatin in Xenopus egg extracts 
(Ito et al., 2007). Moreover, the reassembly of the nuclear lamina is mediated in part by 
dephosphorylation of lamin B (Thompson et al., 1997). The PP1 regulatory subunit A-
kinase anchoring protein (AKAP)-149 recruits PP1 to the NE upon NE assembly in 
vitro and promotes lamin B dephosphorylation and polymerization (Steen et al., 2000). 
Mitotic exit also requires CDK1 inactivation by cyclin B degradation and 
dephosphorylation of CDK1 and other kinases substrates. PP1 activity is repressed at 
early-mid mitosis by CDK1 phosphorylation on PP1 residue Thr320 (Kwon et al., 1997) 
and by binding to inhibitor-1. CDK1 inactivation at the end of mitosis allows PP1 auto-
dephosphorylation promoting partial PP1 activation. PP1 is then able to 
dephosphorylate and inactivate inhibitor-1, allowing for the complete activation of PP1. 
Active PP1 dephosphorylates mitotic phosphoproteins required for mitotic exit (Wu et 
al., 2009). 
A role for PP1 in the regulation of cytokinesis has also been suggested (Cheng et 
al., 2000; Fernandez et al., 1992), consistent with the co-localization of PP1γ and F-
actin at the cleavage furrow and spindle midzone (Trinkle-Mulcahy et al., 2003). PP1γ 
was also found in the center of the midbody during cytokinesis (Zeitlin et al., 2001).  
 
 
I.1.2.2. PP1 signaling in the brain 
 
PP1 isoforms α, β/δ and γ1 are ubiquitously expressed in mammalian tissues but 
have higher abundance in brain. Within the brain, the mRNAs for these isoforms were 
widely distributed with particular incidence in the hippocampus and the cerebellum (da 
Cruz e Silva et al., 1995b). At the protein level PP1α and PP1γ1 have highest levels of 
expression in the striatum, where they are relatively enriched in the medium-sized spiny 
neurons (da Cruz e Silva et al., 1995b; Ouimet et al., 1995).  At the ultrastructural level, 
PP1α and PP1γ1 are highly and specifically concentrated in dendritic spines in the 
striatum. At spines, PP1α and γ1 are concentrated at the postsynaptic density. The 
localization of PP1α and PP1γ1 at dendritic spines, the principal sites for excitatory 
synapses in the central nervous system, suggests that these isoforms are involved more 
extensively in postsynaptic mechanisms of neurotransmission rather than PP1β/δ. In 
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addition, PP1α, γ1 and β/δ are also located at the cell body, dendritic shafts and axons 
(Bordelon et al., 2005; Ouimet et al., 1995). Additionally, PP1β/δ and PP1γ1 were 
detected in all cytoskeletal fractions (neurofilaments, microtubules and actin 
cytoskeleton) from hindbrain proteins. However, PP1β/δ was found enriched in the 
microtubules whereas PP1γ1 was found mostly in the actin cytoskeleton fraction (Strack 
et al., 1999). Indeed, PP1, alongside with PP2A, were reported to have a role in the 
neurite structure. Inhibition of PP1 and PP2A in cultured hippocampal neurons leads to 
decrease number and length of neurites, synapse loss and also hyperphosphorylation of 
the microtubule-stabilizing protein tau (Malchiodi-Albedi et al., 1997). 
Hyperphosphorylation of tau leads to tau aggregation and formation of neurofibrillary 
tangles, a feature of Alzheimer’s disease.  
 
 
I.1.2.2.1. PP1/DARPP-32 signaling pathway 
 
Medium-sized spiny neurons are highly enriched for DARPP-32 (Ouimet et al., 
1984), which has a crucial role in the biology of dopamineceptive neurons. Dopamine 
and others neurotransmitters in the striatum alter the (de)phosphorylation state of 
DARPP-32 (Greengard et al., 1999). When phosphorylated by PKA on Thr34, DARPP-
32 is a potent inhibitor of PP1 (Hemmings et al., 1984). Conversely, phosphorylation of 
DARPP-32 on Thr75 by CDK5 turns DARPP-32 into an inhibitor of PKA and blocks 
phosphorylation on Thr34 (Bibb et al., 1999). Thus, DARPP-32 modulates PP1 and 
PKA activities in the striatum, which in turn regulate the expression of neuropeptides 
and ion channels and pumps (Fig. I.7). Dopamine has opposite effects on PKA 
signalling when bound to D1 or D2 dopamine receptors of medium-sized spiny neurons. 
These neurons contain both D1 class (D1, D5) and D2 class (D2, D3, D4) dopamine 
receptors. However, D1 receptors are predominantly expressed in striatonigral neurons, 
while D2 receptors are mainly found in striatopallidal neurons. Dopamine has an 
excitatory effect on striatonigral neurons expressing D1 receptors and causes increased 
activity of adenylyl cyclase and cAMP-mediated activation of PKA, which 
phosphorylates DARPP-32 on Thr34 converting DARPP-32 into a PP1 inhibitor. 
Ligands that stimulate PKA also promote the dephosphorylation of Thr75 by PP2A. In 
contrast, striatopallidal neurons expressing D2 receptors are inhibited by dopamine by 
two mechanisms: inhibition of adenylyl cyclase and thus PKA; and Ca
2+
 and PP2B-
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mediated dephosphorylation of DARPP-32 and restore of PP1 activity (reviewed in 
Greengard et al., 1999). 
 
 
 
Figure I.7. Regulation of DARPP-32/PP1 signaling pathway. Dopamine acts on D1 receptors to 
increase cAMP formation and activation of PKA, which phosphorylates DARPP-32 on Thr34 leading to 
PP1 inhibition. Conversely, activation of D2 receptors leads to an increase in Ca2
+
 levels and activity of 
PP2B, which dephosphorylates DARPP-32. D2 receptors can also act to decrease cAMP formation. Cdk5 
phosphorylates DARPP-32 on Thr75 converting DARPP-32 into a PKA inhibitor. Further, PP2A 
dephosphorylates DARPP-32 on Thr75. Both adenosin and serotonin act on A2A and 5-HT4/6, 
respectively, and promote cAMP formation, PKA activation and thus DARPP-32 Thr34 phosphorylation. 
Glutamate act on NMDA and AMPA receptors leading to increase Ca
2+
 levels and PP2B activity, whereas 
GABA action on GABAA receptors has an opposite effect. Stimulatory effects are represented as solid 
arrows and inhibitory effects as dashed arrows.  
 
 
DARPP-32/PP1 pathway in medium-sized spiny neurons is also affected by other 
neurotransmitters (Fig, I.7). Adenosine via A2A adenosine receptor stimulates adenylyl 
cyclase and activates PKA, leading to the phosphorylation of DARPP-32 at Thr34 
(Svenningsson et al., 1998). Serotonin binding to 5-HT4/6 receptor also promotes the 
activity of adenylyl cyclase and PKA and thus phosphorylation of DARPP-32 at Thr34 
(Svenningsson et al., 2002). Glutamate acting on N-methyl-D-aspartate (NMDA) and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors stimulates 
DARPP-32 dephosphorylation by PP2B by influx of Ca
2+
. In contrast, γ-aminobutyric 
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acid (GABA) acting on GABAA receptors stimulates DARPP-32 phosphorylation by 
hyperpolarization of the neuron and decreases influx of Ca
2+
, resulting in the 
inactivation of PP2B. Inhibition of PP1 by phospho-DARPP-32, in concert with PKA 
and other kinase activities, results in an increased phosphorylation of various 
downstream effector proteins. Higher levels of phosphorylation are associated with 
decreased activity of GABAA receptors, Na
+
 channels, and the Na
+
/K+-ATPase and 
increased activity of NMDA and AMPA glutamate receptors, L-, N-, and P-type Ca
2+
 
channels and CREB (Greengard et al., 1999).  
 
 
I.1.2.2.2. PP1 regulation of synaptic plasticity 
 
PP1 has been associated with changes in glutamatergic transmission. Glutamate is 
the major excitatory neurotransmitter in the mammalian nervous system and its effects 
are mediated in part by NMDA and AMPA receptors. NMDA and AMPA glutamate 
receptor subunits are pivotal in synaptic plasticity and its activity is regulated by protein 
phosphorylation (Munton et al., 2004; Soderling and Derkach, 2000). The efficiency of 
transmission at glutamatergic synapses can be strengthened (long-term potentiation, 
LTP) by brief, high-frequency stimulation or weakened (long-term depression, LTD) by 
prolonged, low-frequency stimulation (Malenka, 1994). It was reported that inhibition 
of PP1 is required for LTP induction in hippocampal neurons. Stimulation that induces 
LTP leads to cAMP-dependent phosphorylation of inhibitor-1 resulting in decreased 
PP1 activity. Moreover, this also results in increased phosphorylation of 
Ca
2+
/calmodulin-dependent kinase II (CaMKII) at Thr286 and thus increased activity of 
CaMKII (Blitzer et al., 1998), which phosphorylates the AMPA receptor subunits and 
potentiates synaptic current (Soderling and Derkach, 2000). Moreover, at the 
postsynaptic density, PP1 dephosphorylates CaMKII on Thr286 and inactivates it 
(Strack et al., 1997).  
Conversely, LTD was associated with activation of PP1 after dephosphorylation 
and inactivation of inhibitor-1 by PP2B in hippocampus (Mulkey et al., 1994). 
Dephosphorylation of AMPA receptors is correlated with LTD. Introduction of peptides 
that disrupt the binding of PP1 to its regulatory subunits inhibited NMDA receptor-
dependent LTD and addition of active PP1 enhanced LTD. It was also reported that 
synaptic activation of NMDA receptor in cultured hippocampal neurons caused a 
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redistribution of PP1 to synapses (Morishita et al., 2001). Recently, it was reported that 
PP1α regulates the NR2B subunit of the NMDA receptor by dephosphorylating a 
specific residue on N2RB (Farinelli et al., 2012). 
 
 
I.1.2.2.3. Localization of PP1 to dendritic spines 
 
Regulation of dendritic spine motility is mediated by signaling pathways that 
involve PP1 and some of its regulatory subunits. PP1α and PP1γ are specifically 
concentrated at the postsynaptic density of dendritic spines (Bordelon et al., 2005; 
Ouimet et al., 1995). Among the known neuronal PP1 regulators that are also 
postsynaptically localized are spinophilin (Allen et al., 1997), neurabin I (McAvoy et 
al., 1999), yotiao (Westphal et al., 1999), neurofilament light chain (Terry-Lorenzo et 
al., 2000) and AKAP79 (Le et al., 2011). 
Spinophilin (also named neurabin II) and neurabin I can both target PP1 to 
dendritic spines. Spinophilin was identified as a PP1 binding protein enriched in spines 
heads (Allen et al., 1997). Spinophilin binds to F-actin and it was demonstrated that the 
F-actin binding domain is necessary and sufficient for targeting PP1 to dendritic spines 
(Grossman et al., 2002). Spinophilin can also target PP1 to the postsynaptic density in 
close proximity with the AMPA receptors (Yan et al., 1999). Thus, PP1 is important for 
AMPA receptor activity and synaptic plasticity not only through DARPP-32/PP1 
pathway, but also by association with spinophilin. Spinophilin is also important for 
PP1-mediated regulation of NMDA receptors. Consistent with altered glutamatergic 
transmission, spinophilin-knockout mice showed reduced LTD and altered spine density 
and filopodia formation (Feng et al., 2000). Recently, it was reported that spinophilin 
can target CaMKII to F-actin as well as targets PP1 to CaMKII (Baucum et al., 2012).  
Neurabin I is a F-actin binding protein mainly expressed in neural tissues, that 
binds to PP1α and PP1γ. Neurabin I is phosphorylated on Ser461 by PKA disrupting the 
interaction with PP1 (McAvoy et al., 1999).  PP1 also binds yotiao, a protein member of 
the AKAP family. It seems that yotiao attaches PP1 and PKA to NMDA receptors 
regulating synaptic transmission mediated by the NMDA receptor (Westphal et al., 
1999). At the postsynaptic density PP1 also binds to neurofilament light chain, a 
component of the intermediate filament network in neurons, which can be 
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phosphorylated by PKA and by protein kinase N (PKN) (Terry-Lorenzo et al., 2000). 
AKAP79 was recently identified as a PP1 regulatory protein (Le et al., 2011) but it was 
previously described to anchor PKA, protein kinase C (PKC) and PP2B at the 
postsynaptic density regulating AMPA receptors phosphorylation in these pathways 
(Bauman et al., 2004). 
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I.2. THE NUCLEAR ENVELOPE 
 
The eukaryotic nucleus is a complex organelle enclosed by a double membrane, 
the NE. The NE separates the cytoplasm from de the nucleus in eukaryotic cells and is 
structurally composed by the inner nuclear membrane (INM), the outer nuclear 
membrane (ONM), the nuclear lamina and the nuclear pore complexes (NPCs) (Fig. I.8) 
(reviewed in Gerace and Burke, 1988; Worman and Courvalin, 2005). The INM and the 
ONM are separated by a perinuclear space (Stewart et al., 2007) that is 40-50 nm wide 
in mammalian cells. However these membranes are joined in some regions at the NPCs, 
structures that regulate molecular transport between the cytoplasm and the nucleoplasm. 
NPCs are large macromolecular complexes composed of 30 different proteins, termed 
nucleoporins (reviewed in Fahrenkrog and Aebi, 2003). The ONM is continuous with 
the endoplasmic reticulum (ER) and contains various proteins found in the ER and 
associated ribosomes (Pathak et al., 1986). Nonetheless, the ONM also contains specific 
proteins that are involved in nuclear positioning by linking the nucleus to the 
cytoskeleton (Crisp et al., 2006; Starr and Han, 2002; Wilhelmsen et al., 2005). In 
contrast, the INM contains a set of distinctive integral membrane proteins. Using 
proteomic approaches nearly 70 transmembrane proteins were found to associate with 
the INM (Malik et al., 2010; Schirmer et al., 2003) but, so far, few have been 
characterized in detail. The major components of the nuclear lamina are A-type and B-
type lamins (Aebi et al., 1986), which are found in association with proteins of the INM 
and also in the nucleoplasm. 
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Figure I.8. Schematic illustration of the nuclear envelope. The nuclear envelope surrounds the nucleus 
and is composed by the inner nuclear membrane (INM) and outer nuclear membrane (ONM) that are 
separated by the perinuclear space, the nuclear pore complexes (NPCs) and the nuclear lamina. The 
endoplasmic reticulum (ER) is contiguous with the ONM. The nuclear lamina lines the INM and is 
mainly composed by lamins that are also found within the nucleus. 
 
 
I.2.1. Lamins, the main components of the nuclear lamina 
 
The nuclear lamina is located in the inner surface of the INM (Dwyer and Blobel, 
1976) and is mainly composed by lamins, members of the type V intermediate filament 
family (Aebi et al., 1986). Nuclear lamina was originally proposed to be important for 
nuclear structure and anchorage of chromatin and nuclear envelope proteins. In 
addition, nuclear lamins are involved in DNA replication, gene expression, mitosis, 
regulation of chromatin, cell proliferation and differentiation and connection to the 
cytoskeleton (reviewed in Dechat et al., 2010). 
In mammals, three genes encode lamins: LMNA, LMNB1 and LMNB2. LMNA 
encodes lamins A and C and two less abundant isoforms C2 and AΔ10 (A-type lamins), 
which arise from alternative splicing (Furukawa et al., 1994; Lin and Worman, 1993; 
Machiels et al., 1996). Lamin A, C and probably lamin A∆10 are expressed only in 
differentiated cells, while lamin C2 is uniquely expressed in germ cells (Furukawa et 
al., 1994; Rober et al., 1989). Early studies in mouse revealed that A-type lamins are not 
expressed in early embryonic cells (Stewart and Burke, 1987) and some cells (e.g. cells 
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of the central nervous system) express A-type lamins only after mouse birth (Rober et 
al., 1989). However, recent studies reported the presence of low levels of lamin A/C in 
mouse embryonic stem cells (Eckersley-Maslin et al., 2013). LMNB1 and LMNB2 
encode B-type lamins (lamin B1, B2 and B3). Lamin B1 is encoded by LMNB1 gene 
and lamin B2 by LMNB2 gene, and both are expressed in most somatic cells (Hoger et 
al., 1990; Lin and Worman, 1995), while lamin B3 derives from LMNB2 by alternative 
splicing and is germ cell-specific (Furukawa and Hotta, 1993).  
In terms of structure, lamins have conserved α-helical central rod domains and 
head and tail domains that vary in sequence among intermediate filament proteins. 
Unlike cytoplasmic intermediate filaments, lamins also possess a nuclear localization 
signal (NLS) and an immunoglobulin-like β-fold within the tail domain (Fig. I.9). 
Moreover, lamin A and lamins B1 and B2 contain CAAX motifs at their C-terminus, 
which are a signal for farnesylation and carboxy methylation. These modifications at the 
C-terminal of lamins begin immediately after their synthesis. However, lamin A is 
synthesized as a precursor termed pre-lamin A that, after being incorporated in the 
nuclear lamina, is proteolytically cleaved to originate mature lamin A. This process 
abolishes the site for farnesylation and carboxy methylation of lamin A. In contrast, B-
type lamins do not undergo this processing, thereby it remain farnesylated and carboxy 
methylated (reviewed in Burke and Stewart, 2013; Dauer and Worman, 2009). 
Farnesylation is an important modification for membrane association of lamins and may 
also mediate protein-protein interactions (Maske et al., 2003). In addition, lamins are 
post translationally modified by phosphorylation (Gerace and Blobel, 1980; Glass and 
Gerace, 1990), sumoylation (Zhang and Sarge, 2008) or ADP-rybosilation (Adolph, 
1987). Phosphorylation is an important mechanism in the regulation of lamins 
properties. Thus, hiperphosphorylation of lamins was found to lead to disassembly of 
lamins polymers and consequently nuclear envelope disassembly. On the other hand, 
dephosphorylation at the end of mitosis promotes lamina assembly (Gerace and Blobel, 
1980; Glass and Gerace, 1990). 
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Figure I.9. Schematic illustration of lamins structure. Lamins have a head domain followed by a α-
helical central rod domain and a tail domain that includes a nuclear localization signal (NLS) and an 
immunoglobulin (Ig)-like β-fold. Lamin A and lamins B1 and B2 also contain CAAX motifs at their C-
terminus (adapted from Dauer and Worman, 2009).  
 
 
Most proteins of the INM interact directly or indirectly with lamins at the nuclear 
periphery and are sometimes considered a part of the nuclear lamina. The first lamin 
associated proteins to be identified were the lamina associated polypeptide (LAP) 1 and 
2 (Foisner and Gerace, 1993) and the lamin B receptor (LBR) (Worman et al., 1988). 
Many other lamin binding proteins were identified over the years, such as, emerin 
(Clements et al., 2000), MAN1 (Mansharamani and Wilson, 2005), SUN1 and SUN2 
proteins (Crisp et al., 2006; Haque et al., 2006) and nesprin-1 and -2 (Libotte et al., 
2005; Mislow et al., 2002). Besides being part of the nuclear lamina lining the NE, 
lamins are also found within the nucleoplasm. Originally, lamin A/C was observed in 
the nucleus of cells through mitosis and predominantly during early G1 phase. These 
internal lamins seemed to associate with chromatin (Bridger et al., 1993). Lamin B1 
was also found within the nucleus during S-phase coincident with sites of DNA 
replication (Moir et al., 1994). Later, lamin A/C and lamin B1 were found to co-localize 
with RNA splicing factors SC-35 and U5-116 kDa in nuclear speckles (Jagatheesan et 
al., 1999) and lamin A/C was found to associate in vitro and in vivo with the 
transcription factor MOK2 (Dreuillet et al., 2002). Furthermore, lamin A/C was found 
in a complex with the nucleoplasmic LAP2α, which is the only LAP2 isoform not 
integrated in the INM (Dechat et al., 2000).  
 
  
CHAPTER I - INTRODUCTION 
 
 
Characterization of novel LAP1 complexes and their relevance in DYT1 dystonia  43 
 
I.2.2. Properties and targeting of INM proteins 
 
The INM contains specific integral membrane proteins and most interact with 
lamins and/or chromatin, thereby contributing to the NE structure. The majority of the 
INM proteins have the N-terminal domain located in the nucleoplasm and may have one 
or multiple transmembrane domains. According to the “diffusion-retention” model, after 
synthesis in the rough ER, INM proteins with nucleoplasmic domains smaller than 60 
kDa, can diffuse laterally and reach the INM passing through the NPCs. When retained 
at the INM, integral membrane proteins do not diffuse back to the ER. Instead, proteins 
are retained in the membrane by interaction with chromatin and/or nuclear lamina 
(Ellenberg et al., 1997; Soullam and Worman, 1995; Wu et al., 2002). Subsequent 
studies suggested that transport of some proteins to the INM requires energy (ATP 
and/or Ran GTPase). Moreover, the putative NLS present in most mammalian INM 
proteins can also be responsible for targeting integral proteins to the INM in a Ran- and 
karyopherin- dependent manner (King et al., 2006; Zuleger et al., 2011). 
The number of INM proteins identified has grown in the past years and many 
others are likely to be discovered in the future. Most INM proteins (Fig. I.10) have been 
characterized in terms of their interacting partners. Specifically, LBR contains eight 
putative transmembrane domains and was identified by its binding to lamin B1. LBR 
was also found to associate with heterochromatin protein 1 (HP1), histones H3/H4 and 
DNA (reviewed in Mattout-Drubezki and Gruenbaum, 2003). LAP1 was firstly 
identified by a monoclonal antibody (RL13) generated against lamina-enriched fractions 
of rat liver nuclei (Senior and Gerace, 1988). Later on, LAP2 was also identified by a 
monoclonal antibody against rat liver NE (RL29) (Foisner and Gerace, 1993). LAP1 
will be described in detail in the following section. In human, three isoforms of LAP2 
were identified: α, β and γ (Harris et al., 1994). In mouse, six LAP2 isoforms were 
identified: α, β, γ, ε, δ and ζ (Berger et al., 1996). While LAP2β, γ, ε and δ contain a 
transmembrane (TM) domain, LAP2α and ζ are not bounded to the membrane. LAP2β 
binds to B-type lamins and chromatin (Foisner and Gerace, 1993), and to the chromatin 
protein barrier autointegration factor (BAF) (Shumaker et al., 2001). LAP2α binds to 
both lamins A/C and chromatin (Dechat et al., 2000). All LAP2 isoforms have a LEM 
domain near the C-terminus as well as emerin, MAN1 and otefin (Lin et al., 2000). This 
LEM domain mediates binding to the chromatin associated protein BAF (Brachner and 
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Foisner, 2011). Emerin was firstly discovered as the gene responsible for Emery-
Dreifuss muscular dystrophy (Bione et al., 1994) and later found to be located in the 
INM where it interacts with A-type lamins (Lee et al., 2001). Interestingly, a fraction of 
emerin was also detected in the ONM where it can interact directly with microtubules 
and contribute to the positioning of the centrosome near the ONM (Salpingidou et al., 
2007). MAN1 has two putative transmembrane domains and has been linked to three 
related bone disorders: osteopoikilosis, Buschke-Ollendorff syndrome and 
melorheostosis (Hellemans et al., 2004). In contrast with others INM proteins, nurin is 
neither associated with NPCs nor with lamins, and contains 6 putative TM domains 
(Hofemeister and O'Hare, 2005). LUMA contains 4 putative TM domains and 
associates with SUN2, emerin and lamins (Bengtsson and Otto, 2008). Nesprins 
(nuclear envelope spectrin repeat domains) localizes to both NE membranes. Nesprin-1 
and nesprin-2 exist in a variety of isoforms, the largest are ~1 MDa (known as giant 
isoforms) and contain an actin-binding domain, several spectrin repeats, a 
Klarsicht/ANC-1/Syne-1 homology (KASH) domain and a single TM domain (Zhang et 
al., 2001; Zhen et al., 2002). Nesprin-1 co-localizes with LAP1, emerin and lamins at 
the NE and with heterochromatin in the nucleus (Zhang et al., 2001). Nesprin-2 also 
localizes in the INM and ONM and binds to lamins A/C and emerin (Libotte et al., 
2005). Nesprin-3 and nesprin-4 are both located at the ONM (Roux et al., 2009; 
Wilhelmsen et al., 2005). SUN1 and SUN2 proteins are characterized by a Sad1-
UNC84 homology (SUN) domain and interact with the nuclear lamina and also with 
nesprins in the ONM. SUN proteins bind the KASH domain of nesprins in the 
perinuclear space and nesprins form a functional link with the networks of intermediate 
filaments, microtubules and actin filaments (Fig. I.10), thus resulting in a complex that 
links the nucleoskeleton and the cytoskeleton (the LINC complex) (Crisp et al., 2006; 
Haque et al., 2006). 
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Figure I.10. Schematic view of the proteins at the inner nuclear membrane. Most proteins of the 
inner nuclear membrane (INM) have one or multiple transmembrane domains and bind to the nuclear 
lamina. Lamin B receptor (LBR) and the LEM domain-containing proteins [lamina associated 
polypeptide 2β (LAP2β), emerin and MAN1] bind to chromatin associated proteins, like heterochromatin 
protein 1 (HP1) for LBR and barrier autointegration factor (BAF) for LEM-proteins. Nurim does not 
seem to interact with lamins or chromatin. Lamina associated polypeptide 1 (LAP1) may bind indirectly 
to chromatin. SUN proteins interact in the perinuclear space with nesprin-1 and -2 of the outer nuclear 
membrane (ONM) and the last bind to cytoskeleton elements forming the LINC complex (links the 
nucleoskeleton and cytoskeleton). LAP2α is not bound to membrane and interacts with soluble lamins 
A/C. PNS, perinuclear space; NPC, nuclear pore complex. 
 
 
Using proteomic approaches many other proteins were found to be associated 
with the INM (Malik et al., 2010; Schirmer et al., 2003) but are not well characterized. 
Some of these INM proteins are found in vertebrates and Drosophila but are absent in 
C. elegans and yeast, including LBR and nurin. Emerin and MAN1 were found in 
vertebrates, Drosophila and C. elegans but not in yeast. Other proteins might be only 
present in vertebrates, such as LAP1 and LAP2 (reviewed in Cohen et al., 2001). 
Moreover expression of INM proteins may also vary between different tissues or 
analyzed cell lines (Malik et al., 2010; Schirmer et al., 2005; Schirmer and Gerace, 
2005). 
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I.2.3. NE disassembly and reassembly during mitosis 
 
Most eukaryotic cells undergo an “open mitosis” where the NE is disassembled 
at the onset of mitosis (prophase) and reassembled at the end of mitosis (late 
anaphase/telophase). NE breakdown involves the disassembly of the NPCs, 
depolymerization of lamins, and spreading of most NE soluble components in the 
cytoplasm and INM proteins through the tubular mitotic ER (reviewed in Guttinger et 
al., 2009).  
One of the first steps of NE breakdown is the NPC disassembly and release of 
nucleoporins. After this, NPCs are no longer able to regulate the transport between the 
cytoplasm and the nucleus. Most nucleoporins disassemble at the same time, with the 
exception of NUP98 that seems to be the first one to set off NPC breakdown. In early 
prophase the nuclear lamina is depolymerized and lamins are released into the 
nucleoplasm. At the same time, INM proteins are disconnected from lamins and 
chromatin and are dispersed through the ER (reviewed in Guttinger et al., 2009). 
However, while B-type lamins remain attached to the nuclear membranes during 
mitosis, lamin A/C are solubilized throughout the nucleoplasm (Gerace and Blobel, 
1980; Stick et al., 1988). Interestingly, it was described that microtubules are important 
elements for NE breakdown. Microtubules that are connected to the ONM apply pulling 
forces that cause NE invaginations around centrosomes and this seems to open holes in 
the membranes. This mechanical force is provided by the microtubule minus-end 
directed motor protein dynein and its associated protein dynactin. NPCs disassembly, 
lamina depolymerization and the dissociation of proteins from nuclear membranes are 
mediated by phosphorylation (reviewed in Foisner, 2003; Guttinger et al., 2009). 
Among the different kinases involved in this process are CDK1, PKC, Aurora A and 
PLK1. CDK1 is a major kinase that is activated to promote mitosis and inactivated to 
allow mitotic exit. CDK1 phosphorylates lamins leading to lamin depolymerization and 
may also be involved in NPCs disassembly since many nucleoporins are phosphorylated 
in CDK1 sites during mitosis. CDK1 phosphorylation might also cause the dissociation 
of INM proteins from lamins and chromatin (reviewed in Guttinger et al., 2009). LAP2β 
and LAP2α are CDK1 targets (Blethrow et al., 2008) and phosphorylation of LAP2β 
was described to inhibit its binding to chromatin and to lamin B1 (Foisner and Gerace, 
1993). Furthermore, phosphorylation of LBR by CDK1 negatively regulates the binding 
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of LBR to chromatin and is an important mechanism for controlling the NE assembly at 
the end of mitosis (Tseng and Chen, 2011). 
The NE begins to reform in late anaphase and is completely reassembled at 
telophase. The NE reassembly involves the recruitment of membranes, NPCs insertion, 
polymerization of lamins and targeting of INM proteins to chromatin. NPCs assembly 
starts at late anaphase when chromatin recruits the NUP107-160 complex. This step is 
mediated by RanGTP that induces the dissociation of the NUP107-160 complex from 
importin-β and allow the complex to bind to chromatin. Numerous studies showed that 
NE reassembly requires the targeting of lamins and INM proteins to chromosomes in a 
synchronized way. LAP2α appears to be the first lamin binding protein to associate with 
chromosomes in anaphase. Transmembrane proteins LAP2β, LBR and emerin 
assembled around chromosomes approximately at the same time (reviewed in Foisner, 
2003; Guttinger et al., 2009). Lamin B1 associates with chromosomes during late 
anaphase/telophase when the NE begins to reform, while lamin A can not be detected 
until chromosome decondensation and assembly of the major components in daughter 
cells. Thus, it seems that chromosome association of these proteins is regulated by 
different mechanisms (Moir et al., 2000). Nuclear envelope reassembly also requires 
inhibition of mitotic kinases and the action of phosphatases. PP1 and PP2A are 
important regulators of mitosis (as previously described) and its activity is required for 
NE assembly. 
 
 
I.2.4. Lamina associated polypeptide 1 (LAP1) 
 
Members of the LAP1 family were initially identified using monoclonal 
antibodies generated against lamina-enriched fractions of rat liver nuclei (Senior and 
Gerace, 1988). This antibody recognized a major peptide of 75 kDa and two minor 
peptides of 68 and 55 kDa, which were later termed LAP1A, LAP1B and LAP1C, 
respectively. Further, the three peptides were found to be specifically located at the 
INM (Senior and Gerace, 1988). Evidence of lamina association with LAP1, was 
provided by chemical extraction of NEs. For example, after treatment of NEs with 
nonionic detergent and low salt concentration, all LAP1A and LAP1B and most LAP1C 
remain associated with the lamina fraction (insoluble fraction). However, when NEs 
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were incubated with nonionic detergent and high salt concentration most LAP1A and 
LAP1B remain associated with the insoluble lamina fraction while LAP1C was 
solubilized. These results lead to the assumption that LAP1C has a weaker interaction 
with the nuclear lamina than the two other proteins (Foisner and Gerace, 1993; Senior 
and Gerace, 1988). Specifically, LAP1A and LAP1B were found to bind directly to 
lamins A, C and B1 in vitro and probably indirectly to chromosomes (Foisner and 
Gerace, 1993) and LAP1A/C co-immunoprecipitated with B-type lamins (Maison et al., 
1997) 
In 1995 (Martin et al., 1995) the cDNA for LAP1C was completely sequenced in 
rat. Partial characterization of other cDNAs suggested that the three LAP1 family 
members arise from alternative splicing, given that LAP1A and LAP1B partial cDNAs 
were identical to the LAP1C sequence with the addition of two insertions. Moreover, it 
was demonstrated that LAP1C is a type II transmembrane protein, containing a 
nucleoplasmic N-terminal domain, a single TM domain and a lumenal C-terminal 
domain located in the perinuclear space (Martin et al., 1995). The full-length cDNA of 
human LAP1B was only reported in 2002. LAP1B was isolated from an expression 
library of HeLa cells and showed 73.6% amino acid identity with the predicted rat 
LAP1B (Kondo et al., 2002). Human LAP1B has a single TM domain and the lumenal 
domain and the nucleoplasmic domain have 89% and 65.8% amino acid identity with 
the predicted rat LAP1B (Fig. I.11), respectively (Kondo et al., 2002). Additionally, 
another splice variant of LAP1 was identified, but has only one more amino acid 
(alanine) than the previously reported LAP1B. This LAP1B splice variant results from 
the exclusion of three nucleotides (CAG) from exon 3 but did not alter the translational 
frame. Indeed, it was reported that alternative splicing involving a 3’ tandem splice site 
NAGNAG sequence, which results in one amino acid insertion or deletion, is very 
common among other proteins (Tadokoro et al., 2005; Tsai et al., 2007). Analysis of the 
subcellular localization of different LAP1B deletion mutants demonstrated that the 
latter half of the nucleoplasmic domain and the TM domain are responsible for the 
localization of LAP1B at the NE. In contrast, only constructs with the whole 
nucleoplasmic domain were fully resistant to extraction with Triton X-100. Deletion 
mutants containing only a part of the nucleoplasmic domain were extractable using this 
detergent. These data suggested that full retention of LAP1B at the NE requires the 
complete nucleoplasmic domain. Furthermore, interaction with other nuclear 
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components, like lamins or chromatin, may also be important for the proper localization 
of LAP1B (Kondo et al., 2002).  
 
 
 
Figure I.11. Schematic representation of homology between human LAP1B and rat LAP1B. Both 
human and rat LAP1B have a long N-terminal nucleoplasmic domain with 89% of homology and a 
shorter C-terminal lumenal domain with 65.8% of homology, and one transmembrane domain (TM) 
(Kondo et al., 2002). INM, inner nuclear membrane; ONM, outer nuclear membrane. 
 
 
The expression of the three LAP1 isoforms seems to be developmentally 
regulated. Immunoblot analysis of rat tissues and cells, demonstrated that rat LAP1A, B 
and C are present in similar amounts in liver, spleen, brain and kidney tissues, while 
LAP1C is the major peptide identified in cultured cells (Senior and Gerace, 1988). By 
comparing the mouse P19 teratocarcinoma cell line and the differentiated P19MES line, 
LAP1C was found to be similarly expressed in both cells, while LAP1A and LAP1B 
were expressed at higher levels in the differentiated cells (Martin et al., 1995).  LAP1 is 
ubiquitously expressed in neuronal and non-neuronal tissues and also during 
embryogenesis (Goodchild and Dauer, 2005; Goodchild et al., 2005). However, during 
mouse spinal cord development, the expression of each mouse LAP1 isoform is 
different. LAP1A is upregulated approximately at the same time as the NE vesicles 
begin to form (Goodchild et al., 2005)  
As referred above, phosphorylation is an important regulatory mechanism for the 
assembly/disassembly of lamins polymers. Like lamins, LAP1 is also phosphorylated. 
Rat LAP1 isoforms were found to be phosphorylated in vitro and at least LAP1C was 
also phosphorylated in vivo. However, the (de)phosphorylated state of LAP1A and B 
did not influence the binding to lamins in vitro (Foisner and Gerace, 1993). More 
recently, diverse phosphorylated sites of LAP1B (Fig. I.12) were identified by high-
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throughput studies (Chi et al., 2008; Dephoure et al., 2008; Han et al., 2010; Olsen et 
al., 2006; Olsen et al., 2010; Wang et al., 2010; Weber et al., 2012). Moreover, it seems 
that LAP1 is highly phosphorylated during mitosis, as is the case for other nuclear 
proteins (Dephoure et al., 2008; Olsen et al., 2010). Indeed, kinases that regulate cell 
cycle, such as, CDKs, ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia 
and Rad 3-related (ATR) might be involved in LAP1 phosphorylation. Human LAP1B 
was found to be phosphorylated on Ser143, in a proline-directed manner similar to 
CDKs substrates (Chi et al., 2008), and on Ser164 within the ATM/ATR recognition 
sequence motifs (Olsen et al., 2010). Rat LAP1B Ser142 (homologous to human 
LAP1B Ser143) was found to be phosphorylated by CDK1-cyclin B (Blethrow et al., 
2008). In addition, LAP1 was also found to be post-translationally modified by 
ubiquitination (Fig. I.12) (Kim et al., 2011; Wagner et al., 2011). Ubiquitination is a 
crucial regulatory mechanism for various cellular processes, including protein 
degradation, cell division and DNA repair as well as for controlling stability and 
localization of proteins (Ciechanover, 1994). 
 
 
 
Figure I.12. LAP1B post-translational modifications. LAP1B can be phosphorylated in the 
nucleoplasmic domain at numerous serine (S) and threonine (T) residues. Each residue phosphorylated is 
indicated. Ser143 and Ser164 are probably phosphorylated by CDK2 and ATM/ATR kinases, 
respectively. LAP1B can also be modified by ubiquitination at the sites indicated (K). INM, inner nuclear 
membrane; ONM, outer nuclear membrane; TM, transmembrane domain. The sites indicated at relative to 
the GenBank sequence NM_001267578 (Human LAP1B).  
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I.2.4.1. LAP1 distribution during the cell cycle 
 
In interphase cells LAP1 is well described to be located at the INM in association 
with lamins and chromosomes. However, when the NE is completely disassembled at 
prometaphase, LAP1 seems to be redistributed through the ER (Fig. I.13). At this point 
LAP1 is no longer associated with chromosomes or lamins. At late anaphase LAP1 
reappeares at the chromosomes’ surface and by telophase LAP1 acquires again a 
perinuclear location (Foisner and Gerace, 1993; Senior and Gerace, 1988; Yang et al., 
1997). However, it seems that LAP1 reappears in the reforming NE prior to lamins 
(Foisner and Gerace, 1993). Another study (Maison et al., 1997) reported that during 
mitosis LAP1C and lamin B colocalize in mitotic vesicles which associate transiently 
with the mitotic spindle. Moreover, during anaphase, LAP1C was located at the surfaces 
of chromosomes, particularly on the sides facing the mitotic spindle poles. At 
telophase/cytokinesis LAP1C has reassembled at the NE but LAP1C was also detected 
in the mid-body (Fig. I.13). 
 
 
 
Figure I.13. LAP1 localization during the cell cycle. In interphase cells LAP1 is located in the inner 
nuclear membrane but at prometaphase LAP1 is distributed through the endoplasmic reticulum. At 
anaphase LAP1 localizes at chromosomes surface and at telophase LAP1 is redistributed again to the 
inner nuclear membrane, but is also detected in the mid-body. Nuclear pore complex and nuclear lamina 
are also disassembled at prometaphase and NUP107-160 are the first nucleoporins recruited by chromatin 
at anaphase. 
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I.2.4.2. LAP1 physiological function and associated proteins 
 
The function of LAP1 remains poorly understood. The interaction with nuclear 
lamins suggests that LAP1 may be important for attaching the nuclear lamina to the 
INM and thereby contribute to the NE architecture (Foisner and Gerace, 1993; Martin et 
al., 1995). Kim and colleagues (Kim et al., 2010a) assessed the LAP1 function in vivo 
using a mouse model in which the TOR1AIP1 locus (encoding LAP1) was disrupted 
with a gene trap cassette. The nuclear membranes of various tissues and cultured 
neurons of TOR1AIP1
-/- 
mice embryos showed abnormalities. These defects included 
“blebs – vesicle-appearing structures” in the perinuclear space. Moreover, TOR1AIP1-/- 
mice usually die on the last prenatal day or first postnatal day, while TOR1AIP
+/- 
mice 
were identical to wild-type mice (Kim et al., 2010a). Other authors (Neumann et al., 
2010) also proposed a function for LAP1 in the assembly of the mitotic spindle. 
Knockdown of LAP1 in HeLa cells using RNAi cause mitotic spindle formation to fail 
in prometaphase, probably because centrosomes could not form a bipolar mitotic 
spindle or align chromosomes. This lead to anomalous mitosis resulting in cell death. 
Thus, it seems that LAP1 is a crucial protein in the NE and its absence leads to cell 
death.  
LAP1 has been implicated in the pathogenesis of a neurological disorder termed 
DYT1 dystonia. DYT1 dystonia is caused by a mutation in the DYT1 gene that encodes 
the torsinA protein, a member of the AAA
+
 superfamily of ATPases associated with 
several subcellular activities (Ozelius et al., 1997) (described in the following sections). 
LAP1 was found to relocate the torsinA to the NE, although the latter is normally found 
in ER (Goodchild and Dauer, 2005). The torsinA mutant form, which is present in 
DYT1 dystonia patients, is also primarily relocated to the NE (Goodchild and Dauer, 
2004; Naismith et al., 2004). In addition, LAP1 co-immunoprecipitated with all four 
members of the human torsin family: torsinA, torsinB, torsin2 and torsin3 (Kim et al., 
2010a). Introducing a key mutation in the AAA+ domain stabilizes torsin proteins in an 
ATP-bound, substrate-trapped state and causes its redistribution from the ER to the NE. 
However, LAP1 depletion in NIH-3T3 cells and mouse embryonic fibroblasts led to a 
shift of the NE-located torsinA and torsinB to the ER. In contrast the localization of 
torsin2 and torsin3 is not affected by LAP1 depletion. Thus, LAP1 is required for the 
NE localization of torsinA and torsinB (Jungwirth et al., 2010; Kim et al., 2010a). 
Recently, it was described that torsinA alone is catalytically inactive. However, its 
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ATPase activity is induced by the lumenal domains of LAP1 and a protein with a 
lumenal domain- like LAP1 (LULL1) (Zhao et al., 2013a). 
Recently, it was reported that LAP1 binds to emerin and the interaction occurs 
through their nucleoplasmic domains. Moreover, LAP1 was found to be required for the 
normal localization of emerin. Conditional deletion of LAP1 from mouse striated 
muscle caused muscular dystrophy leading to early lethality, thus arguing that LAP1 
plays a crucial role in skeletal muscle maintenance (Shin et al., 2013). 
Other proteins were found to interact with LAP1 (described in table I.1) and may 
uncover potentially nuclear functions for LAP1, such as, the mitotic arrest deficient 2 
(MAD2)-like 1 (MAD2L1) (Hutchins et al., 2010). MAD2 is an element of the mitotic 
spindle checkpoint that prevents the onset of anaphase until chromosomes are aligned at 
the metaphase plate (Luo et al., 2000). In a large-scale screen for telomere interacting 
proteins, human LAP1B was identified as novel putative regulator of telomeres. LAP1B 
was found to associate with the human Rap1, a TRF2 (telomeric repeat binding factor 2) 
binding protein (Lee et al., 2011). Rap1 regulates the telomere length and may modulate 
the recruitment of potential regulators of telomere length (O'Connor et al., 2004). 
Havugimana and colleagues (Havugimana et al., 2012) performed large screens of 
stably associated human protein complexes present in cytoplasmic and nuclear extracts. 
In these screens various proteins were found in association with LAP1B (Table I.1) but 
some are located at subcellular compartments not previously described for LAP1B (e. g. 
mitochondria). Therefore, these interactions should be validated by additional 
methodologies. 
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Table I.1. List of the identified LAP1 interacting proteins. 
Interactor Description 
Experimental 
evidence 
References 
LMNB1 
Lamin B1 
Nuclear lamina protein 
In vitro binding 
assay 
(Foisner and 
Gerace, 1993) 
Co-IP 
(Maison et al., 
1997) 
LMNA 
Lamin A/C 
Nuclear lamina protein 
In vitro binding 
assay 
(Foisner and 
Gerace, 1993) 
TOR1A 
TorsinA 
AAA+ ATPase 
FRAP 
(Goodchild and 
Dauer, 2005) 
Co-IP and MS 
(Naismith et al., 
2009a) 
Co-IP 
(Kim et al., 
2010a) 
TOR1B 
TorsinB 
AAA+ ATPase 
Co-IP 
(Kim et al., 
2010a) 
In-cell competition 
assay 
(Jungwirth et 
al., 2010) 
TOR2 
Torsin2 
AAA+ ATPase 
Co-IP 
(Kim et al., 
2010a) 
TOR3 
Torsin3 
AAA+ ATPase 
ATP1B4 
Na, K-ATPase βm-subunit 
Transcriptional regulator in placental mammals  
Yeast two-bybrid 
Co-IP 
(Pestov et al., 
2007) 
HUR 
Hu antigen R, 
RNA binding protein 
Affinity capture - 
RNA 
(Abdelmohsen 
et al., 2009) 
Tat 
Tat , transcriptional activator of human 
immunodeficiency virus type 1 
Affinity 
chromatography - 
MS 
(Gautier et al., 
2009) 
PPP1CA 
Protein Phosphatase 1 alpha 
Major Ser/Thr phosphatase 
Yeast two-hybrid 
(Esteves et al., 
2012a; Santos, 
2009) 
PPP1CC 
Protein Phosphatase 1 gamma 
Major Ser/Thr phosphatase 
Yeast two-hybrid 
(Esteves et al., 
2013b; Santos, 
2009) 
MAD2L1 
Mitotic arrest deficient-like 1 
Mitotic spindle checkpoint protein 
Affinity capture - 
MS 
(Hutchins et al., 
2010) 
TERF2 
Telomeric repeat binding factor 2 
Telomere nucleoprotein 
Protein 
complementation 
array screen 
(Lee et al., 
2011) 
Rap1 TRF2 binding protein 
Protein 
complementation 
array screen 
GST pull-down 
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Interactor Description 
Experimental 
evidence 
References 
RIF1 RAP1 interacting factor 1 homologue 
Complex 
fractioning - MS 
(Havugimana et 
al., 2012) 
SEPT9 
Septin 9 
Involved in cytokinesis 
NUP50 
Nucleoporin 50kDa 
Nuclear pore complex protein 
HNRNPM 
Heterogeneous nuclear ribonucleoprotein M 
RNA binding protein 
HPDL 
4-hydroxyphenylpyruvate dioxygenase-like 
protein 
S100A16 S100 calcium binding protein A16 
NIT2 
Nitrilase family, member 2 
Omega-amidase activity 
NDUFV1 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
OXCT1 
Succinyl-CoA: 3-ketoacid-coenzyme A 
transferase 1, mitochondrial 
ACA11 
Orphan small nucleolar RNA, encoded within 
an intron of the histone methyltransferase 
WHSC1 
RNA affinity 
purification - MS 
(Chu et al., 
2012) 
EMD 
Emerin 
INM protein 
Co-IP, Pull down, 
MS 
(Shin et al., 
2013) 
RFX7 
DNA-binding protein RFX7  
Transcription factor 
MS 
PRKDC Protein kinase, DNA-activated, catalytic subunit 
E4F1 E4F transcription factor 1 
MATR3 
Matrin 3 
Nuclear matrix protein 
HNRNPUL1 
Heterogeneous nuclear ribonucleoprotein  
U-like 1 
Nuclear RNA-binding protein 
AIFM1 
Apoptosis-inducing factor 1, mitochondrial 
Regulator of apoptosis 
SF3B3 Splicing factor 3B subunit 3 
IMMT 
Mitofilin 
Mitochondrial inner membrane protein 
SMARCC2 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 2 
 
Co-IP, co-immunoprecipitation; FRAP, fluorescence recovery after photobleaching; INM, inner nuclear 
membrane; MS, mass spectrometry. 
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I.2.5. Relevance of nuclear envelope proteins in disease 
 
About 20 different inherited diseases have been linked to NE proteins. The 
diversity of functions of these proteins as well as the range of NE-associated diseases 
suggests that NE proteins have essential regulatory functions. Maintenance of nuclear 
structure and regulation of transcription and cell cycle could explain how NE proteins 
cause these diseases. Moreover mutations in NE proteins may also cause disruption of 
functional protein complexes (Kavanagh et al., 2007).  
Diverse conditions termed laminophaties have been linked to mutations in the 
LMNA gene. LMNA mutations cause tissue-specific phenotypes involving striated 
muscle, adipose tissue, peripheral nerve or multiple systems. Most inherited LMNA 
mutations lead to disorders that affect striated muscles with or without tendon 
involvement and also affect the heart (cardiomyopathy). Mutations that cause muscle 
syndromes mostly result in decreased levels of A-type lamins (reviewed in Dauer and 
Worman, 2009). Although no loss-of-function mutations have been found in B-type 
lamins, two rare diseases affecting the central nervous system (CNS) have been 
associated with high levels of lamin B1. Duplication of the LMNB1 gene has been 
linked to autosomal dominant leukodystrophy (ADLD), a demyelinating disorder, 
(Padiath et al., 2006) and increased levels of lamin B1 were also identified in 
lymphoblast and fibroblasts from patients with ataxia telangiectasia, a 
neurodegenerative disease (Barascu et al., 2012). In contrast, reduced levels of lamin B1 
were observed in fibroblasts from patients with Hutchinson-Gilford progeria syndrome 
(Scaffidi and Misteli, 2005), an accelerated aging condition, and senescent human 
fibroblasts (Dreesen et al., 2013). A recent study identified two missense LMNB1 
mutations in neural tube defects patients that were predicted to compromise the 
interaction of lamin B1 with the nuclear lamina. These mutation may contribute to 
susceptibility to neural tube defects (Robinson et al., 2013). Emerin was firstly 
discovered as the gene responsible for the X-linked form of Emery-Dreifuss muscular 
dystrophy (EDMD), characterized by progressive skeletal muscle wasting, contractures 
and cardiomyopathy (Bione et al., 1994). Diverse disease-causing mutations in the 
emerin gene have been found and most result in reduced levels of emerin and 
mistargeting to the cytoplasm (Manilal et al., 1998). Interestingly, mutations in LMNA 
cause the autosomal type of EDMD (Bonne et al., 1999). Studies using mouse models 
for autosomal dominant EDMD and Hutchinson-Gilford progeria laminophaties showed 
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that accumulation of SUN1 is pathogenic in those conditions (Chen et al., 2012). 
LAP2α gene mutations are associated with dilated cardiomyopathy and the mutated 
LAP2α does not bind to lamin A in vitro (Taylor et al., 2005). As described above, the 
mutant torsinA (in DYT1 dystonia) is relocated to the perinuclear space where it 
interacts with LAP1 (Goodchild and Dauer, 2004, 2005). Rodent models of DYT1 
dystonia present abnormal nuclear membranes in neurons (Goodchild et al., 2005; 
Grundmann et al., 2012). Moreover, similar NE defects were observed for LAP1 null 
mice (Kim et al., 2010a). LBR mutations are associated with Pelget-Huet anomaly, an 
autosomal dominant syndrome characterized by abnormal nuclear shape and chromatin 
organization in blood granulocytes. Mutations in LBR mostly result in reduced protein 
levels (Hoffmann et al., 2002). LBR has also been linked to Greenberg’s skeletal 
dysplasia characterized by lethal skeletal and visceral anomalies (Waterham et al., 
2003). Loss-of-function mutations in MAN1 gene cause osteopoikilosis, Buschke-
Ollendorff syndrome, and melorheostosis. These diseases are characterized by increased 
bone density and may be caused by impairment of MAN1 function in Smad signaling, 
which is important for bone development (Hellemans et al., 2004). Mutations in 
nesprin-1 gene lead to autosomal recessive cerebellar ataxia characterized by lack of 
coordination and impaired walking (Gros-Louis et al., 2007). In mice, deletion of the 
KASH domain of nesprin-1 causes an EDMD-like phenotype (Puckelwartz et al., 2009). 
Mutations in NPC proteins were also found to cause different disorders, such as, atrial 
fibrillation (heart disorder) or infantile striatal necrosis and acute necrotizing 
encephalopathy (CNS disorders) (reviewed in Dauer and Worman, 2009). 
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I.3. TORSINA  
 
TorsinA and its related family members belong to the ATPases associated with a 
variety of cellular activities (AAA
+
) superfamily (Ozelius et al., 1997). AAA
+
 proteins 
are chaperone proteins that mediate conformational changes in target proteins. These 
proteins are involved in several functions, including protein folding and degradation, 
membrane trafficking, DNA replication and repair, mitosis and cytoskeletal regulation 
(reviewed in Ogura and Wilkinson, 2001; Vale, 2000).  
TorsinA is encoded by the TOR1A (or DYT1) gene and has three homologous 
proteins in mammals: torsinB, which is about 70% identical to torsinA; torsin2 and 
torsin3. TOR1A and TOR1B (encodes torsinB) genes are adjacent to each other in 
opposite directions on chromosome 9q. The torsin2 gene (TOR2) is also located on 
chromosome 9, while the torsin3 gene (TOR3) is located on chromosome 1q. Related 
sequences have been found in Drosophila (torp4a), nematodes (OOC-5, tor2 and tor3), 
zebrafish (torsinC), but not in yeast or prokaryotic genomes (Ozelius et al., 1999). 
TorsinA has been the most studied torsin family member due to its relation with DYT1 
dystonia. A mutation of a single glutamic acid within the C-terminal of torsinA 
(ΔE302/303, also referred just as ΔE) was found in most cases of DTY1 dystonia 
(Ozelius et al., 1997). DYT1 dystonia or early-onset torsion dystonia is a movement 
disorder characterized by sustained or intermittent muscle contractions causing twisting 
and repetitive movements, abnormal postures or both (Fahn et al., 1998), as described in 
detail in the following sections.  
The predicted structure of torsinA contains a single AAA
+
 domain, which 
includes Walker A and Walker B nucleotide binding motifs, and the α-helical domains 
sensor-1 and sensor-2 (Fig. I.12), which are are thought to be important for the ATPase 
activity of AAA
+
 proteins. Walker A and Walker B motifs are important for ATP 
binding and hydrolysis, respectively. The sensor-1 and -2 domains have been shown to 
mediate substrate interactions and to be critical for ATP hydrolysis (Iyer et al., 2004; 
Neuwald et al., 1999; Ogura and Wilkinson, 2001). The sequence similarity between 
torsinA and other AAA
+
 proteins is poor within the C-terminal, where the sensor-2 
motif is located (Neuwald et al., 1999). Interestingly, torsinA was the first AAA
+ 
protein 
found to reside inside the ER lumen of eukaryotic cells. Indeed, torsinA is targeted to 
the ER by an N-terminal signal peptide (Figure I.14) that it is cleaved and the mature 
torsinA resides in the lumen of the ER (Hewett et al., 2003; Kustedjo et al., 2000). 
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Some reports indicated that an N-terminal hydrophobic domain anchors torsinA to the 
ER membrane with a type II orientation (Kustedjo et al., 2000; Liu et al., 2003). 
However, recent reports showed that torsinA is not an integral membrane protein. The 
N-terminal domain does not transverse the membrane, defining torsinA as a lumenal 
monotopic membrane protein (Callan et al., 2007; Vander Heyden et al., 2011). 
Additionally, the torsinA sequence revealed the presence of a bipartite nuclear 
localization sequence (aa 76-94) (Shashidharan et al., 2000b). Indeed, torsinA was 
found to also be located in the NE in addition to the ER, when overexpressed. 
Furthermore, a mutation in the Walker B domain (E171Q-torsinA) inhibits ATP 
hydrolysis and results in an ATP-bound state, causing high affinity substrate 
interactions. This mutation causes a redistribution of torsinA from the ER to the NE 
(Goodchild and Dauer, 2004; Naismith et al., 2004). The ΔE-torsinA mutation, located 
within sensor-2 (Figure I.14), also causes a relocalization of torsinA from the ER to the 
NE (Goodchild and Dauer, 2004; Naismith et al., 2009a). 
 
 
 
Figure I.14. Representation of torsinA protein and its characteristic domains. The structure of 
torsinA is predicted to contain an N-terminal signal peptide (SP) sequence which is removed from the 
mature protein, a putative transmembrane domain (TM) and a putative bipartite nuclear localization 
signal (NLS). The site of SP cleavage is indicated, which results in translocation of torsinA into the lumen 
of the endoplasmatic reticulum. Walker A (WA) and Walker B (WB) are nucleotide binding sites and 
sensor 1 (S1) and sensor 2 (S2) are configurational domains of AAA
+
 proteins. The ∆E302/303 mutation 
is located within sensor 2 domain.  
 
 
TorsinA is ubiquitously expressed but shows higher levels in liver, muscle, 
pancreas and brain (Ozelius et al., 1997). In brain, torsinA is expressed in all brain 
regions with higher levels in cerebral cortex, thalamus, hippocampus, striatum, 
substantia nigra pars compacta and cerebellum (Augood et al., 1999; Augood et al., 
1998; Konakova et al., 2001; Rostasy et al., 2003). The expression of torsinA seems to 
be developmentally regulated, with higher expression during prenatal and early 
postnatal periods in mouse brain. Thus it was suggested that torsinA may play a role in 
the developing brain (Vasudevan et al., 2006; Xiao et al., 2004). Neurons showed 
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torsinA immunoreactivity in neuronal bodies, axons, dendrites and synaptic terminals 
(Augood et al., 2003; Rostasy et al., 2003). 
 
 
I.3.1.  TorsinA interactors and related functions 
 
TorsinA has been shown to be involved in several cellular processes by 
interacting with different binding proteins (Fig. I.15). Thus, torsinA is thought to play a 
role in the organization of the NE and ER, cytoskeletal network, protein processing in 
the secretory pathway, synaptic vesicle recycling and response to stress (reviewed in 
Granata et al., 2009).  
 
 
 
Figure I.15. TorsinA interactors and potential functions. TorsinA is located in the endoplasmic 
reticulum (ER), where it interacts with LULL1, and in the nuclear envelope (NE), where it binds to 
LAP1, SUN1 and nesprins-1, -2 and -3. Therefore it could be involved in either the organization of the 
ER and NE. TorsinA may be involved in cytoskeleton dynamics through interaction with kinesin light 
chain 1 (KLC1), vimentin or tau. TorsinA also appears to be involved in synaptic vesicle dynamics 
through association with vesicle-associated membrane protein (VAMP) or snapin and ΔE-torsinA causes 
the entrapment of snapin and vesicular monoamine transporter 2 (VMAT2) in inclusions. 
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I.3.1.1. TorsinA in the endoplasmic reticulum 
 
As previously described, several studies confirmed that torsinA resides inside the 
ER lumen using different techniques, including subcellular fractionation, protease 
resistance in the presence/absence of detergent and co-localization with ER markers 
(Hewett et al., 2000; Hewett et al., 2003; Kustedjo et al., 2000). Recent work has shown 
that torsinA is not an integral membrane protein but it is instead peripherally associated 
with the ER membrane (Callan et al., 2007; Vander Heyden et al., 2011). Moreover, it 
was demonstrated that torsinA is glycosylated in vivo on Asn143 and Asn158, and 
exists as a high mannose, glycosylated state consistent with the primary localization in 
the ER (Hewett et al., 2003; Kustedjo et al., 2000). In the ER, torsinA was found to 
interact with a protein with a lumenal domain like LAP1, termed LULL1. The LULL1 
gene is located adjacent to the LAP1 gene on human chromosome 1q24. 
Overexpression of LULL1 caused the redistribution of the E171Q-torsinA (ATP 
hydrolysis mutant) from the NE to the ER (Goodchild and Dauer, 2005; Naismith et al., 
2009a). Furthermore, a new torsinA interactor termed printor was found in a yeast two-
hybrid screen and both proteins co-localize in the ER. However, ΔE-torsinA abolishes 
the interaction between torsinA and printor (Giles et al., 2009).  
 
 
I.3.1.2. Cytoskeleton and cell polarity 
 
TorsinA has been implicated in cytoskeleton dynamics through interaction with 
kinesin light chain (KLC) 1 (Kamm et al., 2004), vimentin (Hewett et al., 2006; Nery et 
al., 2008), nesprins (Canettieri et al., 2003) and tau (Ferrari-Toninelli et al., 2004). 
KLC1 is a subunit of kinesin-I protein, a plus-end-directed motor protein involved in 
the transport of membranous organelles along microtubules (Goldstein and Philp, 
1999). TorsinA was found to interact directly with the tetratricopeptide repeat domain 
of KLC1, which is a cargo binding site of kinesin-I. Co-localization studies showed that 
wt-torsinA and KLC1 were distributed throughout the cytoplasm and processes of 
neuronal cells, with enrichment at the distal ends, while ΔE-torsinA forms cell body 
inclusions positive for KLC1. Thus, it was suggested that torsinA may participate in 
intracellular trafficking mediated by kinesin (Kamm et al., 2004). TorsinA also binds to 
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the intermediate filament vimentin in cultured fibroblasts. Vimentin is involved in cell 
attachment and changes in neuronal shape associated with initial neurite outgrowth. 
Immunoprecipitation of vimentin not only brings down torsinA, but also other 
cytoskeleton components as α-tubulin, kinesin and actin and the NE protein LAP1. 
Expression of ΔE-torsinA altered the localization of vimentin, induced a delay in 
fibroblast adhesion to a substrate and inhibited neurite extension of SH-SY5Y cells 
(Hewett et al., 2006).  
Furthermore, torsinA was found to associate with the KASH domain of nesprin-1, 
2 and 3 (Nery et al., 2008) and also with SUN1 protein (Jungwirth et al., 2011). 
Nesprin-3 is located in the ONM, binds to SUN proteins of the INM and to vimentin 
through plectin (Wilhelmsen et al., 2005). When torsinA is depleted, nesprin-3 is 
redistributed to the ER, indicating that torsinA is important for the proper localization of 
nesprin-3 at the ONM and participates in the linkage between the NE and the 
cytoskeleton (LINC complex) (Nery et al., 2008). Nesprin-3, plectin and vimentin co-
immunoprecipitated with torsinA. Given the role of vimentin on nuclear shape and the 
involvement of vimentin and plectin in cell migration, it was suggested that torsinA 
affects the positioning of the nuclei and cell migration through its association with 
nesprin-3 (Nery et al., 2008). Further, the torsinA homologue OOC-5 in C. elegans was 
found to be necessary for spindle orientation and cell polarity (Basham and Rose, 2001). 
TorsinA also immunoprecipitates with tau and may be able to modulate the association 
of tau with microtubules, thus influencing microtubules stabilization, neurite outgrowth 
and cell polarity (Ferrari-Toninelli et al., 2004). 
 
 
I.3.1.3. TorsinA in the nuclear envelope 
 
The discovery that torsinA not only resides in the ER but also in the NE, 
suggested that torsinA plays a role in the NE. Wt-torsinA was found in both the ER and 
NE, while E171Q-torsinA (ATP-bound trapped) and ΔE-torsinA were found to 
specifically accumulate in the NE (Goodchild et al., 2005; Naismith et al., 2004). 
Likewise, torsinA abnormally accumulates in the NE in DYT1 patient fibroblasts and 
ΔE-torsinA knock-in mice (Goodchild and Dauer, 2004). Accumulation of ΔE-torsinA 
in the NE causes abnormal morphology of the NE, including formation of blebs and 
herniations in the perinuclear space in cultured neurons from ΔE-torsinA knock-in mice. 
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This was also seen for torsinA null mice (Goodchild et al., 2005; Kim et al., 2010a). In 
cultured cells, overexpression of ΔE-torsinA leads to protein accumulation in 
membranous inclusions around the nucleus. These inclusions may be originated from 
the NE, since they stained for lamin A/C, B1 and emerin (Gonzalez-Alegre and 
Paulson, 2004; Hewett et al., 2000). Moreover, perinuclear inclusions were also 
identified in DYT1 patients’ cholinergic neurons and others neurons, which positively 
stained for torsinA, ubiquitin and nuclear lamin A/C (McNaught et al., 2004). However, 
the accumulation of ΔE-torsinA in the NE and the related abnormalities, seem to be 
specific for neuronal cells and tissues (Giles et al., 2008; Goodchild et al., 2005). A 
study which provides a quantitative analysis of the relative NE/ER distribution, reported 
that accumulation of ΔE-torsinA in the NE is specific of neuronal cells by comparing 
the localization of torsinA in HeLa and SH-SY5Y cells (Giles et al., 2008).  
Abnormal accumulation of ΔE-torsinA in the NE suggests that a NE dysfunction 
may contribute to DYT1 dystonia pathogenesis. The accumulation of torsinA in the NE 
leads to the discovery of LAP1 as a binding partner of torsinA in the perinuclear space 
(Fig. I.16). LAP1 was found to relocate wt-torsinA to the NE in a perinuclear 
distribution (Goodchild and Dauer, 2005). More recently, torsinA was found to interact 
with SUN1, another INM protein. It seems that the presence of SUN1 is required for the 
NE localization of the ΔE-torsinA (Jungwirth et al., 2011). At the NE, torsinA also 
binds to the ONM protein nesprin-1, -2 and -3 (Fig. I.16) and it was shown that torsinA 
is crucial for the correct localization of nesprin-3 (Nery et al., 2008). Further, 
overerexpression of ΔE-torsinA alters the localization of vimentin to the NE and KLC 
to inclusions (Hewett et al., 2006; Kamm et al., 2004). 
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Figure I.16.  Representation of torsinA interactions between the nuclear envelope and the 
cytoskeleton. TorsinA is primarily found in the endoplasmic reticulum (ER) but it is also located in the 
nuclear envelope. In the perinuclear space (PNS), torsinA interacts with LAP1, SUN1 and nesprin-1, -2 
and -3. Nesprin-1 and -2 bind directly to actin, while nesprin-3 associates indirectly with intermediate 
filaments through plectin. Thus, torsinA plays a role in the connection between the nuclear envelope and 
the cytoskeleton. INM, inner nuclear membrane; ONM, outer nuclear membrane. 
 
 
I.3.1.4. Chaperone function 
 
The homology between torsinA and heat shock proteins (HSPs), including the 
HSP100/Clp family of proteins (Ozelius et al., 1997; Zhu et al., 2008), suggested a role 
for torsinA as a chaperone. HSPs are critical for the stress response and are involved in 
folding of proteins, prevention of protein aggregation, ubiquitination and degradation of 
misfolded proteins (Vale, 2000). TorsinA was found to co-localize with HSPs, α-
synuclein and ubiquitin in Lewy bodies (Caldwell et al., 2003; McLean et al., 2002). In 
addition, a study of post-mortem brains of Parkinson’s disease patients showed that 
torsinA accumulates in Lewy bodies (Shashidharan et al., 2000a). Moreover 
overexpresssion of torsinA has the ability to prevent the formation of α-synuclein 
aggregates in cultured cells (McLean et al., 2002), as well as polyglutamine repeat-
induced protein aggregation in C. Elegans (Caldwell et al., 2003). More recently, it was 
reported that torsinA can recognize and bind directly to misfolded proteins and also 
prevent aggregation with specificity for misfolded proteins, thus acting as a chaperone 
(Burdette et al., 2010). 
However, torsinA does not behave as a typical HSP, since its expression is not 
affected by some ER stress agents (Bragg et al., 2004). Nevertheless, torsinA is 
sensitive to some types of oxidative stress (Hewett et al., 2003; Kuner et al., 2003) and 
nerve injury (Zhao et al., 2008b). Additionally, overexpression of torsinA protects 
against oxidative stress induced cell death in cultured cells (Kuner et al., 2003) and 
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reduce ER stress caused by mutant proteins in C. elegans (Nery et al., 2011). 
Overexpression of torsinA and tor2 (torsinA C. elegans homolog) in C. elegans 
dopaminergic neurons can lead to the suppression of neurodegeneration induced by 6-
OHDA treatment or overexpression of α-synuclein (Cao et al., 2005).  
 
 
I.3.1.5. Neurotransmission and synaptic vesicle dynamics 
 
TorsinA is ubiquitously expressed, but the mutant protein for DYT1 dystonia 
(ΔE-torsinA) has a specific neurological phenotype (Giles et al., 2008; Goodchild et al., 
2005), suggesting that torsinA plays a specific role in neuronal cells. In neurons, 
torsinA localization seems to be different from non-neuronal cells. Neurons showed 
torsinA immunoreactivity in neuronal bodies, axons and dendrites (Augood et al., 2003; 
Rostasy et al., 2003). Moreover, torsinA was detected in small vesicles within axons 
and pre-synaptic terminals and it was also enriched in a fraction of synaptosomal 
membranes (Augood et al., 2003). In the neuroblastoma SH-SY5Y cell line, torsinA 
was localized in the cytoplasm, around the NE and in neurites. TorsinA was distributed 
in a punctuate pattern and an intense staining was observed in the synaptic varicosities 
of differentiated SH-SY5Y cells (Ferrari-Toninelli et al., 2004). In addition, co-
localization between torsinA and vesicle-associated membrane protein 
(VAMP)/synaptobrevin was oberved, the latter is a synaptic vesicle marker (Ferrari-
Toninelli et al., 2004; Hewett et al., 2000). TorsinA has also been implicated in vesicle 
transport and consequently neurotransmitter turnover. In differentiated PC12 cells (cell 
line derived from a pheochromocytoma of the rat adrenal medulla) and hippocampal 
neurons, torsinA was found to interact with snapin, a SNAP25 (synaptosomal associated 
protein of 25 kDa) binding protein, on secretory granules at neurite tips (Granata et al., 
2008). Snapin is involved in vesicle exocytosis by enhancing the association between 
the SNARE complex and synaptotagmin I, a synaptic vesicle marker (Ilardi et al., 
1999). Based on the torsinA/snapin interaction, a role for torsinA in synaptic vesicle 
dynamics has been proposed. It was found that overexpression of wt-torsinA negatively 
affects synaptic vesicle endocytosis. Conversely, overexpression of ΔE-torsinA 
increases uptake of a lipophilic dye and causes the persistence of synaptotagmin I on the 
plasma membrane. Knockdown of torsinA causes similar effects. This in turn may 
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disrupt the neuronal pathways involved in the control of movement. (Granata et al., 
2008). In Drosophila, torp4 (torsinA homologous) interacts with the adaptor protein 3, 
which is involved in the transport from the Golgi to the lysosome, synaptic vesicle 
formation and sorting of proteins into synaptic vesicles. A study in Drosophila proposed 
that ΔE-torsinA disrupts the trafficking of transforming growth factor beta (TGF-β) 
receptor and Smads from synapses to cell bodies (reviewed in Granata et al., 2009). 
Overexpression of ΔE-torsinA causes the entrapment of the vesicular monoamine 
transporter 2 (VMAT2), a regulator of dopamine levels, in membranous inclusions. This 
may cause a reduction of monoamine neurotransmitter release (Misbahuddin et al., 
2005). TorsinA can protect C. elegans dopaminergic neurons from 6-OHDA-induced 
neurodegeneration, possibly through downregulation of the dopamine transporter DAT-
1, which is responsible for 6-OHDA uptake (Cao et al., 2005). This is consistent with 
the fact that torsinA can regulate cell-surface distribution of DAT-1 (Torres et al., 
2004). 
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I.4. DYSTONIA 
 
The term dystonia was coined by Oppenheim in 1911 describing a condition that 
he termed Dystonia Musculorum Deformans. The definition and classification of 
dystonia has evolved over time as the condition became better understood (reviewed in 
Fahn, 2011). Since 1984, dystonia has been defined as a “syndrome of sustained muscle 
contractions, frequently causing twisting and repetitive movements, or abnormal 
postures” (Fahn, 1988). However, this definition had some limitations and the Dystonia 
Medical Research Foundation committee proposed in 2013 the following revised 
definition: “Dystonia is a movement disorder characterized by sustained or intermittent 
muscle contractions causing abnormal, often repetitive, movements, postures, or both. 
Dystonic movements are typically patterned, twisting, and may be tremulous. Dystonia 
is often initiated or worsened by voluntary action and associated with overflow muscle 
activation”. This new definition of dystonia attempts to exclude some conditions that 
may mimic dystonia, since it is known that several conditions also cause abnormal 
movements, postures or spasms (Albanese et al., 2013).  
Dystonia is the third most common movement disorder, following essential 
tremor and Parkinson’s disease (Butler et al., 2004) and comprises a large number of 
clinical syndromes. The classification of the diverse dystonia syndromes has been 
changed over time (reviewed in Fahn, 2011). The main difficulties to correctly classify 
dystonia are related with the etiology. For example, the term “primary” has been used to 
describe phenotypes not associated with other neurological features or pathological 
abnormalities. However, it is known that tremor occurs in patients with primary 
dystonia and the presence of other neurological features has been recognized, which 
indicates that the phenomenology may be not purely motor (Albanese et al., 2013; 
Stamelou et al., 2012). Thus, in 2013, dystonia syndromes were primarily classified into 
two axes: clinical features and etiology (Table I.2). Five categories were utilized to 
specify clinical characteristics: age at onset, body distribution, temporal pattern, 
coexistence of other movement disorders, and other neurological manifestations. The 
etiology of many dystonia syndromes is still not well understood, but two characteristics 
were used for classification: identifiable anatomical changes and pattern of inheritance 
(Table I.2) (Albanese et al., 2013).    
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Table I.2. Classification of dystonia (adapted from Albanese et al., 2013). 
Axis I. Clinical characteristics  Axis II. Etiology 
 Clinical characteristics of dystonia   Nervous system pathology 
Age of onset 
Infancy (birth to 2 years)  
Childhood (3-12 years)  
Adolescence (13-20 years)  
Early adulthood (21-40 years)  
Late adulthood (>40 years) 
Evidence of degeneration 
Evidence of structural (often static) 
lesions 
No evidence of degeneration or structural 
lesion 
 Inherited or acquired 
Body distribution 
Focal  
Segmental 
Multifocal 
Generalized 
Hemidystonia 
Inherited 
Autosomal dominant 
Autosomal recessive 
X-linked recessive 
Mitochondrial 
Acquired  
Perinatal brain injury 
 Infection 
 Drug 
Toxic 
Vascular 
Neoplastic 
 Brain injury 
Psychogenic 
 Temporal pattern 
 Disease course 
Static 
Progressive 
 Variability 
Persistent  
Action-specific 
Diurnal  
Paroxysmal Idiopathic 
Sporadic 
Familial   
 Associated features 
Isolated dystonia  
Combined dystonia with another movement 
disorder 
Occurrence of other neurological or systemic 
manifestations 
 
 
 
Most cases of dystonia have revealed an abnormal simultaneous contraction of 
agonist and antagonist muscles at rest that is often exacerbated by movement, which is 
believed to reflect a dysfunction in the central nervous system regions controlling 
movement (Farmer et al., 1998). It is believed that this dysfunction may result from an 
imbalance in neurotransmission, particularly in the basal ganglia, sensorimotor cortex, 
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brainstem and cerebellum. Several studies have linked dystonia to abnormal 
neurotransmitter communication involving striatal dopaminergic and cholinergic 
systems and loss of GABA-mediate inhibition. Despite that multiple neurotransmitter 
systems may contribute to dystonia pathogenesis, the most extensively studied to date is 
dopamine. Indeed, some types of dystonia have been related to a dysfunction in 
dopamine signaling. For example, dopa-responsive dystonia (DYT5 dystonia) can be 
caused by mutations in GTP cyclohydrolase I or tyrosine hydroxylase that result in the 
impairment of dopamine synthesis. Dystonic symptoms in these patients can be 
effectively treated with administration of the dopamine precursor L-DOPA. DYT11 
myoclonus-dystonia is attributed to deficits in the epsilon-sarcoglycan protein, which is 
highly expressed in dopamine neurons (reviewed in Breakefield et al., 2008; Tanabe et 
al., 2009). A mouse model of DYT11 revealed high levels of striatal dopamine and its 
metabolites (Yokoi et al., 2006). X-linked recessive dystonia-parkinsonism (DYT3 
dystonia) seems to be caused by mutations in the transcription factor TATA-box 
binding protein associated factor 1 (TAF1) that leads to reduced expression of TAF1 
and D2 receptor in the caudate nucleus (Makino et al., 2007). DYT1 dystonia has also 
been related with dopaminergic dysfunction and this will be discussed in detail latter. In 
addition to these inherited syndromes, dystonia can also occur in the context of other 
dopamine-related diseases or treatments. Thus, dystonia is frequently a feature of 
Parkinsonism and can appear after Parkinsonian therapy. Moreover, imaging studies 
detected dopamine-related abnormalities in patients with different forms of dystonia 
(reviewed in Wichmann, 2008). 
 
 
I.4.1. Early-onset generalized isolated dystonia 
 
Early-onset dystonia arising in childhood is a progressive disorder that often 
begins in a limb and progresses to generalized dystonia, thus involving other limbs and 
trunk. Generalized dystonia is less common than focal dystonia (normally arising in 
adulthood) and most cases have a genetic origin (reviewed in Ozelius and Bressman, 
2011; Phukan et al., 2011; Standaert, 2011). Several genes have been mapped for 
dystonia. However dystonia associated with the DYT1 gene encoding torsinA protein is 
the best characterized and studied etiology. DYT1 dystonia (also named Opphenheim 
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dystonia) is an autosomal dominant trait with penetrance of around 30% and it is caused 
by a 3 bp (GAG) deletion in the coding region of the DYT1 (TOR1A) gene. This 
deletion results in the loss of a single glutamic acid in the C-terminal of the torsinA 
protein (Ozelius et al., 1997). This mutation in the DYT1 gene is the commonest cause 
of early-onset isolated dystonia and is about five times more frequent in Ashkenazi Jews 
compared to non-Ashkenazi. This difference in disease frequency is thought to result 
from a founder mutation in DYT1 that was introduced into the Ashkenazi population 
(Valente et al., 1998). Three other variations in torsinA have been found but none has 
been unequivocally associated with disease: a 18 bp deletion that causes loss of residues 
323-328 (Leung et al., 2001), a 4 bp deletion that causes a truncation starting at residue 
312 (Kabakci et al., 2004) and a polymorphism that replaces aspartic acid at residue 216 
with histidine in 12% of normal alleles (Kock et al., 2006; Ozelius et al., 1997). 
Typically, DYT1 dystonia appears in childhood or adolescence (onset 9-15 years). 
Initially, it affects one limb and then spreads to involve other body regions and 
represents the most severe form of dystonia. Although it is not degenerative, it is 
chronic and the treatment is purely symptomatic and sometimes not effective. Current 
treatments for dystonia include anticholinergic drugs, botulinum toxin injections and 
surgical interventions as pallidal deep brain stimulation (reviewed in Jankovic, 2013). 
 
 
I.4.1.1. DYT1 dystonia pathology 
 
Early studies on brains from patients with dystonia revealed no consistent 
neuropathological abnormalities. The lack of neurodegeneration and neuropathological 
specific features has been used to distinguish isolated dystonia from other etiologies. 
The identification of dystonia genes (DYT) allowed for the identification of specific 
genetic cases. After defining torsinA as the DYT1 protein, localization studies showed 
that torsinA is highly expressed in dopaminergic neurons of the substantia nigra pars 
compacta (Augood et al., 1999; Augood et al., 1998). This leads to the assumption that 
torsinA may be involved in dopaminergic signaling and DYT1 dystonia may be linked 
with dopaminergic dysfunction. Neurochemical analysis of the few available post-
mortem brains of DYT1 dystonia patients did not clearly detect pathological lesions in 
dopaminergic neurons in the substantia nigra or other brain regions. However, animal 
and imaging studies identified structural alterations, especially involving the basal 
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ganglia and cerebello-thalamo-cortical tracts (reviewed in Bragg et al., 2011; Bressman 
and Saunders-Pullman, 2013).  
 
 
I.4.1.1.1. Human DYT1 dystonia studies 
 
A study of the brain from a patient with DYT1 dystonia showed that nigral 
cellularity was normal but in the putamen and caudate nucleus the striatal dopamine and 
homovanilic acid (HVA) levels was slightly decreased compared to controls (Furukawa 
et al., 2000). Another post-mortem study involving four DYT1-positive brains reported 
an increase of the striatal 3-,4-dihydroxyphenylacetic acid (DOPAC)/dopamine ratio in 
the striatum compared to controls, suggesting an increased dopamine turnover (Augood 
et al., 2002). Moreover, a reduction in D1 and D2 receptor binding and consequent 
hyperactivity of striatal cholinergic interneurons was also reported (Asanuma et al., 
2005; Augood et al., 2002). Despite the absence of neuronal loss, Rostasy el al found 
that, in DYT1-postive brains, neurons in the substantia nigra pars compacta appear to be 
larger and more densely packed when compared to controls (Rostasy et al., 2003). A 
further study examining four DYT1-postive brains found perinuclear inclusion bodies in 
the midbrain reticular formation and periaqueductal gray. The inclusions were located 
within cholinergic and other neurons and stained for ubiquitin, torsinA and lamin A/C. 
Additionally, it was also reported the presence of ubiquitin immunoreactive aggregates 
in pigmented neurons of the substantia nigra pars compacta and locus coeruleus in all 
four DYT1 dystonia cases, but not in controls (McNaught et al., 2004). Further, imaging 
studies showed a significant reduction in D2 receptor availability (Carbon et al., 2009) 
in the striatum of DYT1 mutation carriers compared to controls. Of note, dysfunction of 
GABAA receptor in the sensorimotor system of DYT1 mutation carriers is evident. 
Specifically, DYT1 patients showed a reduction of GABAA receptor expression/affinity 
(Garibotto et al., 2011). Carriers of the DYT1 mutation also showed abnormal motor 
learning in testing paradigms, correlated with abnormal brain activity (Ghilardi et al., 
2003).  
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I.4.1.1.2. Rodent models of DYT1 dystonia 
 
Given the few available human postmortem samples, the investigation using 
animal models could potentially help to elucidate DYT1 dystonia neuropathology and 
the underlying structural changes. Thus, several genetically-modified mouse models 
(Table I.3) have been developed for studying DYT1 dystonia pathogenesis. However, 
none of these models show clear dystonic movements, the different transgenic lines 
showed some histological abnormalities and behavioral and motor defects. Furthermore, 
these changes were not consistent among the different studies and DYT1 mouse models 
used. Histological changes were observed in torsinA knockout and ΔE-torsinA knock-in 
homozygous mice. These animals showed severe abnormalities of the NE ultrastructure 
in the CNS, including formation of vesicles and herniations in the perinuclear space 
(Goodchild et al., 2005; Kim et al., 2010a). Moreover, the mice died within 48 hours of 
birth. A DYT1 transgenic rat model also demonstrated a severally altered NE 
ultrastructure with an irregular perinuclear space (Grundmann et al., 2012). Other 
studies reported the presence of perinuclear inclusions that stained positively for 
torsinA, lamins and ubiquitin in different brain areas of DYT1 mouse models (Dang et 
al., 2005; Grundmann et al., 2007; Shashidharan et al., 2005). Recently, some studies 
have reported structural changes in neurons of ΔE-torsinA knock-in mouse models. 
These changes include reduction of the length of dendrites and number of spines among 
cerebellar Purkinje neurons (Zhang et al., 2011) and striatal medium spiny neurons 
(Song et al., 2013); fewer substantia nigra neurons immunopositive for tyrosine 
hydroxylase (Song et al., 2012); reduction in the ratio of axo-spinous to axo-dendritic 
synaptic inputs from glutamatergic and dopaminergic sources and enlarged interneurons 
immunoreactive for cholineacetyltransferase or parvalbumin (Song et al., 2013). 
Further, neurochemical abnormalities, particularly regarding dopamine function, have 
been described. Data from ΔE-torsinA-overexpressing and torsinA knock-down mice, 
showed altered levels of dopamine or its metabolites, including DOPAC and HVA 
(Dang et al., 2005; Dang et al., 2006; Shashidharan et al., 2005; Song et al., 2012; Zhao 
et al., 2008a). It was also reported that dopamine release is impaired in ΔE-torsinA-
overexpressing mice (Balcioglu et al., 2007; Bao et al., 2010; Page et al., 2010). 
Additionally, a study showed that the DAT activity is reduced in the presence of ΔE-
torsinA. Further, postsynaptic defects in DYT1 mouse models have been described. 
Specifically, these animals exhibited decreased D2 receptor activity and lower D2 
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protein levels compared to the controls (Dang et al., 2012; Giannakopoulou et al., 2010; 
Napolitano et al., 2010; Yokoi et al., 2011). Moreover, it seems that D2 receptor 
impairment can lead to abnormal cholinergic (Pisani et al., 2006) and GABAergic 
signaling (Sciamanna et al., 2009). Furthermore, in ΔE-torsinA knock-in mice, thalamic 
stimulation caused a shortened pause response and triggered an abnormal activity of 
cholinergic interneurons. The abnormal cholinergic signaling affects the integration 
between corticostriatal and thalamostriatal inputs (Sciamanna et al., 2012b). Another 
study, reported microstructural abnormalities in the cerebellothalamocortical pathway in 
ΔE-torsinA knock-in mice using imaging techniques (Ulug et al., 2011). Finally, using 
electrophysiological techniques, deficits in LTD and synaptic depotentiation in DYT1 
mouse models were reported (Dang et al., 2012; Martella et al., 2009). 
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Table I.3. Rodent models of DYT1 dystonia. 
Model Neuronal phenotype 
Neurochemistry and 
electrophysiology 
References 
TorsinA KO 
ΔE-torsinA KI 
NE abnormalities, 
inclusions in the PNS 
 
(Goodchild et 
al., 2005) 
ΔE-torsinA 
overexpression 
1 
Perinuclear ubiquitin and 
torsinA positive inclusions 
↓ striatal DA 
↓ striatal DOPAC/DA 
(Shashidharan 
et al., 2005) 
ΔE-torsinA KI 
Perinuclear ubiquitin and 
torsinA positive inclusions 
↓ striatal HVA 
(Dang et al., 
2005) 
TorsinA KD  ↓ striatal DOPAC 
(Dang et al., 
2006) 
ΔE-torsinA 
overexpression 
2 
 
Abnormal cholinergic response 
to D2 activation 
(Pisani et al., 
2006) 
ΔE-torsinA 
overexpression
2 
 
↓ DA (upon amphetamine) 
Normal DA, DAT, VMAT2, D1 
and D2  
(Balcioglu et 
al., 2007) 
Wt-torsinA 
overexpression
3 
Striatum and brainstem NE 
abnormalities, brainstem 
Perinuclear inclusions 
positive for torsinA, 
ubiquitin and lamin A/C 
↓ striatal DA, serotonin, 5-HIAA 
↓ brainstem HVA  
(Grundmann et 
al., 2007) ΔE-torsinA 
overexpression
3 
↑ brainstem DOPAC, serotonin, 
5-HIAA 
Normal in striatum 
ΔE-torsinA 
overexpression
2 
 ↑ striatal DOPAC/DA, HVA/DA 
(Zhao et al., 
2008a) 
ΔE-torsinA 
overexpression
2 
 
↑ AChe activity 
↓ LTD 
(Martella et al., 
2009) 
ΔE-torsinA 
overexpression
2 
 
↑striatal GABA activity 
(impairment of D2 receptor) 
(Sciamanna et 
al., 2009) 
ΔE-torsinA 
overexpression 
4 
 
↓ striatal DA release (after 
cocaine) (Page et al., 
2010) wt-torsinA 
overexpression
4 
↓ striatal DA, DOPAC 
ΔE-torsinA 
overexpression
1  
 ↓ striatal DA release 
(Bao et al., 
2010) 
ΔE-torsinA 
overexpression
2 
 ↓ DAT function 
(Hewett et al., 
2010) 
ΔE-torsinA 
overexpression
1 
 
↓ SNpc D2 mRNA  
↓ striatal D2 density and binding 
(Giannakopoulo
u et al., 2010) 
ΔE-torsinA 
overexpression
2 
 
↓ striatal D2 protein 
↓ Go/i proteins activation by D2 
(Napolitano et 
al., 2010) 
CHAPTER I - INTRODUCTION 
 
 
Characterization of novel LAP1 complexes and their relevance in DYT1 dystonia  75 
 
Model Neuronal phenotype 
Neurochemistry and 
electrophysiology 
References 
ΔE-torsinA KI 
↓ Length and spines number 
of Purkinje cells dendrites  
 
(Zhang et al., 
2011) 
Purkinje cells-
specific torsinA 
KO 
Striatum-specific 
torsinA KO 
Normal NE in striatal MSN ↓ striatal D2 binding 
(Yokoi et al., 
2011) 
ΔE-torsinA KI  
Microstructural abnormalities in 
cerebellothalamocortical 
pathway 
(Ulug et al., 
2011) 
ΔE-torsinA KI   
↓ D2 binding and D2 protein 
levels 
↓corticostriatal LTD 
(Dang et al., 
2012) 
Cholinergic-
specific torsinA 
KO 
 
Abnormal D2 response 
Altered M2/4 function 
(Sciamanna et 
al., 2012a) 
ΔE-torsinA KI  
↓ pause response by thalamic 
stimulation in ChIs 
(Sciamanna et 
al., 2012b) 
ΔE-torsinA KI 
↓ Number and ↑ size of TH 
positive nigral cells 
↓ midbrain DA 
↑ striatal HVA 
(age-dependent) 
(Song et al., 
2012) 
* ΔE-torsinA 
overexpression
4 
NE abnormalities, irregular 
PNS 
 
(Grundmann et 
al., 2012) 
ΔE-torsinA KI  
↑ Size of interneurons 
immunoreactive for ChAT 
and PV 
↓ Number of  MSN 
dendrites and spines  
 
(Song et al., 
2013) 
 
AChE, acetylcholinesterase; ChAT, choline acetyltransferase; ChIs, cholinergic interneurons; DA, 
dopamine; DAT, dopamine transporter; DOPAC, 3,4-dihydroxyphenylacetic  acid; D1, dopamine D1 
receptor; D2, dopamine D2 receptor; 5-HIAA,  5-hydroxyindoleacetic acid; HVA, Homovanillic acid; 
KD, Knockdown; KI, knock-in; KO, knockout; LTD, long-term depression; MSN, medium spiny 
neurons; NE, nuclear envelope; PNS, perinuclear space; PV, parvalbumin; SNpc, substantia nigra pars 
compacta; TH, tyrosine hydroxylase; VMAT2, vesicular monoamine transporter 2. 
1
Rat
 
neuron-specific 
enolase promoter. 
2
Human cytomegalovirus promoter. 
3
Murine prion protein promoter. 
4
Human TH 
promoter. 
4 
Human torsinA promoter. *Rat model. All the other are mouse models. 
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I.5. OBJECTIVES 
 
DYT1 dystonia is caused by a mutation in the DYT1 gene resulting in the loss of a 
single glutamic acid within torsinA protein (Ozelius et al., 1997). TorsinA resides in the 
ER and NE, but ΔE-torsinA is abnormally relocated to the nuclear envelope. LAP1 was 
found to recruit torsinA to the NE (Goodchild and Dauer, 2005). Previous work from 
our laboratory, using yeast two-hybrid (YTH) screens, resulted in the identification of 
several PP1 binding proteins (Esteves et al., 2012a; Esteves et al., 2012b). One of the 
novel PP1 regulators isolated was LAP1B, whose function is poorly understood. The 
identification of LAP1B as a novel PP1 binding protein opened new perspectives for the 
study of DYT1 dystonia, where protein phosphorylation might be a regulatory 
mechanism. Indeed, aberrant protein phosphorylation of key proteins has been linked to 
many diseases. Therefore, the aim of this thesis was to characterize the PP1/LAP1B and 
PP1/LAP1/torsinA complexes and unravel its potential physiological relevance to 
DYT1 dystonia. Additionally, we identified a novel human LAP1 isoform and provided 
new insights about the family of LAP1 proteins. Hence, the specific aims of this thesis 
were to: 
 
1. Characterize the interaction between LAP1B and PP1. 
 1.1. Determine the functional relevance of the LAP1B/PP1 complex. 
 
2. Validate the existence of new LAP1 isoforms in human cells. 
 2.1. Characterize the human LAP1 isoforms. 
2.2. Analyze the cell and tissue specific expression patterns of human LAP1 
isoforms. 
 
3. Determine the potential role of LAP1 in cell cycle-dependent nuclear dynamics. 
 
4. Test cellular models of DYT1 dystonia. 
 
5. Validate the interaction between LAP1, PP1 and torsinA proteins. 
 5.1. Determine if LAP1 and PP1 form a complex with both wt- and ΔE-torsinA. 
 5.2. Ascertain weither wt- and ΔE-torsinA are regulated by protein phosphorylation.  
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Previous work from our laboratory identified LAP1B as a putative PP1 interacting 
protein using yeast two-hybrid assays (Esteves et al., 2012a; Esteves et al., 2012b; 
Santos, 2009). Therefore the aim of work described in chapter II was to validate and 
characterize the interaction between LAP1B and PP1 and was included in the following 
research paper (manuscript 1): “The nuclear envelope protein, LAP1B, is a novel 
Protein Phosphatase 1 substrate”, PLoS One, 8(10), e76788. doi: 
10.1371/journal.pone.0076788. 
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 “The nuclear envelope protein, LAP1B, is a novel Protein Phosphatase 1 
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Mariana Santos
1
, Sandra Rebelo
1
, Paula J. M. Van Kleeff
2
, Connie E. Kim
3
, William T. 
Dauer
3
, Margarida Fardilha
2
, Odete A. da Cruz e Silva
1
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1 
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Abstract 
Protein phosphatase 1 (PP1) binding proteins are quintessential regulators, 
determining substrate specificity and defining subcellular localization and activity of the 
latter. Here, we describe a novel PP1 binding protein, the nuclear membrane protein 
lamina associated polypeptide 1B (LAP1B), which interacts with the DYT1 dystonia 
protein torsinA. The PP1 binding domain in LAP1B was here identified as the REVRF 
motif at amino acids 55-59. The LAP1B:PP1 complex can be immunoprecipitated from 
cells in culture and rat cortex and the complex was further validated by yeast co-
transformations and blot overlay assays. PP1, which is enriched in the nucleus, binds to 
the N-terminal nuclear domain of LAP1B, as shown by immunocolocalization and 
domain specific binding studies. PP1 dephosphorylates LAP1B, confirming the 
physiological relevance of this interaction. These findings place PP1 at a key position to 
participate in the pathogenesis of DYT1 dystonia and related nuclear envelope-based 
diseases.   
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II.1. INTRODUCTION 
 
Reversible protein phosphorylation is a major mechanism controlling key 
intracellular events that are essential for cell health and viability (Cohen, 1989; da Cruz 
e Silva et al., 2004; Fardilha et al., 2010). Protein phosphatase 1 (PP1) is a ubiquitous 
serine/threonine phosphatase that is estimated to dephosphorylate about one third of all 
proteins in eukaryotic cells (Ceulemans and Bollen, 2004; Cohen, 2002b). PP1 regulates 
a variety of cellular functions, such as glycogen metabolism, transcription, protein 
synthesis, cellular division and meiosis (Bollen, 2001; Ceulemans et al., 2002a; Cohen, 
2002b). In mammalian cells, three genes encode the three PP1 isoforms: PP1alpha 
(PP1α), PP1Beta/Delta (PP1β/δ) and PP1gamma (PP1γ). Furthermore, the PP1γ gene 
undergoes alternative splicing to originate a ubiquitous PP1γ1 variant and a PP1γ2 
variant that is enriched in testis (da Cruz e Silva et al., 1995b; Sasaki et al., 1990). PP1 
isoforms are expressed in virtually all tissues but exhibit different expression levels 
depending on the tissue, and different subcellular distribution (Andreassen et al., 1998; 
Bordelon et al., 2005; da Cruz e Silva et al., 1995b). The versatility of PP1 is largely 
determined by the binding of its catalytic subunit to different specific regulatory 
subunits, that are responsible for the directed targeting of PP1 to a particular subcellular 
compartment and also determine its substrate specificity and activity (Bollen, 2001; 
Bollen et al., 2010; Ceulemans et al., 2002a; Cohen, 2002b). More than 200 
binding/regulatory subunits have been already described, making PP1 an essential 
protein in many distinct cellular processes (Fardilha et al., 2010; Fardilha et al., 2011). 
Most PP1 binding proteins interact with the PP1 catalytic subunit through a conserved 
PP1 binding motif termed the RVxF motif, which has the consensus sequence [R/K] 
XA(0-1) [V/I] XB [F/W], where XA is any amino acid and XB is any amino acid except 
proline (Wakula et al., 2003). More recently, other consensus sequence have been 
proposed for the RVxF motif: [HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-[FW] 
(Meiselbach et al., 2006) and [KRL] [KRSTAMVHNQ][VI]{FIMYDP}[FW] 
(Hendrickx et al., 2009). The binding of PP1 to regulatory proteins through the RVxF 
motif does not cause major effects on the conformation and activity of PP1, but 
mediates the initial anchoring of regulatory subunits and thereby promotes the 
interaction at secondary binding sites (Bollen, 2001; Egloff et al., 1997; Hendrickx et 
al., 2009). Subsequently other PP1 binding motifs have also been reported, such as the 
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apoptotic signature F-X-X-[KR]-X-[KR] (Ayllon et al., 2002), the SILK and the 
MyPhoNE motifs (Hendrickx et al., 2009). The existence of these conserved binding 
sites within regulatory subunits explains the ability of PP1 catalytic subunit to interact 
with numerous regulatory proteins and consequently the binding of most regulatory 
subunits is mutually exclusive (Bollen, 2001). Since the regulatory subunits control the 
specificity and the diversity of PP1 activity, the key to understanding PP1 function lies 
in studying these regulatory subunits and their cellular functions. Several yeast two-
hybrid (YTH) screens of a human brain cDNA library were performed using the three 
PP1 isoforms (PP1α, PP1γ1 and PP1γ2) as baits. From each screen many positive 
clones were identified encoding several different proteins. Among them, were proteins 
already known as PP1 regulators and also novel putative PP1 regulators (Esteves et al., 
2012a; Esteves et al., 2012b). The majority of the novel putative PP1 regulators 
comprise at least one of the conserved PP1 binding motifs. One of the novel PP1 
regulators isolated in the three independent YTH screens was torsinA interacting protein 
1 (TOR1AIP1) or lamina associated polypeptide 1B (LAP1B). LAP1B belongs to a 
family of integral proteins of the inner nuclear membrane, named lamina associated 
polypeptide 1 (LAP1). Members of the LAP1 family (LAP1A, B and C) were initially 
identified using monoclonal antibodies generated against lamina-enriched fractions of 
rat liver nuclei (Senior and Gerace, 1988). The three LAP1 isoforms result from 
alternative splicing of the TOR1AIP1 gene (Martin et al., 1995) and have been poorly 
studied. Moreover, the cDNA for LAP1B isoform was, to date, the only human isoform 
completely sequenced (Kondo et al., 2002). The function of LAP1B is poorly 
understood but it is known that it binds to lamins and chromosomes and that it is 
phosphorylated during interphase and mitosis (Foisner and Gerace, 1993). As indicated 
by the nomenclature, LAP1 was found to interact with torsinA (Goodchild and Dauer, 
2005; Naismith et al., 2009b), the central protein of a neurologic disorder known as 
DYT1 dystonia (Ozelius et al., 1997). However, the physiological relevance of this 
novel complex has not yet been determined. In the present study we validated the novel 
complex LAP1B:PP1 using several in vitro and in vivo techniques, namely a blot 
overlay assay, co-immunoprecipitation and yeast co-transformation. Furthermore, the 
PP1 binding motif responsible for the interaction was mapped. The functional relevance 
of this complex was pursued and we determined that LAP1B is dephosphorylated by 
PP1 in vitro. 
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II.2. MATERIALS AND METHODS 
 
II.2.1. Antibodies 
 
The primary antibodies used were rabbit polyclonal LAP1 (Goodchild and Dauer, 
2005); rabbit polyclonal CBC2C and CBC3C, that recognizes the C-terminal of PP1α 
and PP1γ, respectively (da Cruz e Silva et al., 1995b); rabbit polyclonal lamin B1 (Santa 
Cruz Biotechnology); 6xHis-tag antibody (Novagen), that recognizes 6xHis-tag-
proteins; and Myc-tag antibody (Cell Signaling), that recognizes Myc-fusion proteins. 
The secondary antibodies used were anti-mouse and anti-rabbit horseradish peroxidase-
linked antibodies (GE Healthcare) for ECL detection, and FITC-conjugated anti-mouse 
IgG (Molecular Probes) and Alexa 594-conjugated anti-rabbit IgG (Molecular Probes) 
for co-localization studies.  
 
II.2.2. Expression vectors and DNA constructs 
 
For yeast co-transformation assays, PP1α, PP1γ1, PP1γ2 and the specific C-
terminal of PP1γ2 (PP1γ2End) cDNAs were cloned into the pAS2-1 (Clontech), in 
frame with the GAL4-binding domain, as described in Esteves et al, 2012 (Esteves et 
al., 2012a; Esteves et al., 2012b). pACT2-LAP1B (in frame with the GAL4 activation 
domain) was obtained from a human brain cDNA library (Clontech, HL4004AH) 
(Esteves et al., 2012a; Esteves et al., 2012b). LAP1B binding motif (BM) deletion 
mutants comprising amino acids 1-209 (LAP1B-BM1), 61-508 (LAP1B-BM2), 1-508 
(LAP1B-BM1/2) and 238-584 (LAP1B-BM3) were prepared by PCR amplification 
with appropriate primers (Table II.1). The amplified fragments were subcloned into the 
EcoRI/XhoI restriction sites of the pACT2 vector (Clontech). The same methodology 
was used to clone additional LAP1B deletion mutants comprising amino acids 1-338 
(LAP1B-BM1/2-TM), 1-369 (LAP1B-BM1/2+TM), 332-584 (LAP1B-BM3-TM) and 
365-584 (LAP1B-BM3+TM) into the pET-28c vector (Novagen). Full-length LAP1B 
and the mutants 1-209 (LAP1B-BM1) and 61-508 (LAP1B-BM2) in the pACT2 vector 
were subcloned into the pET-28c vector. Full-length LAP1B and LAP1B-BM2 and 
LAP1B-BM3 in the pACT2 vector were also subcloned into the mammalian expression 
vector pCMV-Myc (Clontech) to obtain a Myc-fusion protein. Additionally a LAP1B 
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(ΔA185) mutation was introduced into pET-LAP1B by site-directed mutagenesis using 
the primers described in Table II.1. The constructs were all verified by DNA sequencing 
using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Porto, Portugal).  
 
Table II.1. Oligonucleotides used to generate LAP1B deletion mutants by PCR. 
 Plasmid 
name 
Oligonucleotide sequence (5’ – 3’) 
FW RV 
pACT2 
vector 
constructs 
LAP1B-
BM1 
GGAATTCATATGGCGGGCG
ACGGG 
CCGCTCGAGTTAGACACTGGTGG
CTTC 
LAP1B-
BM2 
GGAATTCATATGGACGAGCC
GCCAGAA 
CCGCTCGAGTTAGGCTACATCTT
TGAAGGC 
LAP1B-
BM1/2 
GGAATTCATATGGCGGGCG
ACGGG 
CCGCTCGAGTTAGACACTGGTGG
CTTC 
LAP1B-
BM3 
GGAATTCATATGGCCAGATC
CAGGGAT 
CCTCGAGTTATAAGCAGATGCCC
CT 
 
pET-28c 
vector 
constructs 
LAP1B-
BM1/2+TM 
GGAATTCATATGGCGGGCG
ACGGG 
CCTCGAGTTAGAACTCTTGAACA
G 
LAP1B-
BM1/2-TM 
GGAATTCATATGGCGGGCG
ACGGG 
CCTCGAGTTACCGGTTCCTCTTG
AC 
LAP1B-
BM3+TM 
GGAATTCATATGGTCAAGAG
GACGG 
CCTCGAGTTATAAGCAGATGCCC
CT 
LAP1B-
BM3-TM 
GGAATTCATATGGCTGTTCA
AGTTC 
CCTCGAGTTATAAGCAGATGCCC
CT 
LAP1B 
(ΔA185) 
CATACAAGAGGCTCCAGTG
AGTGAAGATCTTG 
CAAGATCTTCACTCACTGGAGCC
TCTTGTATG 
 
 
II.2.3. Yeast co-transformation analysis 
 
Each of the bait plasmids (pAS2-1-PP1α, pAS2-1-PP1γ1, pAS2-1-PP1γ2 or 
pAS2-1-PP1γ2end) was co-transformed with one of the specific target proteins; pACT-
LAP1B or its deletions mutants (pACT-BM1, pACT-BM2, pACT-BM1/2 and pACT-
BM3), into the yeast strain AH109 by the lithium acetate method (according to the 
manufacturer’s instructions, Clontech). In parallel, co-transformations of the vectors 
pAS2-1 and pACT2 were performed as a negative control. The association of murine 
p53 (encoded by plasmid pVA3-1) and SV40 large T antigen (plasmid pTD1) was used 
as a positive control. The transformants were assayed for HIS3, ADE2 and MEL1 
reporter genes. All positive clones were replated in SD/QDO medium containing X-α-
Gal and incubated at 30ºC for 2-4 days.  
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II.2.4. Expression of recombinant proteins in Escherichia coli   
 
Escherichia coli Rosetta cells (DE3) were transformed with one of the pET-
LAP1B constructs and grown overnight in 5 mL of Luria-Bertani/Kanamycin medium 
at 37ºC. Aliquots (500 μL) were transferred to 50 ml of Luria-Bertanini/Kanamycin 
until the OD600 was around 0.5-0.6. Expression was induced by adding 1 mM isopropyl-
β-D-thiogalactopyranoside (IPTG) to the culture at 37˚C for different periods of time (1, 
3 and 5 hours) with shaking. Cells were recovered by centrifugation (4000 rpm for 10 
min), resuspended in 500 μL of 1x PBS and lysed by sonication. Cells were then 
centrifuged (13200 rpm for 30 min), the supernatant was transferred to a new microtube 
(soluble fraction) and the pellet resuspended in 500 μL of boiling 1% SDS (insoluble 
fraction). 
 
II.2.5. Blot overlay assays 
II.2.5.1. LAP1B deletion mutants 
 
Bacterial extracts, prepared as described above, were separated on a 10% SDS-
PAGE and the proteins were subsequently transferred to a nitrocellulose membrane. The 
membrane was overlaid with 1 μg/mL of purified recombinant PP1γ1 protein 
(Watanabe et al., 2003). After washing to remove excess protein, bound PP1γ1 was 
detected by incubating the membrane with PP1γ antibody and developed by enhanced 
chemiluminescence (ECL, GE Healthcare). 
 
II.2.5.2. LAP1B isoforms 
 
LAP1B and LAP1B (ΔA185) proteins were generated by in vitro transcription/ 
translation (IVT) from pET-LAP1B and pET-LAP1B(ΔA185) expression vectors, 
respectively, using the TnT-coupled transcription/translation kit (Promega), according 
to the manufactures’ instructions. For the overlay assays, two samples of 250 ng of 
purified recombinant PP11 protein (Watanabe et al., 2003) were separated on a 12% 
SDS-PAGE. Both proteins were transferred to a nitrocellulose membrane but one was 
overlaid with LAP1B-IVT, while the other was overlaid with LAP1B (ΔA185)-IVT. 
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The bound proteins were detected by incubating the membrane with LAP1 antibody and 
developed by ECL. 
 
II.2.6. Cell culture and transfection 
 
COS-7 (ATCC CRL-1651) and HEK293 (ATCC CRL-1573) cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin and 3.7 g/l NaHCO3 
(Complete DMEM). SH-SY5Y cells (ATCC CRL-2266) were grown in Minimal 
Essential Medium (MEM) supplemented with F-12 Nutrient Mixture (Gibco, 
Invitrogen), 10% FBS (Gibco, Invitrogen), 1.5 mM L-glutamine, 100 U/mL penicillin 
and 100 mg/mL streptomycin (Gibco, Invitrogen). HeLa cells (ATTC CRM-CCL-2) 
were grown in Minimal Essential Medium (MEM) with Earle's salts and GlutaMAX 
(MEM), supplemented with 10% fetal bovine serum, 1% MEM Non-Essential amino 
acids and 100 U/mL penicillin and 100 mg/mL streptomycin. All cultures were 
maintained at 37ºC and 5% CO2. Transient transfections of COS-7 and HeLa cells were 
performed using LipofectAMINE 2000 (Invitrogen Life technologies). After 24 hours 
of transfection, cells were harvested for subsequent immunoprecipitation (IP) 
experiments or were fixed, using 4% paraformaldehyde, for immunocytochemical 
analysis. 
 
II.2.7. Brain dissection 
 
Winstar rats (9-12 weeks) were obtained from Harlan Interfaune Ibérica, SL. All 
experimental procedures observed the European legislation for animal experimentation 
(2010/63/EU). No specific ethics approval under EU guidelines was required for this 
project, since the rats were only euthanized, by cervical stretching followed by 
decapitation, for brain removal. This is within the European law (Council Directive 
86/609/EEC) and during this procedure we took all steps to ameliorate animal suffering 
and used the minimum number of animals possible. The procedures were approved and 
supervised by our Institutional Animal Care and Use Committee (IACUC): Comissão 
Responsável pela Experimentação e Bem-Estar Animal (CREBEA). 
Briefly, animals were euthanized by cervical stretching followed by decapitation 
and the cortex was dissected out on ice. The tissue was then homogenized on ice, in 
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non-denaturing lysis buffer (50 mM Tris-HCl pH 8.0, 120 mM NaCl, 4% CHAPS) 
containing protease inhibitors (1 mM PMSF, 10 mM Benzamidine, 2 µM Leupeptin, 1.5 
µM Aprotinin, 5 µM Pepstatin A), with a Potter-Elvehjem tissue homogenizer with 10-
15 pulses at 650-750 rpm (Rebelo et al., 2013). Resulting tissue extracts were used for 
IP analysis using Dynabeads Protein G (Dynal, Invitrogen) as described below. 
 
II.2.8. Co-immunoprecipitation 
 
COS-7 cells transfected with Myc-LAP1B were collected in lysis buffer (50 mM 
Tris-HCl pH 8, 120 mM NaCl, 4% CHAPS) containing protease inhibitors (1 mM 
PMSF, 10 mM Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin, 5 µM Pepstatin A). 
Dynabeads Protein G (Dynal, Invitrogen) were washed in 3% BSA/1x PBS. Primary 
antibodies were cross-linked to Dynabeads according to the manufacter’s protocol. Cell 
lysates were precleared with 20 µL (0.6 mg) Dynabeads for 1 hour and then incubated 
with antibody-dynabeads for 2h at 4ºC. The immunoprecipitates were washed in 1x 
PBS and proteins eluted by boiling in loading buffer before SDS-PAGE and 
immunoblotting analysis. For analysis of endogenous proteins, COS-7 cells and SH-
SY5Y cells were collected in lysis buffer and immunoprecipitated as described above, 
but cell lysates were incubated with antibody-dynabeads overnight at 4ºC. HEK293 
immunoprecipitation was carried out as previously described (Kim et al., 2010a) 
 
II.2.9. Immunocytochemistry 
 
Once fixed as described above, HeLa cells were permeabilized with methanol for 
2 min. Cells were first incubated with one of the primary antibodies (anti-PP1γ or PP1α) 
for 2 hours, followed by Alexa 594-conjugated secondary antibody. After washing with 
1x PBS, cells were subsequently incubated with a second primary antibody (anti-myc) 
for 2 hours, followed by anti-mouse fluorescein isothiocyanate (FITC) conjugated 
secondary antibody. Preparations were washed with PBS, mounted using Vectashield 
mounting media with DAPI (Vector) and visualized using an LSM510-Meta confocal 
microscope (Zeiss) and a 63x/1.4 oil immersion objective. The argon laser lines of 405 
nm, 488 nm, and a 561nm DPSS laser were used. Microphotographs were acquired in a 
sole section in the Z-axis (xy mode) and represent a mean of 16 scans. Profiles were 
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acquired using the Zeiss LSM 510 4.0 software as previously described (Rebelo et al., 
2013; Vieira et al., 2010). 
 
II.2.10. In vitro dephosphorylation of LAP1B 
 
SH-SY5Y cells were treated with 0.25 nM or 500 nM okadaic acid (OA) for 3 
hours. Then, cells were collected in lysis buffer (50 mM Tris-HCl pH 8, 120 mM NaCl, 
4% CHAPS, 250 mM EDTA, 1 mM sodium orthovanadate, 5 mM sodium fluoride) 
containing protease inhibitors (1 mM PMSF, 10 mM Benzamidine, 2 µM Leupeptin, 1.5 
µM Aprotinin, 5 µM Pepstatin A) and immunoprecipitated with LAP1 antibody, as 
described above. Immunoprecipitates were incubated at 30ºC for 1 hour with or without 
100 ng of purified PP1γ1 protein in PP1 buffer (50 mM Tris-HCl ph 7.5, 0.1 mM 
EGTA, 1 mM MnCl2, 5 mM DTT). Samples were further analyzed by 7.5 % SDS-
PAGE followed by immunoblotting. 
 
II.2.11. SDS-PAGE and Immunobloting 
 
Samples were separated on SDS-PAGE and electrophoretically transferred onto 
nitrocellulose, followed by immunological detection with specific antibodies as 
indicated. Membranes were saturated in 5% non-fat dry milk in TBS-T for 3 hours and 
further incubated with primary antibodies. The incubations with the CBC2C, CBC3C 
and LAP1 antibodies were performed overnight. The incubations with the His-tag and 
Myc-tag antibodies were carried out for 2 hours. Detection was achieved using 
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgGs as secondary 
antibodies and proteins visualized by ECL (GE Healthcare). 
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II.3. RESULTS 
 
II.3.1. Identification of LAP1B as a novel putative PP1 regulatory protein  
 
In order to identify novel potential PP1 regulatory proteins, the three PP1 
isoforms (PP1α, PP1γ1 and PP1γ2) were used as baits to screen a human brain cDNA 
library by the YTH system. From these screens 298, 241 and 228 positive clones were 
identified using PP1α, PP1γ1 and PP1γ2 as baits, respectively (Esteves et al., 2012a; 
Esteves et al., 2012b). Detailed analysis revealed 14, 4 and 2 positive clones, encoding a 
potentially novel PP1 regulatory protein - LAP1B, for the PP1α, PP1γ1 and PP1γ2 
screens, respectively (Table II.2) (Santos, 2009). Sequencing of the identified clones 
determined that all correspond to the LAP1B variant 1, recently reported in the 
GenBank database (NM_001267578.1). The variant 1 differs from the variant 2 
(NM_015602) only by a CAG insertion, which results in an additional alanine in the 
coding sequence, otherwise the sequence is identical to the first human LAP1B 
sequence reported in 2002 (Kondo et al., 2002). Moreover, others reports showed that 
TOR1AIP1 gene possesses a 3’ tandem splice site, TAGCAG, at the exon 3 boundary, 
which results in an amino acid insertion or deletion in the encoded protein (Tadokoro et 
al., 2005; Tsai et al., 2007). From all LAP1B clones obtained we selected a full-length 
clone (clone 135; Table II.2) for further studies. The latter comprises a short 5’ 
untranslated region followed by the ATG start codon, an open reading frame of 2000 
nucleotides, that encodes 584 amino acids, followed by a stop codon and a short 3’ 
untranslated region (Fig. II.1.A). LAP1B was previously described as a type 2 integral 
membrane protein, with an N-terminal nucleoplasmic domain, one predicted 
transmembrane domain (TM) and a C-terminal lumenal domain (Kondo et al., 2002). 
Our in silico analysis also revealed that LAP1B has three conserved PP1 binding motifs 
(BM): REVRF (amino acids 55-59), KVNF (amino acids 212-215) and KVKF (amino 
acids 538-541), that were called BM1, BM2 and BM3, respectively. BM1 and BM2 are 
localized in the nucleoplasm, while BM3 is localized in the lumen of the perinuclear 
space. Additionally, a second generic PP1 binding motif termed SILK (amino acids 
306-309) was also identified (Fig. II.1A). Further in silico characterization of these four 
potential PP1 binding motifs (BM1, BM2, BM3 and SILK) was achieved using the 
ClustalW algorithm, which allowed for the determination of the homology between 
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species (Fig. II.1B). Interestingly, the BM1 and BM3 are totally conserved motifs 
among the species analyzed (Human, Chimpanzee, Orangutan, Mouse, Rat). The other 
binding motifs (BM2 and SILK) are also completely conserved between Human, 
Chimpanzee and Orangutan but do deviate markedly in mouse and rat; with two 
residues common to all species in the SILK domain and only one residue is common to 
all species for the BM2 domain (Fig. II.1B). Subsequent to the in silico LAP1B 
characterization, the novel LAP1B:PP1 complex was validated in vitro and in vivo. 
 
Table II.2.  Summary of LAP1B clones isolated from the yeast-two hybrid (YTH) screens. 
Bait 
Nº of 
screened 
clones 
Nº of positive 
clones 
Nº of LAP1B 
clones 
YTH clone ID Insert (Kb) 
Start 
position 
PP1α 2 x 10
7
 298 14 
12 2.0 384 
31 1.75 382 
36 2.25 268 
45 2.15 382 
50 2.75 274 
61 3.85 265 
76 3.5 262 
96 2.2 383 
184 4.3 265 
192 3.75 274 
261 4.0 265 
262 2.1 382 
271 2.2 382 
273 3.75 365 
PP1γ1 1 x 10
6
 241 4 
120 2.4 261 
124 1.5 266 
135 2.0 382 
164 1.6 268 
PP1γ2 6.6 x 10
5
 228 2 
124 1.8 262 
164 0.3 270 
 
Clone 135 (interaction with PP1γ1) was selected for further study. The start position indicated is relative 
to the GenBank sequence NM_001267578. 
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Figure II.1. Human LAP1B sequence and domains. A- Nucleotide and corresponding amino acid 
sequence of human LAP1B encoded by clone 135. Stop and start codons are coloured blue. The three 
well conserved PP1 binding motifs (RVxF) are highlighted in red (positions 55-59, 212-215 and 538-541 
in aa sequence) and a second generic PP1 binding motif (SILK) is coloured green (position 306-309 in aa 
sequence). The transmembrane domain is highlighted in orange (position 339-361 in aa sequence). B- 
Schematic illustration of LAP1B domains. Sequence of human LAP1B was aligned against others species 
using ClustalW algorithm. Sequence conservation is indicated by asterisks (identical sequences), colons 
(conserved substitutions) and periods (semi-conserved substitutions). BM1, BM2 and BM3, RVxF-like 
PP1 binding motif 1, 2 and 3, respectively; INM, inner nuclear membrane; ONM, Outer nuclear 
membrane; SILK, a second generic PP1 binding motif; TM, transmembrane domain  
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II.3.2. LAP1B and PP1 interact in vitro 
 
The in vitro validation of this novel complex as well as the identification of the 
binding motif responsible for the interaction was accomplished using a blot overlay 
assay. Several deletion mutants were prepared as described above, each comprising at 
least one of the PP1 binding motifs as represented in Fig. II.2A. The importance of the 
TM was also addressed by evaluating the binding in the presence or absence of the latter 
(Fig. II.2A). Thus, both full-length LAP1B and the different deletion mutants were 
expressed in bacteria as 6xHis-tag fusion proteins by adding 1 mM IPTG to the growing 
cultures at 37ºC. All recombinant proteins (full-length and mutants) were efficiently 
expressed in bacteria, including the deletion mutants with or without the TM domain 
(data not shown). The proteins thus expressed were used to carry out the blot overlay 
assay. Briefly, the different recombinant proteins were separated by SDS-PAGE and 
electrotransferred onto nitrocellulose membranes. Recombinant protein detection was 
achieved with the His-tag antibody (Fig. II.2B) and for the overlay assay the purified 
PP1γ1 protein was applied (Fig. II.2C). The negative controls used included the pET-
28c vector without an insert or with a non-induced insert. As a positive control the 
pET28c-Nek2A was used, given that Nek2A is a well known protein that strongly 
interacts with PP1 (Fardilha et al., 2004). The immunoblotting using His-tag antibody 
(Fig. II.2B) of both full-length and deletion mutants revealed that all the expressed 
proteins have the expected molecular weight as indicated in Figure 2A. Additional 
bands were sometimes detected for LAP1B, LAP1B-BM1 and LAP1B-BM2, these 
could possibly correspond to proteolytic fragments (Fig. II.2B). The overlay assays 
revealed increased PP1γ1 binding concomitant with increasing amounts of recombinant 
full-length LAP1B (Fig. II.2C). Additionally, we also demonstrated that PP1γ1 binds to 
the deletion mutant that comprises the residues 1-209 encompassing the BM1, and also 
to the construct that comprises both BM1 and BM2 with or without the TM (Fig. II.2C). 
However, PP1γ1 does not bind to the recombinant protein comprising only the BM2 or 
the BM3 (Figure II.2C). Thus, using in vitro techniques we established that LAP1B 
binds to PP1γ1 through the BM1 (REVRF).  
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Figure II.2 . Blot overlay assay with PP1γ1. Immunoblotting analysis using a His-tag antibody is also 
shown. A-Schematic representation of LAP1B deletion mutants cloned into the pET-28c vector. The 
expected molecular weight (MW) of each construct is indicated. The red boxes represent the RVxF 
motifs, the green boxes correspond to the SILK motif, and the yellow boxes represent the transmembrane 
domain. B- Blot overlay assay of full-length LAP1B. Increasing amounts of recombinant full-length 
LAP1B (12, 24 and 48 μL) were loaded on each well as indicated. C- Blot overlay assay of LAP1B 
deletion mutants. Deletion mutants: 1, LAP1B–BM1; 2, LAP1B–BM2; 3, LAP1B–BM1/2+TM; 4, 
LAP1B–BM1/2-TM; 5, LAP1B-BM3+TM; 6, LAP1B-BM3-TM. Non-induced (NI) and pET-28c vector 
without an insert (pET) were used as negative controls and Nek2A (Nek) as positive control. Bacterial 
cultures were collected 3 hours after IPTG (1mM) induction at 37ºC. 
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II.3.3. The novel complex LAP1B:PP1 is also formed in vivo  
 
Having shown that the LAP1B:PP1 complex is formed in vitro the ability of the 
same to be formed in vivo was addressed. Yeast co-transformations were carried out in 
order to validate the novel complex formation and to simultaneously confirm relevant 
domains in LAP1B for the interaction, as well as to test different PP1 isoforms. Firstly, 
co-transformations were carried out with full-length LAP1B and different PP1 isoforms 
(α, γ1 or γ2), the assay took advantage of α-Galactosidase activity in the presence of the 
blue chromogenic substrate X-α-gal, producing a blue colour in the event of an 
interaction. The results (Fig. II.3) clearly show that LAP1B interacts with all PP1 
isoforms tested (PP1α, PP1γ1 and PP1γ2; Fig. II.3A) but does not interact with the C-
terminal portion of PP1γ2 isoform (PP1γ2end; Fig. II3A). Subsequently, the relevant 
domain in LAP1B for the interaction was again tested using the in vivo conditions. 
These LAP1B deletion mutants, previously produced, were co-transformed in yeast 
with the PP1γ1 isoform and the results are presented in Fig. II.3B. Unequivocally, the 
results were positive for the deletion mutant that comprises the residues 1-209 including 
the BM1 (Fig. II.3B) and also with the construct that comprises both BM1 and BM2 
(BM1/2). In sharp contrast the results were negative with the LAP1B-BM2 and LAP1B-
BM3 (Fig. II.3B). The positive and negative controls are presented in Fig. II.3C. These 
results show that it is the BM1 (REVRF) that mediates the interaction between LAP1B 
and PP1. 
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Figure II.3. Yeast co-transformation assay in SD/QDO/X-α-gal medium. Full-length LAP1B and its 
deletion mutants cloned in the pACT2 vector are represented. The red boxes represent the RVxF motifs 
present in the constructs, the green boxes correspond to the SILK motif, and the yellow boxes represent 
the transmembrane domain. A- Positive interactions were observed between LAP1B and PP1α, PP1γ1 
and PP1γ2, but not with the C-terminus of PP1γ2 (PP1γ2End). B- PP1γ1 interacted with LAP1B-BM1 
and BM1/2 but not with LAP1B-BM2 and BM3. C- Association of murine p53 and SV40 large T antigen 
was used as positive control (+) and co-transformation of pAS2-1 and pACT2 vectors as negative control 
(-).  
 
 
Additionally, the in vivo occurrence of the complex was further investigated and 
distinct models were used, namely a non-neuronal cell line (COS-7), a neuronal-like cell 
line (SH-SY5Y) and rat brain. Thus, co-IPs using the specific antibodies against PP1α, 
PP1γ and LAP1B were carried out. Firstly, COS-7 cells were transfected with Myc-
LAP1B and Myc-LAP1B deletion mutants (LAP1B-BM2 and LAP1B-BM3) and 
further immunoprecipitated using the PP1γ antibody (Fig. II.4A). The Myc-LAP1B 
deletion mutants are similar to those tested in yeast co-transformation assays. Our 
results showed that PP1γ binds only to the full-length LAP1B but not to LAP1B 
deletion mutants (LAP1B-BM2 and LAP1B-BM3). Once more our results clearly 
showed that PP1γ only binds LAP1B when the BM1 is present. Non-transfected COS-7 
(Fig. II.4B) and SH-SY5Y (Fig. II.4C) cellular extracts were also immunoprecipitated 
with PP1α and PP1γ antibodies. Rat cortical extracts were also immunoprecipitated with 
the same antibodies as well as with the LAP1 antibody and the results are presented in 
Fig. II.4D. Endogenous LAP1B was also detected after IP with PP1α and PP1γ in COS-
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7 cells (Fig. II.4B) and SH-SY5Y cells (Fig. II.4C). Finally, using rat cortical brain 
extracts we confirmed that the LAP1B:PP1 complex is also formed in brain, since we 
detected LAP1B after IP with PP1α or γ antibodies. Further, when we 
immunoprecipitated with LAP1 antibody we could also detect both PP1 isoforms (Fig. 
II.4D). The complex was also detected in other brain regions, namely rat striatum and 
cerebellum (data not shown) were PP1 is highly abundant. 
 
 
Figure II.4. Co-immunoprecipitation of the PP1:LAP1B complex in COS-7 cells, SH-SY5Y cells 
and rat cortex. A- COS-7 cells were transfected with Myc-LAP1B, Myc-LAP1B-BM2 or Myc-LAP1B-
BM3 and immunoprecipitated with PP1γ bound to protein G- DynaBeads. B- Non-transfected COS-7 
cells were immunoprecipitated with PP1γ or PP1α antibodies bound to protein G- Dynabeads. C- SH-
SY5Y cells were immunoprecipitated with PP1γ or PP1α antibodies bound to protein G- Dynabeads. D- 
Rat cortex extracts were immunoprecipitated with PP1γ, PP1α or LAP1 antibodies bound to protein G- 
Dynabeads.  The negative controls were performed by incubating cell extracts with beads. IP, 
immunoprecipitation. IB, immunoblotting. 
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II.3.4. Both LAP1B isoforms bind to PP1  
 
Thus far we have unequivocally shown that LAP1B is a novel PP1 regulatory 
protein and that the complex formed by the two proteins can occur both in vitro and in 
vivo. Given the high degree of similarity between both LAP1B variants and the fact that 
both comprise the BM1 (REVRF) responsible for the interaction, it is reasonable to 
deduce that both variants interact with PP1. In order to confirm this hypothesis we 
generated, by site directed mutagenesis, the LAP1B (ΔA185) construct that corresponds 
to LAP1B variant 2 reported in GenBank. The interaction of both LAP1B isoforms with 
PP1 was indeed confirmed by in vitro overlay assay. Briefly, 250 ng of recombinant 
purified PP1γ1 protein were separated by SDS-PAGE and electrotransferred to a 
nitrocelulose membrane that was subsequently overlaid with each of the LAP1B 
variants. As expected both LAP1B variants are able to interact with PP1γ1 since we can 
detect a band of approximately 37 kDa (Fig. II.5) that corresponds to the molecular 
weight of PP1γ1. 
 
 
Figure II.5. Blot overlay assay of LAP1B variants. Two samples of purified recombinant PP1 protein 
were separated by SDS-PAGE and the resulting blot was overlaid with LAP1B-IVT (1) or LAP1B 
(ΔA185)-IVT (2). IB, immunoblotting. 
 
 
II.3.5. Localization of the LAP1B:PP1 complex 
 
Given the confirmation that this novel complex is formed in vivo, it is evident that 
these two proteins are functionally related and therefore it becomes important to 
describe their localization. Co-localization of both proteins indicated that the complex 
exists in vivo and has physiological relevance. HeLa cells were transiently transfected 
with Myc-LAP1B and subjected to immunocytochemistry using a Myc-tag antibody. 
The Myc-LAP1B was mainly found in the nuclear envelope and also in the nucleus 
where it co-localizes with lamin B1 (Fig. II.6A). Endogenous PP1γ and PP1α were 
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detected using specific antibodies. All proteins have the expected subcellular 
distribution; each has been previously described individually (Andreassen et al., 1998; 
Kondo et al., 2002; Senior and Gerace, 1988). The PP1γ was found predominantly in 
the nucleus, including the nucleolus, and throughout the cytoplasm (Fig. II.6B). The 
PP1α was also found predominantly in nucleus, excluding the nucleolus, and throughout 
the cytoplasm (Fig. II.6B). Despite the quite different subcellular distribution of LAP1B 
and PP1 isoforms it is evident that they co-localize at specific points within the nucleus 
and very near to the nuclear envelope, as observed by the yellow color indicated in the 
ROIs (Fig. II.6B). The co-localizing points were confirmed by confocal profiling 
(denoted with *), where we demonstrated that the fluorescence intensity of the two 
channels correlated, particularly in those points, through the white line represented in 
the image (Fig. II.6C and D). The co-localization quantitative analysis was performed 
(Fig. II.6E) using a specific co-localization software (Zeiss LSM 510 4.0 software) as 
previously described (Rebelo et al., 2013; Vieira et al., 2010). Essentially, LAP1B co-
localizes similarly with both PP1 isoforms (27.6 ± 0.65% and 27.1 ± 0.8% with PP1γ 
and PP1α, respectively). The percentage of PP1γ and PP1α that co-localize with LAP1B 
is lower (13.5 ± 0.48 and 13.8 ± 0.8, respectively). 
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Figure II.6.  Subcellular distribution of the LAP1B:PP1 complex in HeLa cells. HeLa cells were 
transfected with Myc-LAP1B and then processed for immunocytochemistry using specific antibodies to 
Myc-tag and endogenous lamin B1 and PP1γ and α isoforms. A- Immunolocalization of both myc-
LAP1B and lamin B1. B- Immunolocalization of myc-LAP1B and PP1γ and α isoforms. The presence of 
the complexes is evidenced by the ROI (region of interest). C, D- Confocal profiles representing the 
green fluorescence intensity (FITC-conjugated secondary antibody labelling Myc-LAP1B) and the red 
fluorescence intensity (Alexa Fluor 594- conjugated secondary antibody labelling PP1γ [C] or PP1α [D]) 
in a specific distance (arrow); asterisks denote co-localizing points. E- Quantification of % of co-
localization between LAP1B and PP1 isoforms. Values are mean ± SEM, n= 75 cells (for PP1γ) and 55 
cells (for PP1α). Photographs were acquired using a LSM 510-Meta confocal microscope. Bars, 10 µm.  
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II.3.6. PP1 specifically binds to LAP1B 
 
Many nuclear membrane proteins are primarily or ultimately linked to each other 
via direct or indirect interactions involving the nuclear lamina. To test the specificity of 
the LAP1B:PP1 complex we tested whether other inner nuclear membrane proteins 
(NPC62, emerin and LAP2β) also bound to PP1. Co-IPs were performed using PP1 
antibody and the potential binding partners were further screened using specific 
antibodies (Fig. II.7). The results presented, clearly show that PP1 only binds to LAP1 
and not to the other proteins tested (NPC62, emerin and LAP2β). These results 
strengthen our hypothesis that LAP1 and PP1 are functionally associated, since they 
bind specifically in regions near the nuclear envelope (Fig. II.6). 
 
 
Figure II.7. Co-immunoprecipitation of PP1 binding proteins at the nuclear envelope. HEK293 cells 
were immunoprecipitated with PP1 antibody bound to protein A- sepharose beads. The negative controls 
were performed by incubating cell extracts with beads. IP, immunoprecipitation. IB, immunobloting. 
 
 
II.3.7. LAP1B is a novel substrate for PP1 
 
It is well established that PP1 versatility is largely determined by its regulatory 
proteins. The latter define subcellular targeting, substrate specificity and even the 
activity PP1.  Having determined that LAP1B is a novel PP1 regulatory protein, since 
the complex is formed both in vitro and in vivo and the two proteins co-localize in 
human cell lines, it is reasonable to deduce that the two proteins are functionally 
associated. We went on to test if LAP1B is a substrate for PP1, given that LAP1B can 
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be phosphorylated at several residues (Dephoure et al., 2008; Olsen et al., 2010; Wang 
et al., 2010). SH-SY5Y cells were incubated with two different concentrations of OA (a 
protein phosphatase inhibitor), followed by IP with LAP1 antibody and further 
incubation with recombinant purified PP1γ1 protein (Fig. II.8). Analysis of figure 8 
showed that when we inhibit PP2A and PP1 (500 nM OA) a slight decrease in the 
migration of LAP1B is detected, consistent with an increase in its protein 
phosphorylation level, this is not evident when only PP2A is inhibited (0.25 nM OA) 
(Fig. II.8, lysates). In contrast, when we immunoprecipitate LAP1B from cells treated 
with 500 nM OA and incubated the resulting immunoprecipitates with 100 ng of 
purified PP1γ1 protein (Fig. II.8, IP) a clear shift in the opposite direction is observed, 
indicating an in vitro dephosphorylation by PP1γ1. 
 
 
Figure II.8. In vitro dephosphorylation of LAP1B. SH-SY5Y cells were incubated with 0, 0.25 or 500 
nM okadaic acid (OA) for 3 hours and immunoprecipitated with LAP1 antibody. Immunoprecipitates 
were incubated at 30ºC for 1 hour with or without 100 ng of PP1γ1 protein.  The negative controls were 
performed by incubation of cells extracts with beads. In the left panel are presented the cell lysates 
correspondent of each condition immunoprecipitated (right panel). IP, immunoprecipitation. IB, 
immunobloting. 
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II.4. DISCUSSION 
 
PP1 regulates numerous cellular functions by binding to different regulatory 
subunits, which are, in turn, responsible for the targeting of PP1 to a particular 
subcellular compartment, but also determine substrate specificity and activity (Bollen, 
2001; Bollen et al., 2010; Ceulemans et al., 2002a; Cohen, 2002b). In this study we 
show that LAP1B is a novel PP1 regulatory protein. This LAP1B interaction was 
originally identified in YTH screens of a human brain cDNA library using three PP1 
isoforms (α, γ1 and γ2) as baits (Esteves et al., 2012a; Esteves et al., 2012b). Moreover, 
LAP1B variant 1, from all these screens, was isolated and fully sequenced (Santos, 
2009). In each case the variant obtained was the one recently reported in the GenBank 
database (NM_001267578) and differs from the LAP1B variant 2 (NM_015602) by 
only a 3 nucleotide (CAG) insertion, which results in the introduction of a single alanine 
residue at position 185 of the coding sequence. Typically such variants are generated by 
alternative splicing (Tadokoro et al., 2005; Watanabe et al., 2003) and this has been 
shown to be so for the TOR1AIP1 gene. Despite this subtle difference, both LAP1B 
variants have the same conserved PP1 binding domains and bind to PP1 (Fig. II.5). 
Consistent with the YTH results the data here presented, for the yeast co-transformation 
assays, confirmed that LAP1B is able to bind to all the PP1 isoforms tested (α, γ1 and 
γ2), but not to the C-terminus of PP1γ2 isoform (Fig. II.3). Thus, this novel LAP1B:PP1 
complex was validated not only in vivo but also in vitro by a blot overlay assay (Figure 
2). LAP1 is expressed in both non-neuronal and neuronal tissues (Kim et al., 2010a), as 
are PP1α and PP1γ1; even though the latter has higher expression levels in brain (da 
Cruz e Silva et al., 1995b). Thus, we performed co-IP assays in COS-7 cells (non-
neuronal cell line), SH-SY5Y cells (neuronal-like cell line) and rat cortex (Fig. II.4). 
Moreover, the complex LAP1B:PP1 was also found in rat hippocampus and striatum, 
regions where PP1α and PP1γ are particularly enriched (data not shown) 
LAP1B is not a well characterized protein and its main cellular function remains 
to be defined. However, it is an integral membrane protein of the inner nuclear 
membrane that interacts with lamins and chromosomes and this is functionally relevant 
for the maintenance of the nuclear architecture during interphase and mitosis (Foisner 
and Gerace, 1993). Recently, it was demonstrated that LAP1 recruits torsinA to the 
nuclear envelope (Goodchild and Dauer, 2005), although the latter is normally located 
at the endoplasmic reticulum. In contrast, a torsinA mutant form (ΔE302/303-torsinA), 
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which is present in DYT1 dystonia patients, is primarily relocated to the nuclear 
envelope (Goodchild and Dauer, 2004; Naismith et al., 2004). Protein:protein 
interactions can be regulated by protein phosphorylation and consequently by protein 
kinases and phosphatases. It is therefore highly relevant that LAP1B should bind to 
PP1. Thus, several LAP1B deletion mutants were generated to determine the binding 
region responsible for the binding to PP1. In silico analysis revealed that LAP1B has 
three potential PP1 binding RVxF motifs: REVRF (amino acids 55-59) and KVNF 
(amino acids 212-215) located in the nucleoplasm and KVKF (amino acids 538-541) 
located in the lumen of the perinuclear space. An additional generic PP1 binding motif 
termed SILK (Fig. II.1) is also present in the nucleoplasmic domain. We defined that 
LAP1B:PP1 interaction occurs primarily through a region that comprises the REVRF 
domains (BM1). These results (Fig. II.2C, 3B, 4A) support an interaction, which in 
topological terms provides physiological relevance, given that the BM1 is located in the 
nucleoplasmic portion of LAP1B and PP1 is particularly abundant in the nucleus. The 
BM2 and the SILK motif are also located in the nucleoplasm but our results clearly 
showed that these motifs do not mediate the interaction between LAP1B and PP1. BM3 
is located in the perinuclear space making this an unlikely domain for the association of 
both proteins. Moreover, BM1 is conserved among different species (Fig. II.1B) while 
BM2 and SILK are not. Another remarkable aspect is that RVxF motif is often N-
terminal flanked by basic residues and C-terminal flanked by acidic residues and this 
affects the binding affinity for the RVxF motif (Wakula et al., 2003). Concordantly, 
BM1 is preceded by basic residues (arginine) and followed by acidic residues (aspartic 
and glutamic acid) (Fig. II.1B). Further, the SILK motif is always N-terminal to the 
RVxF motif (Hendrickx et al., 2009), but this is not the case with LAP1B where in fact 
it is C-terminal to the BM1, reinforcing that the SILK motif is not important for the 
interaction.  
PP1 regulatory proteins can be substrates that directly associate with the PP1 
catalytic subunit, but can also be substrate specifiers and/or targeting proteins. Having 
established that LAP1B is a novel PP1 regulatory protein and that the BM1 is 
responsible for the interaction, the physiological significance of this complex was 
addressed. Immunolocatization of LAP1B and PP1 (for both PP1α and PP1γ isoforms) 
showed that they co-localize near the nuclear envelope (Fig. II.6). These results are in 
agreement with PP1 interacting with LAP1B through its nucleoplasmic domain, as 
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discussed above. Furthermore, LAP1B is well described to interact with lamin A/C and 
B1 (Foisner and Gerace, 1993; Senior and Gerace, 1988). Lamins are not only located at 
the nuclear membrane periphery but are also found within the nucleus (Bridger et al., 
1993; Moir et al., 1994). Indeed, we showed that LAP1B co-localizes with lamin B1 at 
the nuclear envelope and also in specific intranuclear areas (Fig. II.6). Originally, 
nuclear lamins were proposed to have a role in supporting the nuclear envelope and 
binding to chromatin. However, recent reports suggest many other roles for nuclear 
lamins, namely in DNA replication, transcription, mitosis, apoptosis and cell 
differentiation (Dechat et al., 2010). Potentially, and in a similar fashion, LAP1B may 
be involved in other nuclear functions. LAP1B is known to be phosphorylated during 
both interphase and mitosis and several phosphorylated residues have been identified 
(Dephoure et al., 2008; Olsen et al., 2010; Wang et al., 2010). However, the 
involvement of specific kinases and/or phosphatases had not hitherto been documented. 
Since we validated the interaction between LAP1B and PP1 it is reasonable to deduce 
that LAP1B may indeed be a substrate for PP1. When PP1 is inhibited with OA a slight 
shift in the LAP1B migration is observed, consistent with an increase in its protein 
phosphorylation state (Fig. II.8). Additionally, upon adding purified PP1γ1 protein to 
LAP1B immunoprecipitates, from cells previously incubated with 500 nM OA, an 
increase in the migration of LAP1B was detected, indicating that in vitro PP1 
dephosphorylates LAP1B.  
Many PP1 regulators identified thus far are located in the nucleus and are 
involved in diverse cellular functions, such as, cell cycle regulation, splicing and 
transcription (Ceulemans and Bollen, 2004; Cohen, 2002b; Esteves et al., 2012b). 
However, the only known PP1 regulator located specifically at the nuclear membrane is 
AKAP-149. AKAP149 is a component of the endoplasmic reticulum/nuclear system but 
the discovery that it interacts with lamins A/C and B (Steen and Collas, 2001), suggests 
that AKAP149 is associated with both the outer and inner nuclear membranes. AKAP-
149 recruits PP1 to the nuclear envelope upon nuclear envelope assembly in vitro and 
promotes lamin B dephosphorylation and polymerization (Steen et al., 2003; Steen et 
al., 2000). Indeed, PP1 may mediate nuclear lamina reassembly, in part by 
dephosphorylation of lamin B at the end of mitosis (Thompson et al., 1997). Following 
nuclear envelope disassembly at mitosis, LAP1B and lamin B have similar localization 
and both reassemble around the nuclear envelope during telophase (Maison et al., 
1997).  
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In conclusion, we have identified a novel PP1 regulatory protein, LAP1B. Both 
proteins co-localize in the close proximity of the nuclear envelope. LAP1B is mainly 
localized to the nuclear envelope whereas PP1 is rich in the nucleus. Co-localization of 
the LAP1B:PP1 to the nuclear envelope is indicative of specific protein recruitment for 
signaling events, and this will be addressed in the future. This interaction occurs 
through the REVRF motif, located in the nucleoplasmic domain of LAP1B. Further we 
also determined that LAP1B is a substrate for PP1 and PP1 in turn will dephosphorylate 
LAP1B. 
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LAP1 exist, at least, as three alternatively spliced isoforms in rat (Martin et al., 
1995; Senior and Gerace, 1988). However, it remains unclear if the same occurs with 
the  human LAP1, since only the LAP1B isoform had thus far been identified in human 
cells  (Kondo et al., 2002). Therefore, the work described in the chapter III addresses 
the novel human LAP1 isoforms and characterizes them. This work was included in the 
manuscript (manuscript 2) entitled: “Identification of a novel human LAP1 isoform that 
is regulated by protein phosphorylation”, submitted for publication in the Plos One 
journal. 
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Abstract 
Lamina associated polypeptide 1 (LAP1) is an integral protein of the inner nuclear 
membrane that is ubiquitously expressed. LAP1 binds to lamins and chromatin, 
probably contributing to the maintenance of the nuclear envelope architecture. 
Moreover, LAP1 also interacts with torsinA and emerin, proteins involved in DYT1 
dystonia and X-linked Emery-Dreifuss muscular dystrophy disorder, respectively. 
Given its relevance to human pathological conditions, it is important to better 
understand the functional diversity of LAP1 proteins. In rat, the LAP1 gene 
(TOR1AIP1) undergoes alternative splicing to originate three LAP1 isoforms (LAP1A, 
B and C). However, it remains unclear if the same occurs with the human TOR1AIP1 
gene, since only the LAP1B isoform had thus far been identified in human cells. 
Our in silico analysis suggested that, across different species, potential new LAP1 
isoforms could be generated by alternative splicing. Using shRNA to induce LAP1 
knockdown and HPLC-mass spectrometry analysis we described and validated the 
presence of two isoforms in human cells: LAP1B and LAP1C; the latter is N-terminally 
truncated. LAP1B and LAP1C expression profiles appear to be dependent on the 
specific tissues analyzed and in cultured cells LAP1C was the major isoform detected. 
Moreover, LAP1B and LAP1C expression increased during neuronal maturation, 
suggesting that LAP1 is relevant in this process. Both isoforms were found to be post-
translationally modified by phosphorylation and methionine oxidation and two 
LAP1B/LAP1C residues were shown to be dephosphorylated by PP1. This study 
permitted the identification of the novel human LAP1C isoform and partially unraveled 
the molecular basis of LAP1 regulation.  
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III.1. INTRODUCTION 
 
The eukaryotic nucleus is a complex organelle enclosed by a double membrane, 
the nuclear envelope (NE). The NE separates the cytoplasm from de the nucleus in 
eukaryotic cells and is structurally composed by the inner nuclear membrane (INM), the 
outer nuclear membrane (ONM), the nuclear lamina and the nuclear pore complexes. 
The perinuclear space is located between the INM and the ONM, however these 
membranes are joined in some regions at the nuclear pore complexes (reviewed in 
Gerace and Burke, 1988). The INM contains specific integral membrane proteins 
(Malik et al., 2010; Schirmer et al., 2003) and most of them interact with lamins (the 
main components of the nuclear lamina) and/or chromatin. 
One of the first lamin associated proteins identified was the lamina associated 
polypeptide 1 (LAP1) (Senior and Gerace, 1988). LAP1 was initially identified using a 
monoclonal antibody generated against lamina-enriched fractions of rat liver nuclei. 
This antibody recognized three rat proteins corresponding to LAP1A, B and C with 
molecular weights of 75, 68 and 55 kDa, respectively (Senior and Gerace, 1988). These 
proteins are type 2 transmembrane (TM) proteins, comprising a nucleoplasmic N-
terminal domain, a single TM domain and a lumenal C-terminal domain, located in the 
perinuclear space (Martin et al., 1995). Moreover, rat LAP1 family members are 
generated by alternative splicing and differ only in their nucleoplasmic domain. The 
full-length cDNA of rat LAP1C was isolated from a cDNA expression library prepared 
from rat liver polyA
+
 mRNA. Additionally, partial clones of LAP1B and LAP1C were 
also isolated. These clones were identical to some sequences of LAP1C cDNA but have 
two additional insertions (Martin et al., 1995). To date, only one isoform had been 
identified and characterized in human cells and it corresponded to LAP1B. Kondo et al, 
isolated a clone from HeLa cells that was similar to the rat LAP1C cDNA, and encoded 
a protein with a molecular weight (66.3 kDa) very close to the expected size for rat 
LAP1B. Therefore, it was concluded that this clone should correspond to the human 
LAP1B isoform (Kondo et al., 2002). Additionally, another human variant of LAP1B 
was identified, but it has only one amino acid (alanine) less (Tadokoro et al., 2005; Tsai 
et al., 2007) than the previously reported LAP1B. Of note, and up to the date of this 
publication, it remains unclear whether LAP1 is also alternatively spliced in human 
cells, giving rise to human LAP1A and C isoforms.  
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Moreover, the function of LAP1 remains poorly understood. However, it was 
described that LAP1 binds directly to lamins and indirectly to chromosomes (Foisner 
and Gerace, 1993). Thus, LAP1 may be involved in the positioning of lamins and 
chromatin in close proximity with the NE, thereby contributing to the maintenance of 
the NE structure (Gerace and Huber, 2012; Martin et al., 1995). LAP1 gained more 
attention when it was reported to interact with torsinA in the NE (Goodchild and Dauer, 
2005). A mutation of a glutamic acid within torsinA is responsible for most cases of 
DYT1 dystonia, a neurological and movement disorder (Ozelius et al., 1997). Thus, 
LAP1 is also known as torsinA interacting protein 1 (TOR1AIP1) and the gene 
encoding LAP1 is termed TOR1AIP1. More recently, LAP1 was found to interact with 
the INM protein emerin (Shin et al., 2013), which is associated with the X-linked 
Emery-Dreifuss muscular dystrophy disorder (Bione et al., 1994). Furthermore, it was 
reported that conditional deletion of LAP1 from mouse striated muscle causes muscular 
dystrophy leading to early lethality (Shin et al., 2013). We have recently reported that 
human LAP1B binds to protein phosphatase 1 (PP1) in the nucleoplasm and also that it 
is dephosphorylated in vitro by this phosphatase (Santos et al., 2013). In agreement, 
previous studies showed that rat LAP1 isoforms were phosphorylated in vitro and at 
least LAP1C was also phosphorylated in vivo (Foisner and Gerace, 1993).  
In the present study, we took advantage of the shRNA technology to knockdown 
LAP1 in human cells, so as to determine whether other human LAP1 isoform exist. 
Subsequently two isoforms, LAP1B and LAP1C, were identified. Using HPLC-mass 
spectrometry (MS) analysis, we showed that human LAP1C is N-terminally truncated. 
LAP1C was never identified in human cells, thus this is the first time that two human 
LAP1 isoforms have been described in human cells. Furthermore, the relative 
abundance of LAP1 isoforms in human cell lines was also estimated. Finally, our data 
provided evidences that PP1 is responsible for dephosphorylating both Ser306 and 
Ser310 residues of LAP1B/LAP1C.  
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III.2. MATERIALS AND METHODS 
 
III.2.1. Antibodies 
 
The primary antibodies used were rabbit polyclonal LAP1 (Goodchild and Dauer, 
2005); rabbit polyclonal lamin B1 (Santa Cruz Biotechnology); mouse monoclonal β-
tubulin (Invitrogen); mouse monoclonal synaptophysin (Synaptic Systems); rabbit 
polyclonal CBC3C that recognizes the C-terminal of PP1γ (da Cruz e Silva et al., 
1995b); and Myc-tag antibody (Cell Signaling), that recognizes Myc-fusion proteins. 
The secondary antibodies used were anti-mouse and anti-rabbit horseradish peroxidase-
linked antibodies (GE Healthcare) for ECL detection.  
 
III.2.2. Expression vectors and DNA constructs 
 
Myc-LAP1B and pET-LAP1B constructs have been previously described (Santos 
et al., 2013). The pSIREN-RetroQ vector (Clontech) was kindly provided by Dr. Celso 
Cunha from the Instituto de Higiene e Medicina Tropical , Lisbon (Casaca et al., 2011). 
 
III.2.3. Brain dissection 
 
Winstar rats (9-12 weeks) were obtained from Harlan Interfaune Ibérica, SL. All 
experimental procedures observed the European legislation for animal experimentation 
(2010/63/EU). No specific ethics approval under EU guidelines was required for this 
project, since the rats were only euthanized, by cervical stretching followed by 
decapitation, for brain removal. This is within the European law (Council Directive 
86/609/EEC) and during this procedure we took all steps to ameliorate animal suffering 
and used the minimum number of animals possible. The procedures were approved and 
supervised by our Institutional Animal Care and Use Committee (IACUC): Comissão 
Responsável pela Experimentação e Bem-Estar Animal (CREBEA). Animals were 
sacrificed by cervical stretching followed by decapitation, and the cortex was dissected 
out on ice. The tissue was then homogenized on ice, lysis buffer (50 mM Tris-HCl pH 
8.0, 120 mM NaCl, 4% CHAPS) containing protease inhibitors (1 mM PMSF, 10 mM 
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Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin, 5 µM Pepstatin A), with a Potter-
Elvehjem tissue homogenizer with 10-15 pulses at 650-750 rpm (S. Rebelo., 2013). 
 
III.2.4. Cell culture and transfection 
 
SH-SY5Y cells (ATCC CRL-2266) were grown in Minimal Essential Medium 
(MEM) supplemented with F-12 Nutrient Mixture (Gibco, Invitrogen), 10% fetal 
bovine serum (FBS, Gibco, Invitrogen), 1.5 mM L-glutamine and 100 U/mL penicillin, 
100 µg/mL streptomycin and 0.25 µg/mL amphotericin B (Gibco, Invitrogen). In order 
to promote SH-SY5Y cells differentiation, cells were plated at a density of 1 x 10
5 
and 
grown for 10 days in MEM/F12 medium with 10% FBS in the presence of 10 µM 
retinoic acid (Rocha et al., 2012). HeLa cells (ATTC CRM-CCL-2) were grown in 
MEM with Earle's salts and GlutaMAX (Gibco, Invitrogen), supplemented with 10% 
FBS, 1% Non-Essential amino acids (Gibco, Invitrogen) and 100 U/mL penicillin, 100 
µg/mL streptomycin and 0.25 µg/mL amphotericin B (Gibco, Invitrogen). SKMEL-28 
cells were handled as previously described (Espona-Fiedler et al., 2012). PC12 cells 
(ATCC CRL-1721) were cultured in RPMI1640 medium (Alfagene) supplemented with 
5% FBS, 10% horse serum (Gibco, Invitrogen) and 100 U/mL penicillin, 100 µg/mL 
streptomycin and 0.25 µg/mL amphotericin B (Gibco, Invitrogen). These cells were 
plated onto poly-L-ornithine coated dishes (Rebelo et al., 2004). All cultures were 
maintained at 37ºC and 5% CO2.  
Rat cortical primary cultures were established from embryonic day 18 embryos as 
previously described (Henriques et al., 2007). Briefly, after dissociation with 0.45 
mg/ml trypsin, cells were plated onto poly-D-lysine-coated dishes at a density of 
1.0x10
5
 cells/cm
2
 in B27-supplemented Neurobasal medium (Gibco, Invitrogen), a 
serum-free medium combination (Brewer et al., 1993). The medium was supplemented 
with glutamine (0.5 mM) and gentamicin (60 µg/ml). Cultures were maintained in an 
atmosphere of 5% CO2 at 37ºC until 14 days in vitro (DIV) before being used for 
experimental procedures. 
Transient transfections of SH-SY5Y cells were performed using TurboFect 
(Thermo Scientific) according to the manufacturer’s protocols. After 24 hours of 
transfection, cells were harvested for experimental procedures.  
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III.2.5. LAP1B knockdown 
 
The knockdown of endogenous LAP1 in SH-SY5Y cells was achieved using a 
short hairpin RNA (shRNA) strategy. To construct shRNA-expressing vectors, 
oligonucleotides targeting the human LAP1B mRNA and the corresponding 
complementary sequences, were inserted into the pSIREN-RetroQ vector. The 
oligonucleotide sequences were designed using the online designer tool of Clontech, 
available at http://bioinfo.clontech.com/rnaidesigner. Two pairs of oligonucleotides 
were chosen: one aligning between exon 7 and 8 (5’-
gatccGTGCTAAGCTCAGGATATCTTCAAGAGAGATATCCTGAGCTTAGCACTT
TTTTACGCGTg-3’) and other in exon 10 (5´- gatccGGAAGAGACACTTGGAACA 
TTCAAGAGATGTTCCAAGTGTCTCTTCCTTTTTTACGCGTg-3’) of the LAP1 
mRNA (NM_001267578). The underlined sequences denote the LAP1 shRNA 
sequence targeting in the LAP1 mRNA. A control shRNA was also generated, by using 
a negative control oligonucleotide that does not target any human transcript (5´-
gatccGCTTCATAAGGCGCATAGCTATTCAAGAGATAGCTATGCGCCTTATGCT 
TTTTTg-3’). The oligonucleotides were annealed and subcloned into the BamHI and 
EcoRI sites of the pSIREN-RetroQ vector. The generated constructs pSIREN-LAP1-C1 
(targeted to exon 7/8), pSIREN-LAP1-C2 (targeted to exon 10) and pSIREN-CMS 
(control) were verified by restriction analysis and DNA sequencing using an ABI 
PRISM 310 Genetic Analyzer (Applied Biosystems, Porto, Portugal). Constructs were 
then transfected using the TurboFect reagent (Thermo Scientific) according to the 
manufacturer’s protocols. 
 
III.2.6. RT-PCR and sequencing 
 
Adult brain poly A+ RNA (Clontech) was reverse transcribed using the 
SuperScript
TM 
First Strand Synthesis System (Invitrogen) and the TOR1AIP1 gene 
specific primer E10RV (5’-CTTGGCCTGACCTACTCTTAAGAC-3’) or the 
oligo(dT)20 primer. The synthetized cDNA was amplified using the following primer 
pairs: forward primer E1FW (5’-CAGGAGAACCTAGGGTCCATAAAG-3’) and 
reverse primer E10BRV (5´- GTGAACAATTCTCAGAACTTGGGAC-3’); forward 
primer E2FW (5’-CATTCC TCTGAAGAGGATG-3’) and reverse primer E10BRV; 
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forward primer E5FW (5’CTGAAGAAGATGATCAAGACAGCTC-3’) and reverse 
primer E10CRV (5’-GTGAGCAGTAAGATAGCAGGCTG-3’). The PCR products 
were excised from agarose gel and purified using QIAquick Gel Extraction Kit 
(Promega). The purified fragments were cloned into the Nzy-blunt PCR cloning kit 
(Nzytech). One clone from each reaction was selected and the inserts sequenced using 
an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Porto, Portugal). 
 
III.2.7. RNA isolation  
 
Total RNA was isolated from SH-SY5Y cells using Trifast
TM
 reagent (Peqlab 
Biotechnologie GmbH) following the supplier’s protocols. Briefly, cells were 
homogenised in 500 µl of Trifast
TM
 reagent with a 20 G needle. Then, cell lysates were 
incubated at room temperature for 5 min before 100 µL of chloroform were added. 
Samples were shaken vigorously for 15 seconds and kept at room temperature for 5 min 
before centrifugation at 12000 g for 15 min. The upper aqueous phase, containing RNA, 
was transferred into a new tube and the RNA precipitated by adding 250 µl of 
isopropanol followed by incubation at 4ºC for 10 minutes. The RNA was spun down for 
10 min at 12000 g and the pellet washed twice with 500 µl of ice cold 75% ethanol and 
subsequently centrifuged for 10 min at 12000 g. The RNA was air-dried at room 
temperature and dissolved in RNAse free water. 
 
III.2.8. Northern blot analysis 
 
Northern blot analysis was performed following the protocol provided with the 
Odyssey Infrared Imaging System (LI-COR Biosciences) with some alterations. Briefly, 
20 µg of total RNA from SH-SY5Y cell were mixed with formaldehyde/formamide 
RNA loading buffer. The samples were incubated at 65ºC for 15 minutes, chilled on ice 
followed by the addition of loading buffer (50% glycerol, 1 mM EDTA pH 8.0, 0.25% 
bromophenol blue and 0.25% xylene cyanol FF). Then, the samples were loaded on 1% 
agarose gel in formaldehyde gel running buffer (0.02 M MOPS pH 7.0, 8 mM sodium 
acetate, 1 mM EDTA pH 8.0 and 2.2 M formaldehyde). Samples were transferred onto 
nitrocellulose membranes by capillary elution in 20x SSC buffer overnight. RNA was 
cross-linked to the membrane using a UV cross-linker. Membranes were hybridized 
with a LAP1 biotinylated probe. To generate the biotinylated probe, clone 1A (from the 
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RT-PCR reaction E1FW+E10BRV) was used as a template for PCR amplification in the 
presence of biotin-16-dUTP (Roche) and the primers E10FW (5´-
CAAGGTCAAGATGAGAAGCTG-3)’ and E10BRV (5´- 
GTGAACAATTCTCAGAACTTGGGAC-3’), both targeting exon 10 of LAP1. A 
probe directed to human β-actin was also generated using cDNA obtained by RT-PCR 
from human brain poly A+ RNA, and the primers AFW (5'-
GCTCGTCGTCGACAACGGCT C-3') and ARV (5'-CAAACATGAT 
CTGGGTCATCTTCTC-3'). The membrane was pre-hybridized at 42ºC with 
ULTRAhyp-Oligo Buffer (Ambion) and hybridized overnight at 42ºC with biotinylated 
probes (diluted in ULTRAhyp-Oligo Buffer) and then washed with Low and High 
Stringency Washes (Ambion). Membranes were blocked for 1 hour with Odyssey 
Blocking Buffer plus 1% SDS (LI-COR Biosciences) and then incubated for 1 hour 
with Streptavidin IRDye800 CW conjugate (1:10000) in blocking buffer plus 1% SDS 
(LI-COR Biosciences). Blots were washed three times with PBS-T 1x and one with 
PBS 1x before scanning on an Odyssey IR Imaging System (LI-COR Biosciences). 
 
III.2.9. Co-immunoprecipitation 
 
SH-SY5Y cells were collected in lysis buffer (50 mM Tris-HCl pH 8, 120 mM 
NaCl, 4% CHAPS) containing protease inhibitors (1 mM PMSF, 10 mM Benzamidine, 
2 µM Leupeptin, 1.5 µM Aprotinin, 5 µM Pepstatin A). Dynabeads Protein G (Dynal, 
Invitrogen) were washed in 3% BSA/1x PBS. LAP1 antibody was cross-linked to 
Dynabeads according to the manufacter’s protocol. Cell lysates were precleared with 20 
µL (0.6 mg) Dynabeads for 1 hour and then incubated with antibody-dynabeads 
overnight at 4ºC. The immunoprecipitates were washed in 1x PBS and proteins eluted 
by boiling in loading buffer before SDS-PAGE. 
 
III.2.10.  LAP1 solubilization assay 
 
For the LAP1 solubilization we performed a procedure adapted from Goodchild, 
2005 (Goodchild and Dauer, 2005). SH-SY5Y cells were collected in the following 
buffers supplemented with protease inhibitors (1 mM PMSF, 2 µM Leupeptin, 1.5 µM 
Aprotinin): 50 mM Tris-HCl pH 7.5; 50 mM Tris-HCl pH 7.5 and 1% triton X-100; 50 
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mM Tris-HCl pH 7.5, 1% triton X-100 and 50 mM NaCl or 500 mM NaCl. 
Homogenates were incubated on ice for 20 minutes and centrifuged at 20000 g for 15 
min to separate supernatant (soluble) and pellet (insoluble) fractions. Pellet fractions 
were solubilized in 150 µl of 1x loading buffer at 90ºC and supernatants were brought 
to a 150 µl volume and 1x concentration by adding 4x loading buffer. Equal volumes of 
pellet and supernatant were loaded on SDS-PAGE. 
 
III.2.11.   Nano-HPLC and Mass spectrometry  
 
For nano-HPLC-MS analysis, SH-SY5Y total cell lysates, SH-SY5Y cells 
membrane-containing fraction (pellet collected by centrifugation in 50 mM Tris-HCl 
pH 7.5, as previously described) and LAP1 immunoprecipitates (obtained as previously 
described) were resolved by 10% SDS-PAGE. Gels were stained with Coomassie blue 
colloidal (Sigma-Aldrich) using standard procedures (Korrodi-Gregorio et al., 2013). 
Two bands were excised from the gel: one below 75 kDa and other above 50 kDa, 
corresponding to the molecular weights of LAP1B (68 kDa) and the putative LAP1C 
(56 kDa) protein, respectively. Bands were then excised from the gel and destained. The 
measurements were performed on a nano-HPLC system Ultimate 3000 (Dionex, 
Germany), coupled on-line to a quadrupole-orbitrap mass spectrometer (Q Exactive; 
Thermo Fischer Scientific, Germany). Samples were loaded on a C18 trap column 
(Thermo, 100 µm ˣ 2 cm, particle size 5 µm, pore size 100 Å, C18) with 1.1% TFA and 
30 µl/min flow rate. Then the trap column was online switched with an analytical C18 
column (Thermo, 75µm ˣ 50 cm, particle size 2 µm, pore size 100 Å). The separation 
was performed with a flow rate of 400 nl/min using the following solvent system: (A) 
0.1% FA; (B) 84% ACN, 0.1% FA. The separation gradient was from 4-40% B in 95 
min, followed by a washing step at 95% B (5min) and an equilibration step at 4% B 
(5min). After nano-HPLC separation the eluent was ionized by a nano electrospray 
ionization source (ESI) and analyzed in data dependent scan mode in a Q Exactive. In 
the ESI/MS-MS analysis full MS spectra were scanned between 350 – 1400 m/z with a 
resolution of 70,000 at 200 m/z (AGC target 3e6, 80 ms maximum injection time). The 
capillary temperature was set at 250°C and the spray voltage at 1600 V (+). Lock mass 
polydimethylcyclosiloxane (m/z 445.120) was used for internal recalibration. The m/z 
values initiating MS/MS were set on a dynamic exclusion list for 30 s and the 10 most 
intensive ions (charge +2, +3, +4) were selected for fragmentation. MS/MS fragments 
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were generated by higher energy collision induced dissociation (HCD) and the 
fragmentation was performed with 27% normalized collision energy (NCE). The first 
MS/MS mass was fixed at 130.0 m/z and isolation window 2.2 m/z. The fragment 
analysis was performed in an orbitrap analyzer with 35,000 resolution at 200 m/z (AGC 
1e6, maximum injection time 120 ms).  
 
III.2.12.  In vitro translation (IVT) 
 
LAP1B was generated by in vitro translation (IVT) from pET-LAP1B expression 
vector using the TnT-coupled transcription/translation kit (Promega), according to the 
manufacturer’s instructions. 
 
III.2.13.  SDS-PAGE and immunoblotting 
 
Samples were separated on SDS-PAGE and electrophoretically transferred onto 
nitrocellulose. Nitrocellulose membranes were incubated in Ponceau S solution for 5 
minutes and then scanned in a GS-800 calibrated imaging densitometer (Bio-Rad), in 
order to assess equal gel loading. Membranes were washed in TBST 1x to remove 
Ponceau S staining, followed by immunological detection with specific antibodies as 
indicated. Membranes were saturated in 5% non-fat dry milk and further incubated with 
primary antibodies. Detection was achieved using horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse IgGs as secondary antibodies and proteins visualized by ECL 
(GE Healthcare). 
 
III.2.14.  Bioinformatics analysis 
 
Database searches to find homologies between sequences were performed using 
BLAST algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al., 1990). 
Multiple sequence alignments were performed using the CLUSTAL OMEGA alignment 
tool (http://www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers and Higgins, 2014). The splice 
prediction was achieved by using the programs NNSPLICE 
(http://www.fruitfly.org/seq_tools/splice.html) and GENSCAN 
(http://genes.mit.edu/GENSCAN.html ) (Burge and Karlin, 1997; Reese et al., 1997). 
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The prediction of promoter and transcription factor binding sites was performed using 
the NNPP program (http://www.fruitfly.org/seq_tools/promoter.html) (Reese, 2001) and 
the TSSG (http://linux1.softberry.com/berry.phtml) (Solovyev and Salamov, 1997). 
 
III.2.15.  Quantification and Statistical Analysis 
 
Autoradiograms were scanned in a GS-800 calibrated imaging densitometer (Bio-
Rad) and protein bands quantified using the Quantity One densitometry software (Bio-
Rad). Data were expressed as mean ± SEM of at least three independent experiments. 
Statistical significance analysis was conducted by Student’s test, with the level of 
statistical significance being considered P < 0.05. 
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III.3. RESULTS 
 
III.3.1. Knockdown of human LAP1 
 
To date little information is available regarding the human LAP1 family of 
proteins and their physiological functions. Recently, we described that one of the family 
members, LAP1B, is a novel PP1 binding protein (Santos et al., 2013). To clarify the 
existence of additional human LAP1 family members and their physiological impact, 
we generated LAP1 specific shRNAs to reduce the cellular levels of LAP1 protein. For 
this purpose, we designed a pSIREN-RetroQ vector coding for LAP1-specific shRNAs: 
pSIREN-LAP1-C1 and pSIREN-LAP1-C2 were designed to align between exons 7/8 
and in exon 10 of LAP1, respectively. SH-SY5Y cells were transfected with one of the 
pSIREN-LAP1 plasmids or with both for 24 hours. In parallel, SH-SY5Y cells were 
also transfected with the negative control, the pSIREN-CMS construct. The efficiency 
of LAP1 knockdown was monitored by immunoblotting with a LAP1 specific antibody 
(Goodchild and Dauer, 2005). LAP1 antibody was raised against residues 463-478 
(exon 10) of mouse LAP1 and is able to detect the three LAP1 splice variants in mouse 
cells (Goodchild and Dauer, 2005). Given that the amino acid identity between mouse 
and human LAP1 is very high in the region recognized by this antibody, the same 
antibody was used to detect human LAP1. Two major peptides, with reduced 
endogenous levels in cell lysates, were detected upon transfecting with the pSIREN-
LAP1-C1, pSIREN-LAP1-C2 or both constructs simultaneously (Fig. III.1A). The 
higher migrating band (approximately 68 kDa) corresponds to the molecular weight of 
the known LAP1B isoform, while the lower band (approximately 56 kDa) has not been 
previously reported in human cells, but has the same molecular weight of rat LAP1C, 
described in the literature. Therefore we hypothesized that this novel immunoreactive 
band is likely to correspond to the human LAP1C isoform. The intracellular levels of 
LAP1B were reduced by 34%, 45% and 47% upon transfection with pSIREN-LAP1-
C1, pSIREN-LAP1-C2 or both constructs, respectively (Fig. III.1A). In a similar 
fashion the intracellular levels of the putative LAP1C were also reduced by 31%, 41% 
and 51%, upon transfection with pSIREN-LAP1-C1, pSIREN-LAP1-C2 or both 
constructs together, respectively. Ponceau S staining was used as loading control (data 
not shown). The response obtained also permits to conclude that both LAP1B and the 
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putative LAP1C have in common the regions of exon 7, 8 and 10 targeted by the 
shRNAs used, which corroborates the fact that all LAP1 isoforms have a conserved C-
terminal. 
In order to clarify that the new putative human LAP1C isoform is not a product of 
cleavage or post-translational proteolytic processing of LAP1B, we transfected SH-
SY5Y cells with two different amounts of Myc-LAP1B (0.5 µg and 1µg). After 
immunoblotting with Myc antibody, only one band was detected corresponding to the 
transfected Myc-LAP1B (Fig. III.1B). Moreover, we performed immunoblotting with 
LAP1 antibody and did not detect an increase in the expression of the putative LAP1C 
immunoreactive band upon transfection (Fig. III.1B). These results support the fact that 
the putative LAP1C is not a product of LAP1B cleavage or proteolytic processing, but 
in fact a distinct isoform. 
   
 
 
Figure III.1. Identification of a new putative human LAP1 isoform. A- Transfection of SH-SY5Y 
cells with pSIREN-RetroQ vector coding for LAP1-specific shRNAs resulted in the knockdown of two 
LAP1 isoforms:  LAP1B and putative LAP1C. Data are presented as mean ± SEM of at least three 
independent experiments. Statistically different from CMS transfected cells, *p < 0.05, **p < 0.01. C1, 
pSIREN-C1 (directed against exon 7/8 of LAP1), C2, pSIREN-C2 (directed against exon 10 of LAP1); 
CMS, pSIREN-CMS (control missense). B- Transfection of SH-SY5Y cells with Myc-LAP1B (0.5 or 
1µg). NT, non-transfected; IB, immunoblotting  
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III.3.2. In silico analysis of the TOR1AIP1 gene 
 
In silico analysis of the TOR1AIP1 gene was performed to predict the potential 
diversity of human LAP1 proteins. Two human LAP1 transcripts have in fact been 
reported (Tadokoro et al., 2005; Tsai et al., 2007). Bioinformatic analysis of those 
transcripts and the alignment with the genomic sequence, revealed the presence of 10 
exons (Fig. III.2A). Transcript variant 1 [GenBank: NM_001267578] represents the 
longest transcript and is identical to the first human LAP1B sequence reported in 2002 
(Kondo et al., 2002). This transcript differs from variant 2 [GenBank: NM_015602], 
only by a CAG insertion, which results in an additional alanine in the coding sequence 
(Figure III.2B). Some reports showed that TOR1AIP1 gene possesses a 3’ tandem splice 
site, TAGCAG, at the exon 3 boundary, which results in one amino acid insertion or 
deletion in the encoded protein (Tadokoro et al., 2005; Tsai et al., 2007).  
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Figure III.2. Gene structure and splice variants of human, rat and mouse TOR1AIP1. A- Structure 
of the human, rat and mouse TOR1AIP1 gene. Non-coding sequences in exons are represented by open 
boxes and coding exons are represented by black filled boxes. Predicted exons 1b and 3b in human and 
rat genes, and exon 2b in human gene are represented by grey boxes and denoted by an asterisk. The in-
frame ATG codons are indicated by arrows. B- Schematic representation of the alternative splicing 
patterns and resulting LAP1 transcripts variants (human, rat and mouse). The translation initiation codons 
(ATG) and the stop codons (TAA or TGA in human and mouse/rat sequences, respectively) are indicated 
in each transcript. Human LAP1 transcripts variants differ only in exon 3 (dark grey) by three nucleotides 
through an alternative 3’ splicing event. 
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Sequencing of rat LAP1C and partial characterization of rat LAP1A and LAP1B 
suggested that rat LAP1 family members arise from alternative splicing (Martin et al., 
1995). However, despite what is reported in the literature, it was only found one 
Reference Sequence (RefSeq) transcript in GenBank that corresponds to rat LAP1B 
isoform (Fig. III.2B) [GenBank:NM_145092]. Nevertheless, two related sequences 
(non-RefSeq sequences) were found in GenBank: U20286 (transcript 2), a transcript 
that lacks an N-terminal segment and U19614 (transcript 3), a transcript that lacks an 
internal segment (Figure III.2). Alignment of the rat LAP1 genomic sequence with the 
known rat LAP1B transcript, using the BLAST algorithm, revealed the presence of 10 
exons (Fig. III.3). Taking into account the exon structure of rat LAP1 transcripts, we 
infer that U20286 has a truncated exon 1 in the N-terminal, while in the U19614 
transcript, exon 5 was skipped. 
 
 
 
Figure III.3. Schematic representation of LAP1 non-RefSeq transcripts. The translation initiation 
codons (ATG) and the stop codons (TAA or TGA in human and mouse/rat sequences, respectively) are 
indicated in each transcript. 
 
 
For mouse there are three RefSeq records corresponding to three different mouse 
LAP1 transcripts: transcript 1 [GenBank: NM_001160018] that represents the longest 
transcript; transcript 2 [GenBank: NM _144791] that is shorter than transcript 1 and 
lacks an internal segment; and transcript 3 [GenBank: NM_001160019] that represents 
the smallest transcript and lacks the N-terminus (Fig. III.2B). Additionally, we found 
other related sequences corresponding to two different mouse LAP1 transcripts in 
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GenBank: AK152751 (transcript 4), a transcript that lacks an N-terminal segment and 
AB251963 (transcript 5), a transcript that has an additional internal segment (Figure 
III.3). Alignment of the mouse LAP1 genomic sequence with the known transcripts 
revealed the presence of 12 exons (Fig. III.2). Taking into account the exon structure of 
mouse LAP1 transcripts, we showed that exon 7, 8 and 9 are absent in transcript 2. 
Transcript 3 lacks exon 1, but has an additional first exon, that we termed exon 1b. 
However translation is not initiated at the exon 1b, but exon 3 does have an in frame 
ATG, encoding for a protein with a different N-terminal. Transcript 4 has a truncated 
exon 1 in the N-terminal and transcript 5 has an alternative exon 5b that is not found in 
any of the other transcripts. Of note, the C-terminal (exon 10) seems to be the most 
conserved region among mouse LAP1 isoforms. 
In order to predict alternative exons, which would lead to distinct human LAP1 
isoforms, we aligned mouse LAP1 transcripts against the genomic sequence of the 
TOR1AIP1 gene, using BLAST algorithm. Further, we identified intron-exon junctions 
by comparing genomic and cDNA sequences and making use of in silico tools 
NNSPLICE and GENSCAN (Table III.1). The alignment revealed high identity 
between exons 1-5 and 7-10, while exon 6 of human gene does not align with any 
mouse transcript. Moreover, mouse transcripts have three different exons (that we 
termed 1b, 3b and 5b) that are not found in the human LAP1B transcripts. The 
alignment of mouse exons 1b and 3b against the human genomic sequence revealed the 
presence of putative alternative exons 1b and 3b in the human gene (Fig. III.2A). In the 
GenBank database, a human expressed sequence tag (EST) was found [GenBank: 
DB454036], which shares homology with exon 1b. Alignment of this EST with human 
genomic sequence also revealed the presence of an alternative exon, that we termed 
exon 2b (Fig. III.2B). This exon is not conserved in mouse or rat genomic sequences 
(Table III.1). In contrast, a human EST (GenBank: CX760895) encoding an exon with 
high homology with mouse exon 3b was found in the GenBank database. The splice 
sites of putative exon 2b and 3b are according to the consensus rules (GT/AG). 
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Table III.1. Intron/exon junctions in the TOR1AIP1 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nucleotides sequences of the 5’ and 3’ end of exons and the donor and acceptor sites at the 
intron/exon junctions (in upper case) of the human, mouse and rat TOR1AIP1 genes are deduced from the 
TOR1AIP1 genomic sequences. Sequences of intron ends are given in lower case, except for the donor 
and acceptor sites in upper case. Exons and introns are numbered as referred in Fig. III.1 and exon sizes 
are given. Homologies between human and mouse/rat sequences are shown by asterisks. Exon 1b and 3b 
in human and rat sequences and exon 2b in the human sequence are putative exons. 
  
 Intron 3’end 5’end – Exon size (bp) – 3’end Intron 5’end 
Exon 1    
Human   ACTGCCTC – 936 - CTCTGAAG GTgaggac 
Mouse   CGG*AG** - 723 - *CGCG*** **a*cagt 
Rat   *AAA*ACA – 672 – *CGC*G** **a*cagt 
Exon 1b    
*Human  ATAGTTTG - 92 -  TCGTGAAG GTactgac 
Mouse   GA*CAGGA – 137 – *TT**G*T ***ag**g 
*Rat  AA*GAGGA – 136 - *TT**A*T ***ac**g 
Exon 2    
Human  ttttttAG AGGATGAA – 78 - GGCTCCAG GTaagaat 
Mouse *gc*g*** ******** – 75 - ****T*** *******g 
Rat  *gc*a*** ******** - 75 - *A**T*** *******t 
Exon 2b    
*Human  ttctctAG CTGCTGTA – 131 - AAAGAAGG GTacttga 
Mouse - - - 
Rat - - - 
Exon 3    
Human  tatattAG CAGTGAGT – 60 - AAGATATG GTaagaga 
Mouse **c*cc** G*TGA*TG – 60 - ****CT** ******t* 
Rat  **t*cc** TGATG*GT – 60 - ****CC** ******g* 
Exon 3b    
*Human tcttgcAG ATTCGACA – 45 - TTAATTAT GTtcgttt 
Mouse ****a*** ****A*** – 45 – *G**AG*G ***t**** 
*Rat ct*ata** **C*A*** - 45 – GC*CAAGT **GT**GC 
Exon 4    
Human tcttctAG AAGCCACC – 42 - TGAAGAAG GTatttta 
Mouse ******** ****T*CC – 39 – C******* ***a***c 
Rat ******** *C**TT** - 39 – GC*GTTT* ***a***t 
Exon 5    
Human ctctttAG GAGAAAAC – 87 - ATCTGGAG GTaatatt 
Mouse *ct*g*** ******C* - 81 – G**AA*** *****g** 
Rat  *ct*g*** ******C* – 81 – G***A*** ****ca** 
Exon 5b    
Human - - - 
Mouse  tggtttAG ATGAAGCC - 56 - GCCACACA GTtaagta 
Rat - - - 
Exon 6    
Human  atttttAG ATAAAACC – 57 - ATCACAAA GTaagtaa 
Rat  g****c** **G**G** – 57 - *C****C* *******c 
Mouse - - - 
Exon 7    
Human  tgtttcAG GTCAAAAC – 42 - AGTGCTAA GTaagtag 
Mouse ****ct** A***GG** – 42 - *C****G* ******tc 
Rat  ****ct** ***GGGGG – 45 - *C****GC ******gc 
Exon 8    
Human  tgcttcAG GCTCAGGA – 69 - GATGCAAA GTaagtag 
Mouse ******** C******* - 69 – A***GCGT ******** 
Rat  ******** C*A***** - 69 – A***GC*T ******** 
Exon 9    
Human  accattAG ATGGCAGC – 57 - CAGCCGAC GTaagttt 
Mouse tatt**** **AA**A* – 57 - ***G*C** ******c* 
Rat  tatt**** **AA**A* – 57 - ***G*A*G ******** 
Exon 10    
Human  ctgagtAG AAGTGACT – 2624 - ATACTCTC  
Mouse *****c** **TC*G** – 3111 - **GT*A*A  
Rat  *****c** **GCAG** – 1547 - *AAG*T*T  
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Additionally, search in Genbank database for human ESTs and alignments of 
detected human ESTs against the genomic sequence of human LAP1 was performed, in 
order to identify alternative exons. It was found that the 3’ end of exon 8, exon 9 and 
the 5´end of exon 10 were skipped in one EST [GenBank: AU154882]. Furthermore, a 
non-RefSeq protein record [GenBank: EAW91067] that matches with this EST was 
found. Finally, several human ESTs (e.g. AL530866, BM907999, DA552747 and 
DA539545) and non-RefSeq mRNAs records (BC023247, AK023204 and AK021613) 
that lack the 5’ end region of exon 1 were found in GenBank. These sequences lack the 
start codon present in LAP1B but have an additional in frame ATG, 363 nucleotides 
downstream of the first one (Fig. III.2A). This second in frame ATG is conserved 
between species (human, mouse and rat). Once more the analysis of the identified 
transcripts reveals that the C-terminal region of LAP1 transcripts remains highly 
conserved. 
 
III.3.3. Analysis of LAP1 transcripts 
III.3.3.1. RT-PCR 
 
Given that two human LAP1 immunoreactive bands were detected (Fig. III.1) and 
since there is evidences that LAP1 isoforms are originated by alternative splicing (Fig. 
III.2), we went on to test if the smaller LAP1 transcript (putative LAP1C) has 
alternative exons, using RT-PCR. Briefly, cDNA was synthetized from adult brain poly 
A+ RNA using a reverse primer in the 3’ UTR of exon 10 (E10RV) of human LAP1B 
or an oligo(dT)20 primer that aligned with the poly A+ tail of mRNAs (Fig. III.4A). 
Subsequent amplification reactions were carried out using different primer pairs. The 
primer set E1FW (targeted to exon 1) and E10BRV (targeted to exon 10) amplified a 
fragment of 1.86 Kb (Fig. III.4B). This PCR fragment was ligated into the Nzy-blunt 
vector and the insert fully sequenced. Sequence results showed that the PCR fragment 
corresponds to the LAP1B transcript already described, as it was expected by its size. 
Given that only one fragment was amplified, using primers that aligned in exon 1 and 
10, one can deduce that the N- or the C-terminal of the putative LAP1C transcript 
should be different. Additionally, and in order to exclude the possibility of internal 
alternative exons, the cDNA was also amplified using the following primer sets: E2FW 
(targeted to the boundary between exon 1 and 2) and E10BRV (targeted to exon 10); 
E5FW (targeted to exon 5) and E10CRV (targeted to an internal region of exon 10). The 
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first primer set (E2FW+E10BRV) used, generated a fragment of 1.34 kb (Fig. III.4C), 
which corresponds to the expected size of the transcript without alternative exons. 
Additionally, a larger fragment of 1.6 kb was also obtained which, after sequencing 
analysis, corresponded to an unspecific band. The second primer set (E5FW+E10CRV) 
used, generated a fragment of 0.58 kb (Fig. III.4D) that matched with the expected 
transcript without alternative exons. In addition, total RNA from SH-SY5Y cells was 
extracted and RT-PCR was perfomed using the oligo(dT)20 primer. The synthesized 
cDNA was amplified using the primers E1FW and E10BRV and once more a single 
PCR fragment of 1.86 kb was obtained, corresponding to the LAP1B transcript (Fig. 
III.4E). 
 
 
Figure III.4. RT-PCR of human LAP1. A- Localization of the primers used for RT-PCR on human 
TOR1AIP1 gene. The cDNA was synthesized from adult brain poly A+ RNA (Clontech) (B, C and D) or 
SH-SY5Y cell total RNA (E) using a reverse primer targeted to exon 10 (E10RV) or an oligo(dT)20 
primer. Amplification of the cDNA was performed using specific primer pairs. B- cDNA amplification 
using primers E1FW (targeted to exon 1) and E10BRV (targeted to exon 10). C- cDNA amplification 
using primers E2FW (targeted to exon 1/2) and E10BRV (targeted to exon 10). D- cDNA amplification 
using primers E5FW (targeted to exon 5) and E10CRV (targeted to the middle of exon 10). E- cDNA 
amplification using primers E1FW (targeted to exon 1) and E10BRV (targeted to exon 10). 1kb, DNA 
size marker 1kb ladder (Invitrogen); 1, cDNA synthesized using E10RV primer; 2, cDNA synthetized 
using oligo(dT)20 primer.  
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III.3.3.2. Northern Blot 
 
The RT-PCR methodology did not produce a transcript corresponding to the 
putative LAP1C isoform, nor did it corroborate the presence of alternative exons that 
would lead to the translation of LAP1C. Consequently, in order to test whether different 
mRNAs or a single mRNA encodes LAP1 isoforms, Northern blot analysis was 
performed. If a single RNA is present, LAP1 isoforms could be generated by an 
alternative translation initiation mechanism, instead of alternative transcription. Hence, 
a probe was designed, directed against a region of exon 10 (span nucleotides 1602-
2265) that is conserved in LAP1 isoforms. Total RNA from SH-SY5Y cells was 
isolated, given that this cell line expresses high levels of the putative LAP1C isoform 
(Fig. III.1B). Both undifferentiated and differentiated (with 10 µM retinoic acid for 4 
days) SH-SY5Y cells were used to isolate total RNA. The results showed that the probe 
hybridized with two bands in both conditions (Fig. III.5). The higher band corresponds 
to the LAP1B transcript but appears to migrate slower than expected, bearing in mind 
its characterized mRNA size of 4.05 kb (GenBank: NM_001267578). The presence of a 
lower band is consistent with the existence of a second LAP1 transcript, corresponding 
to putative LAP1C transcript. Both RNAs appear to be of similar abundance in SH-
SY5Y cells, which is not in direct proportion to the protein levels of LAP1B and 
putative LAP1C isoforms detected by immunoblotting. A probe directed to human β-
actin was used as a control and hybridized to a single band bellow 3.7 kb (Fig. III.5), as 
expected.  
 
 
Figure III.5. Northern blot analysis of LAP1 RNAs in SH-SY5Y cells. A- Total RNA was isolated 
from SH-SY5Y cells and membranes hybridized with a biotinylated probe directed against exon 10 of 
LAP1. β-actin was probed as control. RNA size markers are depicted on the left. 1, RNA isolated from 
SH-SY5Y cells non-differentiated; 2, RNA isolated from SH-SY5Y celsl differentiated with retinoic acid. 
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Additionally, we showed that in vitro translation of LAP1B does not generate any 
low molecular weight protein, indicating that LAP1C is not generated by alternative 
translational initiation (Fig. III.6) 
 
 
Figure III.6. In vitro translation (IVT) of LAP1B. IVT of pET-LAP1B generates only His-tagged 
LAP1B.  
 
 
III.3.4. Identification of LAP1C isoform liquid chromatography-mass 
spectrometry 
 
Northern blot analysis supported the existence of two LAP1 isoforms in human 
cell lines, but data was not as clear from the other methodologies, as described above. 
Thus, HPLC-MS analysis was employed. Two approaches were used for enrichment of 
LAP1 peptides. In the first procedure, membrane proteins from SH-SY5Y cells were 
enriched by centrifugation in 50 mM Tris-HCl buffer (insoluble fraction, pellet) and in 
the second, SH-SY5Y cell lysates were immunoprecipitated with the LAP1 specific 
antibody. SH-SY5Y total cell lysates were also employed for HPLC-MS analysis. All 
three samples were loaded on SDS-PAGE followed by Coomassie blue colloidal 
staining. The bands corresponding to LAP1B (68 kDa) and LAP1C (56 kDa) were 
excised and analyzed by HPLC-MS. Following careful excision, bands were tryptically 
digested, and the resulting peptides analysed in a nano-HPLC system online coupled to 
a Q Exactive mass spectrometer (Thermo Fisher Scientific, Germany). Overall, 80 
unique peptides of LAP1B/LAP1C were identified, for all the conditions analysed. 
Immunoprecipitation of LAP1 and isolation of membrane proteins showed to be 
efficient techniques for the enrichment of LAP1 isoforms, since a large number of 
peptides were identified in comparison with the number of peptides identified from total 
cell lysates (Table III.2).  
  
 132 
 
 
Table III.2. LAP1 peptides identified by mass spectrometry analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three different samples were analyzed by mass spectrometry analysis: total cell lysates, membrane 
containing-fraction and LAP1 immunoprecipitates (IP), as described in the methods section. Samples 
were loaded on SDS-PAGE, gels stained with Coomassie blue colloidal and 68 kDa and 56 kDa bands 
(corresponding to LAP1B and LAP1C, respectively) excised from the gel before mass spectrometry 
analysis. The different peptides identified are listed on the right and the presence of the peptides in each 
condition analyzed (lysate, membrane fraction or IP) is marked by an x. The number of peptides 
identified in each condition is also shown. In total, 80 unique peptides were identified, taking in account 
all conditions analyzed. 
  
 
  
 68 kDa band (LAP1B) 56 kDa band (LAP1C) 
Peptides Lysate 
Membrane 
fraction  
IP Lysate 
Membrane 
fraction 
IP 
EGWGVYVTPR  x x    
LAPQNGGSSDAPAYR   x    
FSDEPPEVYGDFEPLVAK  x x    
LQQQHSEQPPLQPSPVMTR x x  x x x 
LQQQHSEQPPLQPSPVMTRR     x  
DSHSSEEDEASSQTDLSQTISK  x x   x 
DSHSSEEDEASSQTDLSQTISKK   x   x 
SIQEAPVSEDLVIR x x x x x x 
RPPLRYPR    x x  
VNFSEEGETEEDDQDSSHSSVTTVK  x x x  x 
SSSQYIESFWQSSQSQNFTAHDK      x 
QPSVLSSGYQK   x   x 
TPQEWAPQTAR     x x 
TRMQNDSILKSELGNQSPSTSSR     x  
MQNDSILKSELGNQSPSTSSR    x x x 
QVTGQPQNASFVK x x x x x x 
QVTGQPQNASFVKR  x x x x x 
NKYQGQDEKLWK    x x  
SQPAILLLTAAR  x x  x x 
SQPAILLLTAARDAEEALR    x x  
IDGTDKATQDSDTVKLEVDQELSNGFK      x 
ATQDSDTVKLEVDQELSNGFK  x x  x x 
LEVDQELSNGFK   x  x x 
FESFPAGSTLIFYK  x x  x x 
DVALVLTVLLEEETLGTSLGLK      x 
FTNSNTPNSYNHMDPDKLNGLWSR     x  
ISHLVLPVQPENALKR x x  x x x 
ISHLVLPVQPENALK x x  x x x 
Nº peptides 5 13 14 11 18 19 
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After comparison of all peptides, 28 different peptides of LAP1B/LAP1C were 
identified. Overall, only 3 peptides were specifically identified in the 68 kDa band 
(LAP1B) and 11 peptides were only found in the 56 kDa (LAP1C) band. However, all 
these 11 peptides also match with the known sequence of LAP1B (Table III.3). The 
overall sequence coverage was 47% for LAP1B and 75.3% for LAP1C. Since the 
LAP1C protein is more abundant in SH-SY5Y cells than LAP1B, it was expected that 
more peptides in the 56 kDa band (LAP1C) would be identified. Taking into account 
the exons boundaries of LAP1B represented in table 1, it is reasonable to conclude that 
the three unique peptides found in the LAP1B-containing bands correspond to the 5’ 
end region of exon 1. Moreover, we identified peptides that aligned fully or partially 
with the 10 exons of LAP1B (Table III.3). Moreover, we identified a methionine at 
position 122, which is a few amino acids upstream of the location of the first peptide 
identified in the LAP1C-containing bands (Table III.3), indicating a potential start 
codon for LAP1C translation. This data is in agreement with GenBank AAH23247 
sequence, in which the amino acid sequence was deduced by conceptual translation of 
the BC023247 mRNA sequence. When these values are compared with the expected 
molecular weight of LAP1 isoforms (Table III.4), one can conclude that the band 
migrating at 56 kDa is consistent with the existence of a LAP1 isoform with a truncated 
exon 1 (LAP1C). Therefore, the newly identified LAP1C has a shorter exon 1 when 
compared to LAP1B, generating an N-terminal truncated protein. Given its molecular 
weight similarity with rat LAP1C the authors propose that the new human LAP1 
isoform should also have the designation LAP1C. 
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Table III.3. LAP1B and LAP1C peptides identified by liquid chromatography-mass spectrometry. 
 
The peptides identified in the 68 kDa band (corresponding to LAP1B) and in the 56 kDa band 
(corresponding to LAP1C) are listed. The localization of those peptides (highlighted in grey) is shown in 
the amino acid sequence of the known LAP1B for comparative analysis. Amino acids located in exon 
boundaries are represented in upper case and underlined. A second methione, that may represent the 
translation start site of LAP1C, is boxed.  
 
  
 Peptides Position of peptides in the known LAP1B sequence 
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EGWGVYVTPR 
  1 magdgrraea vregwgvyvt prapiregrg rlapqnggss dapayrtpps rqgrrevrfs 
 61 deppevygdf eplvakersp vgkrtrleef rsdsakeevr esayylrsrq rrqprpqete 
121 emktrrttrl qqqhseqppl qpspvmtrrg lrdshsseEd eassqtdlsq tiskktvrsi 
181 qeapAvsedl virlrrpplr ypryEatsvq qkvnfseeGe teeddqdssh ssvttvkars 
241 rdsdesgDkt trsssqyies fwqssqSqnf tahdkqpsvl Ssgyqktpqe wapqtarirt 
301 rmqNdsilks elgnqspsts srQvtgqpqn asfvkrnrww llpliaalas gsfwffstpe 
361 vettavqefq nqmnqlknky qgqdeklwkr sqtflekhln sshprsqpai llltaardae 
421 ealrclseqi adayssfrsv rairidgtdk atqdsdtvkl evdqelsngf kngqnaavvh 
481 rfesfpagst lifykycdhe naafkdvalv ltvlleeetl gtslglkeve ekvrdflkvk 
541 ftnsntpnsy nhmdpdklng lwsrishlvl pvqpenalkr gicl 
LAPQNGGSSDAPAYR 
FSDEPPEVYGDFEPLVAK 
LQQQHSEQPPLQPSPVMTR 
DSHSSEEDEASSQTDLSQTISK 
DSHSSEEDEASSQTDLSQTISKK 
SIQEAPVSEDLVIR 
VNFSEEGETEEDDQDSSHSSVTTVK 
QPSVLSSGYQK 
QVTGQPQNASFVK 
QVTGQPQNASFVKR 
SQPAILLLTAAR 
ATQDSDTVKLEVDQELSNGFK 
LEVDQELSNGFK 
FESFPAGSTLIFYK 
ISHLVLPVQPENALK  
ISHLVLPVQPENALKR 
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LQQQHSEQPPLQPSPVMTR  
 
 
 
 
 
  1 magdgrraea vregwgvyvt prapiregrg rlapqnggss dapayrtpps rqgrrevrfs 
 61 deppevygdf eplvakersp vgkrtrleef rsdsakeevr esayylrsrq rrqprpqete 
121 emktrrttrl qqqhseqppl qpspvmtrrg lrdshsseEd eassqtdlsq tiskktvrsi 
181 qeapAvsedl virlrrpplr ypryEatsvq qkvnfseeGe teeddqdssh ssvttvkars 
241 rdsdesgDkt trsssqyies fwqssqSqnf tahdkqpsvl Ssgyqktpqe wapqtarirt 
301 rmqNdsilks elgnqspsts srQvtgqpqn asfvkrnrww llpliaalas gsfwffstpe 
361 vettavqefq nqmnqlknky qgqdeklwkr sqtflekhln sshprsqpai llltaardae 
421 ealrclseqi adayssfrsv rairidgtdk atqdsdtvkl evdqelsngf kngqnaavvh 
481 rfesfpagst lifykycdhe naafkdvalv ltvlleeetl gtslglkeve ekvrdflkvk 
541 ftnsntpnsy nhmdpdklng lwsrishlvl pvqpenalkr gicl 
 
LQQQHSEQPPLQPSPVMTRR 
DSHSSEEDEASSQTDLSQTISK 
DSHSSEEDEASSQTDLSQTISKK 
SIQEAPVSEDLVIR 
RPPLRYPR 
VNFSEEGETEEDDQDSSHSSVTTVK 
SSSQYIESFWQSSQSQNFTAHDK 
QPSVLSSGYQK 
TPQEWAPQTAR 
TRMQNDSILKSELGNQSPSTSSR 
MQNDSILKSELGNQSPSTSSR 
QVTGQPQNASFVK 
QVTGQPQNASFVKR 
NKYQGQDEKLWK 
SQPAILLLTAAR 
SQPAILLLTAARDAEEALR 
IDGTDKATQDSDTVKLEVDQELSNGFK 
ATQDSDTVKLEVDQELSNGFK 
LEVDQELSNGFK 
FESFPAGSTLIFYK 
DVALVLTVLLEEETLGTSLGLK 
FTNSNTPNSYNHMDPDKLNGLWSR 
ISHLVLPVQPENALK 
ISHLVLPVQPENALKR 
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Table III.4. Human LAP1 transcripts and isoforms. 
 
Organization and exon size (bp) of the previously described LAP1B transcripts and the new LAP1C 
transcript is described. The number of amino acids, calculated molecular weight (MW) and MW inferred 
through migration in SDS-PAGE gel of LAP1 isoforms are also shown. NC, not confirmed. The full size 
of exon 1 and the mRNA of LAP1C was not confirmed. 
 
 
III.3.5. Identification of a putative promoter in LAP1C sequence 
 
This study clearly demonstrates that two LAP1 isoforms are present in human cells 
and are most likely generated by the translation of two different mRNAs. Therefore, the 
regulatory mechanism underlying the expression of two LAP1 isoforms may be due to 
the transcriptional regulation of LAP1. Therefore, we analyzed the genomic sequence of 
the first exon of the human TOR1AIP1 gene in order to find putative alternative 
promoters that would lead to a downstream alternative transcription initiation and 
produce the smaller LAP1C transcript. NNPP and TSSG programs permitted the search 
for candidate promoters. These programs predicted a promoter in the region 
downstream of the translation initiation site of LAP1B and upstream of the translation 
initiation site of LAP1C (Fig. III.7). A putative TATA box was predicted 29 nucleotides 
downstream from the predicted transcription initiation site, using the TSSG program. 
 Human LAP1 transcripts 
 LAP1B (variant 1) LAP1B (variant 2) LAP1C 
Exon Total Coding Total Coding Total Coding 
1 936 475 693 475 NC 112 
2 78 78 78 78 78 78 
3 60 60 57 57 60 60 
4 42 42 42 42 42 42 
5 87 87 87 87 87 87 
6 57 57 57 57 57 57 
7 42 42 42 42 46 46 
8 69 69 69 69 69 69 
9 57 57 57 57 57 57 
10 2624 785 2624 785 2624 785 
mRNA size (bp) 4054 1752 4051 1749 > 3358 1386 
 Human LAP1 isoforms 
Nº of amino acids 584 583 462 
Calculated MW (kDa) 66.3 65.6 52.5 
Migration in SDS-
PAGE (kDa) 
68 68 56 
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Furthermore, the region of the predicted transcription initiation site is conserved 
between species (Fig. III.7). 
 
 
Figure III.7. Predicted promoter and alternative transcription initiation site of human LAP1C. A- 
Localization of a predicted promoter in the TOR1AIP1 genomic sequence. The promoter region predicted 
using the NNPP program is underlined. The transcription initiation site predicted by the TSSG program is 
indicated by an arrow and the one predicted by the NNPP program is indicated by a double arrow. The 
putative TATA box predicted using the TSSG program is indicated by a box. B- Alignment of the 
predicted human promoter region with the homologous mouse and rat sequences. 
 
 
III.3.6. Functional characterization of LAP1 isoforms  
III.3.6.1. Solubilization properties of LAP1 isoforms 
 
Analysis of the subcellular localization of different LAP1B deletion mutants 
demonstrated that only constructs with the whole nucleoplasmic domain were fully 
resistant to extraction with triton X-100. Deletion mutants containing only a part of the 
nucleoplasmic domain were extractable using this detergent (Kondo et al., 2002). 
Furthermore, it was also reported that most of rat LAP1C is solubilized using triton X-
100 plus 100 mM NaCl, while LAP1A and LAP1B remain in the pellet (insoluble 
fraction) as well as lamins (Foisner and Gerace, 1993). Therefore, we went on to test if 
the human LAP1C isoform is less resistant to extraction from nuclear membranes using 
triton X-100 and increasing salt concentrations (NaCl). Our results showed that LAP1C 
is partially solubilized after triton X-100 addition, while LAP1B remains in the pellet 
(Fig. III.8). Furthermore, the majority of LAP1C is solubilized after extraction with 
triton X-100 plus 50 mM NaCl and it is not found in the pellet using high salt 
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concentration (500 mM). In contrast, LAP1B is only fully solubilized after extraction 
with triton X-100 plus 500 mM NaCl (Fig III.8). Lamin B1 and β-tubulin were used as 
controls. As expected, lamin B1 is found in the pellet fraction while β-tubulin is found 
in the supernatant in all conditions analyzed (Fig. III.8). There is just a minor amount of 
β-tubulin in the pellet fraction when neither triton nor NaCl are added. These results are 
in agreement with the fact that human LAP1C differs from LAP1B in the first exon 
located in the nucleoplasmic domain.  
 
 
Figure III.8. Solubilization properties of human LAP1 isoforms. Solubilization of LAP1 in Tris-HCl 
buffer or Tris-HCl buffer containing 1% triton X-100, 1% triton X-100 and 50 mM NaCl or 500 mM 
NaCl. Equal fractions of supernatant (SN) and pellet (P) were loaded. IB, immunoblotting. 
 
 
III.3.6.2. Cell and tissue specific expression pattern of LAP1 isoforms 
 
It was previously reported that rat LAP1A is the major isoform identified in rat 
liver tissue, while LAP1C is highly expressed in cultured cells (Senior and Gerace, 
1988). Therefore, immunoblotting with LAP1 antibody in human samples was 
performed, in order to establish if human LAP1 isoforms are differentially expressed in 
human cell lines and distinct tissues. In fact for the different human cell lines (HeLa, 
SKMEL-28 and SH-SY5Y cells, derived from a cervical cancer, skin melanoma and 
neuroblatoma, respectively) tested, LAP1C protein is more abundant than LAP1B (Fig. 
III.9A), in agreement with previous reports. In rat, LAP1C is the major isoform in the 
pheochromocytoma rat cell line PC12, while in rat cortex lysates, the ratio between 
LAP1C and LAP1B decreases (Fig. III.9A), although in the latter case expression of 
both isoforms is quite similar. In contrast, LAP1B and LAP1C expression profiles, in 
human tissues, appear to be dependent on the specific tissue (Fig. III.9B). LAP1C has 
 138 
 
higher expression levels in lung, kidney and spleen, compared to LAP1B. In contrast, 
LAP1B is the major isoform present in liver, brain and heart, while in ovary, testis and 
pancreas the expression of both LAP1B and C is quite similar. An interesting aspect is 
the fact that in human brain, the expression of LAP1B is higher than LAP1C. Other 
bands appear in these blots and their significance deserves further attention. 
 
 
Figure III.9. LAP1 expression in different cell lines and tissues. A- Endogenous LAP1 isoforms were 
detected in HeLa, SKMEL-28 and SH-SY5Y human cells and in rat PC12 cell line and rat cortex lysates. 
B- Human tissue blot (Clontech) was immunoblotted with LAP1 antibody. 1, liver; 2, brain; 3, lung; 4, 
kidney; 5, spleen; 6, testis; 7, ovary; 8, heart, 9, pancreas. C- Endogenous expression of LAP1 isoforms 
was detected in primary cortical neurons for 14 DIV, using a LAP1 antibody. Synaptophysin and PP1γ 
were used as controls for expressing patterns D- Endogenous expression of LAP1 isoforms was detected 
in SH-SY5Y cells differentiated with retinoic acid for 10 DIV using a LAP1 antibody. β-tubulin and PP1γ 
were used as controls.  
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Previous reports suggested that the expression of the three mouse LAP1 isoforms 
seems to be developmentally regulated. By comparing the mouse P19 teratocarcinoma 
cell line and the differentiated P19MES line, mouse LAP1A and LAP1B were strongly 
expressed only in the differentiated cells, while LAP1C was found in both cell types 
(Martin et al., 1995). Therefore, we also analyzed the expression pattern of LAP1 
isoforms during the establishment of cortical primary cultures for 14 days in vitro 
(DIV). Our data showed that LAP1B and LAP1C expression increases during neuronal 
development (Figure 7C). However, LAP1C expression in cortical neurons reaches a 
maximum a 10 DIV and remains almost constant thereafter. In contrast, LAP1B is 
expressed at very low levels until 10 DIV and increases over 14 DIV (Fig. III.9C). 
LAP1B is barely detected at 2 and 4 DIV, in comparative terms (longer exposure times 
will produce more intense bands). The pre-synaptic marker synaptophysin and PP1γ 
were used as controls. These results indicate that LAP1B is highly expressed in 
functional mature neurons since its intracellular levels correlate very well with 
synaptophysin levels, a pre-synaptic marker.  
Similar results were obtained when SH-SY5Y cells were differentiated. Briefly, 
SH-SY5Y cells were plated at a density of 1 x 10
5 
and grown for 10 days in MEM/F12 
medium with 10% FBS in the presence of 10 µM retinoic acid. Under the experimental 
conditions tested, the expression of both LAP1B and LAP1C increased during 
differentiation (Fig. III.9D). However the increase of LAP1B levels were more marked 
than LAP1C levels, as demonstrated by the ratio between both proteins (Fig. III.9D) and 
its intracellular levels are high when the cells are differentiated. Of note, 
undifferentiated SH-SY5Y cells also express the LAP1B isoform and it was visible 
when membranes were exposed for longer periods of time.  
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III.3.7. Regulation of both isoforms by pos-translational modifications 
 
We have recently reported that human LAP1B is dephosphorylated in vitro by 
PP1 (Santos et al., 2013). Protein phosphorylation is a crucial mechanism for signal 
transduction that regulates the biological activity of diverse proteins (Barford et al., 
1998; Cohen, 1989). Thus, it is important to understand if human LAP1C is likewise 
regulated by protein phosphorylation and if PP1 is responsible for its 
dephosphorylation, as occurs with LAP1B. Hence we performed an assay similar to that 
previously reported by us and developed for LAP1B (Santos et al., 2013). Hence, SH-
SY5Y cells were incubated with two different concentrations of OA (0.25 nM and 500 
nM that inhibit PP2A and PP1/PP2A, respectively) and cell lysates were further 
incubated with 100 ng of recombinant purified PP1γ1 protein (Fig. III.10A). The results 
showed that after addition of purified PP1γ1 an increase in the migration of both LAP1 
isoforms is detected (Fig. III.10A), consistent with the dephosphorylation of these 
proteins by PP1γ1. Therefore, it appears that both human LAP1B and LAP1C are 
desphosphorylated by PP1.  
Further, HPLC-MS analysis unequivocally showed that both isoforms are 
regulated by protein phosphorylation. SH-SY5Y cells were incubated with 0.25 nM OA 
or 500 nM OA. A control, i.e. cells not treated with OA, was also included in the 
experiment. Then cells were lysed and immunoprecipitated with LAP1 specific 
antibody. Immunoprecipitates were loaded on SDS-PAGE and 68 kDa and 56 kDa 
bands (corresponding to LAP1B and LAP1C, respectively) were excised and 
subsequently analysed by nanoHPLC-MS in a Q Exactive mass spectrometer. In total, 
four phosphorylated residues (Ser216, Ser306, Ser310, and Thr221) were identified in 
the peptides resultant from digestion of LAP1C protein (Fig. III.10B). Since LAP1B 
protein sequence is equal to LAP1C, with the exception of a longer N-terminal, we infer 
that LAP1B could be also phosphorylated in the same residues. Thus, the numeration of 
the residues is relative to the human LAP1B protein sequence for comparative analysis. 
Peptides phosphorylated on Ser216 and Thr221 residues were identified in the control 
condition (without OA treatment) and also when PP1 was inhibited (500 nM OA 
treatment). Moreover, two additional residues, Ser 306 and Ser310, were found to be 
phosphorylated specifically in the latter condition (Fig. III.10B). These results 
demonstrated that PP1 is likely involved in the dephosphorylation of Ser306 and 
Ser310, since these residues were not found to be phosphorylated in the control 
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condition (without OA treatment) neither in the PP2A-inhibited condition (0.25 nM OA 
treatment). Further, membrane enriched fraction from SH-SY5Y cells, acquired as 
previously described, was also loaded on SDS-PAGE and the LAP1B and LAP1C 
bands analysed by HPLC-MS following the same procedures described above. This 
analysis resulted in the identification of one additional phosphorylated LAP1B/C 
residue: Ser143 (Fig. III.10B). From overall, we identified 5 different phosphorylated 
residues of LAP1B/C, but only Ser306 and Ser310 residues were associated with PP1 
activity. Furthermore, Ser143, Thr221 and Ser310 residues are conserved between 
human, rat and mouse species while Ser216 and Ser306 are not conserved (Fig. 
III.10B).  
Additionally, another post-translational modification of human LAP1B and 
LAP1C was identified by HPLC-MS. Three methionines (Met146, Met302 and 
Met553) were modified by the addition of oxygen (Fig. III.10B). None of these 
methionines serves as an initiation site for LAP1B or LAP1C proteins synthesis. 
Furthermore, Met146 residue is not conserved, but Met302 and Met553 residues are 
conserved between human, rat and mouse species (Fig. III.10B)  
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Figure III.10. Human LAP1 post-translational modifications. A- SH-SY5Y cells were incubated with 
0, 0.25 or 500 nM okadaic acid (OA) for 3 hours. Lysates were incubated at 30ºC for 1 hour with or 
without 100 ng of PP1γ1 protein. B-. LAP1 isoforms are phosphorylated on Ser 143, Ser 216, Thr 221, 
Ser 306 and Ser 310 residues. PP1 was found to be responsible for Ser 306 and Ser 310 residues 
dephosphorylaton (indicated by arrows). Methionine residues 146, 302 and 553 residues were found to be 
oxidized. Post-translational modified residues and flanking regions were aligned against others species 
using Clustal Omega algorithm. The residues numeration is relative to the LAP1B sequence and the 
translation initiation site of LAP1C is indicated by a dashed line. IB, immunoblotting. 
. 
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III.4. DISCUSSION 
 
The work here presented permitted the identification of a novel LAP1 isoform 
(LAP1C) in human cells using a variety of methods and confirmed by HPLC-MS 
analysis. LAP1C has a short N-terminal domain, when compared to LAP1B. 
Furthermore it appears that human LAP1 isoforms (LAP1B and LAP1C) are regulated 
at the transcriptional level and can be subject to post-translational modifications, 
namely protein phosphorylation and methione oxidation. Additionally we established 
that PP1 mediates the dephosphorylation of LAP1C and B at Ser306 and Ser310 
residues.  
The genomic structure of TOR1AIP1 genes from human, rat and mouse species is 
conserved. Indeed, human and rat TOR1AIP1 genes have 10 conserved exons, while 
mouse has 12 exons in total and 9 exons present high identity compared to rat and 
human exons (Fig. III.1). Additional exons 1b, 3b and 5b were found in mouse 
transcripts. Alignment of these exons against the human and rat genomic sequences 
revealed the presence of putative alternative exons 1b and 3b in the respective genes. 
However, we were not able to identify alternative exons in human transcripts by RT-
PCR (Fig. III.4). However, our in silico data suggest that potential new isoforms of 
LAP1 could be generated by alternative splicing. In eukaryotes, transcript variants arise 
from a combination of alternative transcription start sites selection, alternative splicing 
and differential usage of polyadenylation sites (Carninci et al., 2005). It was previously 
reported that rat LAP1 isoforms are generated by alternative splicing (Martin et al., 
1995). In addition to alternative splicing, our data also suggests that alternative 
transcription start sites or alternative promoters could generate distinct LAP1 isoforms. 
We found non-RefSeq mRNAs and ESTs in GenBank that lack the 5´end region of 
exon 1, thereby they do not have the first translation start site present in the full-length 
exon 1- transcripts. This is common to the three species analyzed (human, rat and 
mouse). A significant number of genes use one or more alternative promoters. The 
usage of alternative promoters can induce alterations in the N-terminal of the protein 
coding sequence or create alternative ORFs, thereby potentiating the diversity of 
eukaryotic genome expression (Landry et al., 2003; Trinklein et al., 2003; Zhang et al., 
2007). Moreover, alternative promoters are also functionally correlated with alternative 
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splicing. Thus alternative promoter usage and alternative splicing are two major 
mechanisms for increasing transcript diversity (Meshorer et al., 2004; Xin et al., 2008). 
Although we were unable to produce an additional LAP1 human transcript by RT-
PCR we showed that an alternative LAP1 transcript exists in human cells given that: (i) 
transfecting SH-SY5Y cells with two specific LAP1 shRNAs resulted in the knockdown 
of two LAP1 immunoreactive bands (68 and 56 kDa) (Fig. III.1); (ii) the lower band of 
56 kDa has the same molecular weight as the rat LAP1C isoform; (iii) Northern blot 
analysis revealed the presence of two differently sized RNAs (Fig. III.5); (iv) alternative 
exons were found by in silico analysis. Furthermore and conclusively, the SDS-PAGE 
extracted 56 kDa protein (LAP1C), when analyzed by HPLC-MS, was shown to be 1 
exon shorter when compared to LAP1B, thus generating an N-terminal truncated 
protein. A methionine at position 122 (relative to LAP1B sequence) was also identified, 
indicating a potential start codon for LAP1C translation (Table 3). The non-RefSeq 
mRNAs present in GenBank have different N-terminal sequences thus excluding the 
start codon used for LAP1B. Consistently, the downstream in frame start codon is 
present at position 122, in agreement with our HPLC-MS results. Moreover, the 
theoretical molecular weight of the identified LAP1C isoform (Table 4) is in agreement 
with the band of 56 kDa identified by immunoblotting using the LAP1 antibody.  
Previous reports showed that deletion of a part of the nucleoplasmic domain of 
LAP1B increase the solubilization of this protein after detergent addition (Kondo et al., 
2002). Hence, the resistance of the LAP1 isoforms (in particular LAP1C) to extraction 
from nuclear membranes was tested, using triton X-100 and increasing salt 
concentrations (NaCl). We demonstrated that LAP1C is more easily solubilized (Fig. 
III.8) than LAP1B, in agreement with the observation that human LAP1C differs from 
LAP1B in the 5´end region of the first exon located in the nucleoplasmic domain. 
Although it becomes clear that human LAP1 isoforms contain different N-termini, the 
origin of these proteins has to be established. The identification of two human LAP1 
RNAs by Northern blot analysis and the existence of non-RefSeq mRNAs matching 
with the putative LAP1C sequence in GenBank, suggests that LAP1B and LAP1C are 
products of different RNAs and thereby their generation is regulated at the 
transcriptional level. Therefore, LAP1 isoforms could arise from alternative splicing or 
alternative promoter usage and consequently use an alternative transcription initiation 
site. Database searches for alternative promoters, identified an upstream putative 
LAP1C translation initiation site (Fig. III.7). Despite this, resolution of this question 
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will require additional experiments. Several reports showed that the 5’ UTR region is 
shorter in certain mRNAs and arise via alternative splicing or activation of a 
downstream alternative promoter. Normally, this process leads to the increased 
synthesis of a specific protein, meaning that the translation of short 5’ UTR mRNAs is 
more efficient in those cases. On the other hand, extension of the 5’ UTR may provide a 
more complex and controlled regulation of gene expression (Charron et al., 1998; Han 
et al., 2003; Meshorer et al., 2004). It will also be interesting to understand the 
consequences in the lost of the N-terminal domain of LAP1C in protein-protein 
interactions. Previous reports suggested that rat LAP1C has a weaker interaction with 
the nuclear lamina in comparison with rat LAP1A and LAP1B (Foisner and Gerace, 
1993; Senior and Gerace, 1988). Moreover, rat LAP1A and LAP1B were found to bind 
directly to lamins A, C and B1 in vitro and probably indirectly to chromosomes (Foisner 
and Gerace, 1993), while rat LAP1A/C was found to immunoprecipitate with B-type 
lamins (Maison et al., 1997).  
We have recently reported that LAP1B is dephosphorylated in vitro by PP1 
(Santos et al., 2013). Protein phosphorylation is a major signaling mechanism in 
eukaryotic cells that is able to regulate the biological activity of diverse proteins 
(Barford et al., 1998; Cohen, 1989), including proteins involved in pathological 
conditions (Fardilha et al., 2010; Rebelo et al., 2013; Rebelo et al., 2007; Vieira et al., 
2010). In the work here described, the newly identified human LAP1C isoform was 
shown to be also dephosphorylated by PP1 (Fig. III.10). In addition, phosphorylation 
sites were mapped by HPLC-MS. Five phosphorylated residues were identified (Ser143, 
Ser216, Thr221, Ser306 and Ser310) in LAP1B/LAP1C and PP1 was shown to be 
associated with the dephosphorylation of two of these residues (Ser306 and Ser310, the 
numeration of the residues is relative to the human LAP1B protein sequence). 
Moreover, Ser143, Thr221 and Ser310 residues are conserved between the species 
analysed. Functional phosphorylation sites are more conserved during evolution than 
sites without characterized function (Landry et al., 2009). Therefore, it will be 
interesting to understand the effects of reversible protein phosphorylation on LAP1 
function. In addition, we found that LAP1 is also post-translationally modified by 
methionine oxidation. Methionine is oxidized to methionine sulfoxide by the addition of 
an extra oxygen atom (methionine oxidation) and this process may function as a protein 
regulatory mechanism (reviewed in Kim et al., 2013). 
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LAP1 is ubiquitously expressed in neuronal and non-neuronal tissues (Goodchild 
and Dauer, 2005; Goodchild et al., 2005). Previous reports also showed that LAP1A, B 
and C are all detected in liver, spleen, brain and kidney rat tissues, but LAP1A seems to 
be the major isoform present in rat liver. In contrast,  LAP1C is the major isoform found 
in rat cultured cells (Senior and Gerace, 1988). Our results are in agreement with 
previous data, since we detected higher expression of human LAP1C isoform in 
different cultured cells in comparison to LAP1B (Fig. III.9A). However, when we 
analyzed human tissues we found that the expression of LAP1B/LAP1C is dependent 
on the specific tissue (Fig. III.9B). Nevertheless, the human LAP1 isoform with higher 
molecular weight identified so far, LAP1B, is more abundant in liver than the smallest 
LAP1C isoform, in agreement with previous studies in rat liver tissue. Of particular 
interest is the profile of LAP1 expression in brain. LAP1 was found to interact with 
torsinA, the protein involved in the neurological disorder DYT1 dystonia. LAP1 is able 
to relocate torsinA to the NE, although the latter is normally found in ER (Goodchild 
and Dauer, 2005). The torsinA mutant form, which is present in DYT1 dystonia 
patients, is also primarily relocated to the NE (Goodchild and Dauer, 2004; Naismith et 
al., 2004). Therefore, it was suggested that abnormal accumulation of torsinA in the 
nuclear envelope may lead to a nuclear envelope dysfunction through LAP1 binding, 
thus contributing to DYT1 dystonia pathogenesis.  
Furthermore, the expression of the LAP1 isoforms seems to be regulated during 
mouse spinal cord development and maturation (Goodchild et al., 2005). In order to 
understand if LAP1 isoforms are also differentially regulated in neuronal models, its 
expression profile during neuronal differentiation of SH-SY5Y cells (0-10 DIVs) (Fig. 
III.9D) and during maturation of rat cortical primary cultures (2-14 DIVs) (Fig. III.9C) 
was analyzed. Thus, we showed that in both models, LAP1C is already detected at 0/2 
DIV while LAP1B is barely detected at this time point. However, the expression 
differences between LAP1C/LAP1B decrease during DIVs, which means that LAP1B is 
upregulated later when compared to LAP1C. Moreover, the expression of LAP1C is 
maintained at late DIVs while LAP1B continues to increase. Previous studies reported 
that LAP1A and LAP1B are strongly expressed in mouse liver cells and differentiated 
P19MES cells, while in mouse embryonic 3T3 cells and undifferentiated P19 cells 
LAP1A and LAP1B are barely detected. In contrast LAP1C is expressed in all cells 
(Martin et al., 1995). In our work, we provide a link between LAP1 expression and the 
state of neuronal differentiation of SH-SY5Y cells and maturation of neurons, 
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suggesting that LAP1 may play a role in those processes. It was previously reported that 
knockout of TOR1AIP1 gene in mouse results in perinatal lethality and the nuclear 
membranes of various tissues and cultured neurons of those mouse embryos showed 
severe abnormalities (Kim et al., 2010a). Therefore, disturbances in the expression of 
LAP1 may compromise neuronal survival. 
In conclusion, this is the first report of human LAP1C isoform recovery from 
human cells. Some related mRNA sequences have been already described in GenBank, 
however they were not identified as splice variants of human LAP1. Moreover, this 
work provides new insights with respect to TOR1AIP1 genomic structure, potential 
transcripts and protein isoforms. Our data suggest that new potential human LAP1 
isoforms could be generated by alternative splicing and deserve further investigation. 
We also showed that human LAP1B and LAP1C isoforms are differentially expressed 
and post-translationally regulated by protein phosphorylation and methionine oxidation. 
Finally, it was shown that PP1 is likely involved in the dephosphorylation of at least 
two LAP1B/LAP1C residues (Ser306 and Ser310). 
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LAP1 was one of the first lamin associated proteins identified (Senior and Gerace, 
1988), however its function remains poorly understood. Nevertheless, LAP1 is probably 
involved in the regulation of the NE structure and mitosis progression. Thus the work 
described in chapter IV provides particular insights with respect to the localization and 
phosphorylation state of LAP1 during the cell cycle and its importance for nuclear 
integrity and cell cycle progression. The results presented in this chapter provide a basis 
for future studies and will be submitted for publication in the Molecular and Cellular 
Biochemistry journal, and the manuscript (manuscript 3) is entitled: “Cell cycle 
progression is LAP1 dependent”.  
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Abstract 
Cell division in eukaryotes requires the disassembly of the nuclear envelope (NE) 
when cells enter mitosis and reassembly at the end of mitosis. These processes are 
complex and involve coordinated steps where NE proteins have a crucial role. Lamina 
associated polypeptide 1 (LAP1) is an inner nuclear membrane protein that is 
potentially associated with cell cycle-dependent events. In support of this role, LAP1 
has been implicated in the regulation of the NE reassembly (Gerace and Foisner, 1994; 
Martin et al., 1995) and assembly of the mitotic spindle (Neumann et al., 2010) during 
mitosis. In this study, we demonstrated that LAP1 intracellular levels vary during the 
cell cycle in SH-SY5Y cells, and that LAP1 is highly phosphorylated during mitosis. 
We also observed that LAP1 co-localized with α-tubulin acetylated in the mitotic 
spindle and with γ-tubulin in centrosomes (main microtubule organizing center) in 
mitotic cells. Moreover, LAP1 knockdown resulted in decrease number of mitotic cells 
and decrease levels of α-tubulin acetylated (marker of microtubules stability) and lamin 
B1. These findings place LAP1 at a key position to participate in the maintenance of the 
NE structure and progression of cell cycle.  
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IV.1. INTRODUCTION 
 
In eukaryotes, chromosomes are enclosed in the nucleus by the nuclear envelope 
(NE) that separates the nuclear content from the cytoplasm one. During mitosis, the NE 
remains intact (“closed mitosis”) in organisms such as yeast, or is only partially 
disrupted at later stages of mitosis, as it happens in Caenorhabditis elegans and 
Drosophila melanogaster. In sharp contrast, in most higher eukaryotes, the NE is 
completely disassembled at the onset of mitosis and reassembled at the end of mitosis 
(“open mitosis”). Microtubules that form the mitotic spindle are exclusively 
cytoplasmic but have to come in contact with chromosomes for correct chromosome 
segregation during cell division. Thereby, NE breakdown allows the access of spindle 
microtubules to chromosomes (reviewed in Arnone et al., 2013; Foisner, 2003; 
Guttinger et al., 2009). The NE breakdown involves the disassembly of the nuclear pore 
complex (NPCs), depolymerization of lamins, and spreading of most NE soluble 
components and inner nuclear membrane (INM) proteins to the cytoplasm and ER 
networking, respectively. The NE is reassembled at the end of mitosis by the 
concentration of INM proteins and lamins on the decondensing chromatin, lamin 
polymerization and NPCs assembly (Guttinger et al., 2009; Moir et al., 2000).  
One of the first lamin associated proteins identified was the lamina associated 
polypeptide 1 (LAP1) (Senior and Gerace, 1988), which is a type II transmembrane 
protein of the INM (Kondo et al., 2002; Martin et al., 1995). In interphase cells LAP1 is 
located at the INM in association with lamins and chromosomes. The interaction 
between LAP1 and lamins during the interphase might be important for targeting lamins 
to the NE and thereby contributing for the maintenance of the NE architecture. 
However, when the NE is disassembled during prometaphase, LAP1 seems to be 
redistributed through the ER, losing its association with chromosomes and lamins, 
thereby contributing to the NE breakdown. (Foisner and Gerace, 1993; Martin et al., 
1995; Senior and Gerace, 1988; Yang et al., 1997). Moreover, it seems that LAP1 is 
regulated by protein phosphorylation during mitosis, as it happens for other nuclear 
proteins (Dephoure et al., 2008; Olsen et al., 2010). Protein phosphorylation represents 
a pivotal regulatory mechanism in diverse aspects of cell cycle progression (Bollen et 
al., 2009; Guttinger et al., 2009). More recently, Neumann et al reported that LAP1 may 
play a role in the the assembly of the mitotic spindle and consequently in mitosis 
 154 
 
progression (Neumann et al., 2010). Nevertheless, the role of LAP1 during mitosis is 
not yet well defined.  
In this study, the intracellular levels and localization of human LAP1 was 
analyzed in cell cycle-synchronized SH-SY5Y cells. Given that phosphorylation is a 
crucial regulatory mechanism for cell cycle progression, the phosphorylation state of 
human LAP1 was also evaluated. Moreover, we established a relation between LAP1 
deficiency and decrease intracellular levels of acetylated α-tubulin which in turn 
correlates with decrease microtubules stability. This study provides a basis for a detailed 
analysis of the role of LAP1 in NE structure at interphase and dynamics during cell 
cycle.  
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IV.2. MATERIALS AND METHODS 
 
IV.2.1.  Antibodies 
 
The primary antibodies used were rabbit polyclonal LAP1 (Goodchild and Dauer, 
2005); mouse monoclonal α-tubulin (Zymed), mouse monoclonal acetylated α-tubulin 
(Sigma), mouse monoclonal γ–tubulin (Sigma), rabbit polyclonal lamin B1 (Santa Cruz 
Biotechnology) and histone H3 Ser10 (Genetex). The secondary antibodies used were 
anti-mouse and anti-rabbit horseradish peroxidase-linked antibodies (GE Healthcare) for 
ECL detection. Alexa 488-conjugated anti-mouse IgG and Alexa 594-conjugated anti-
rabbit IgG (Molecular Probes) were used for the immunolocalization studies.  
 
IV.2.2.  Cell culture and cell cycle arrest 
 
SH-SY5Y cells (ATCC CRL-2266) were grown in Minimal Essential Medium 
(MEM) supplemented with F-12 Nutrient Mixture (Gibco, Invitrogen), 10% fetal 
bovine serum (FBS, Gibco, Invitrogen), 1.5 mM L-glutamine, 100 U/mL penicillin and 
100 mg/mL streptomycin (Gibco, Invitrogen). Cell cycle arrest at G0/G1 was achieved 
by removing serum from the culture medium for 48 hours. For synchronization in 
mitosis, SH-SY5Y cells were accumulated in prometaphase by adding 100 ng/ml 
nocodazole to complete medium for 18 hours. Cells were selectively harvested by 
mechanical shock, washed and resuspended in nocodazole-free medium for 30 minutes 
for expression and phosphorylation studies. For immunolocalization studies, cells were 
washed and nocodazole-free medium was added to let cell cycle to progress for 1h. 
After that period the SH-SY5Y cells were harvested or fixed using 4% 
paraformaldehyde and preceded for immunocytochemistry analysis. 
 
IV.2.3.  Immunocytochemistry 
 
Once fixed as described above, SH-SY5Y cells were permeabilized with triton X-
100 for 10 minutes, washed with PBS 1x and then blocked in 3% BSA/PBS 1x for 1 
hour. Cells were incubated with the primary antibodies for 2 hours, followed by 
secondary antibodies for 1 hour. Preparations were washed with PBS, mounted using 
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Vectashield mounting media with DAPI (Vector). Preparations were visualized using an 
Olympus IX81 epifluoresence microscope (Olympus, Optical Co. GmbH) equipped 
with the appropriate filter combinations and a 100×objective (Plan-Neofluar, 100x/1.35 
oil objective). Images were acquired with an F-view II CCD camera (Soft Imaging 
System GmbH, Münster, Germany) driven by Soft Imaging software. Alternatively, 
preparations were also visualized using an LSM510-Meta confocal microscope (Zeiss), 
as previously described (Rebelo et al., 2013; Santos et al., 2013). 
 
IV.2.4.  LAP1 knockdown 
 
The knockdown of endogenous LAP1 in SH-SY5Y cells was achieved using a 
short hairpin RNA (shRNA) strategy as previously described (Santos, 2014). Briefly, 
SH-SY5Y cells were transiently transfected with both pSIREN-LAP1-C1 and pSIREN-
LAP1-C2 plasmids or with the pSIREN-CMS (negative control). 
 
IV.2.5.  Protein phosphorylation analysis 
 
Cellular lysates were resolved in 7.5% SDS-PAGE containing 50 µM Phos-tag 
(AAL-107, Wako) and 100 µM MnCl2. After protein electrophoresis, Phos-tag 
acrylamide gels were washed with transfer buffer (25 mM Tris, 192 mM glycine and 
20% methanol) containing 10 mM EDTA for 10 min to chelate MnCl2 and then with 
transfer buffer without EDTA for 10 min according to the manufacturer’s protocol. 
 
IV.2.6.  SDS-PAGE and immunoblotting 
 
Samples were separated on SDS-PAGE and electrophoretically transferred onto 
nitrocellulose membranes. Nitrocellulose membranes were incubated in Ponceau S 
solution for 5 minutes and then scanned in a GS-800 calibrated imaging densitometer 
(Bio-Rad), in order to assess equal gel loading. Membranes were washed in TBST 1x to 
remove Ponceau S staining, followed by immunological detection with specific 
antibodies as indicated. Membranes were saturated in 5% non-fat dry milk in TBS-T 
and further incubated with primary antibodies. Detection was achieved using 
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgGs as secondary 
antibodies and proteins visualized by ECL (GE Healthcare). 
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IV.2.7.  Quantification and Statistical Analysis 
 
Autoradiograms were scanned in a GS-800 calibrated imaging densitometer (Bio-
Rad) and protein bands quantified using the Quantity One densitometry software (Bio-
Rad). Data were expressed as mean ± SEM of at least three independent experiments. 
Statistical significance analysis was conducted by Student’s test, with the level of 
statistical significance being considered P < 0.05.  
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IV.3. RESULTS 
 
IV.3.1.  Intracellular levels and phosphorylation state of LAP1 during mitosis 
 
A large number of genes are differentially expressed throughout the cell cycle 
(Cho et al., 2001; Shedden and Cooper, 2002). Interestingly, expression of genes 
encoding nuclear proteins (e.g. lamins) increases at the end of mitosis and beginning of 
G1 phase (van der Meijden et al., 2002). Moreover, cell cycle progression is tightly 
regulated by protein phosphorylation and several nuclear proteins were found to be 
highly phosphorylated specifically during mitosis (Dephoure et al., 2008; Olsen et al., 
2010). Therefore, we tested if LAP1 is regulated in a similar manner. For that, SH-
SY5Y cells were arrested in G0/G1 phase by incubation in serum-free medium for 48 
hours and in mitosis by treatment with nocodazole for 18h, followed by incubation in 
nocodazole-free medium for additional 30 minutes. Firstly, we analyzed the intracellular 
levels of both human LAP1 isoforms (LAP1B and LAP1C) by immunoblotting using a 
specific LAP1 antibody (Goodchild and Dauer, 2005). Our results showed that the 
intracellular levels of both LAP1 isoforms were significantly higher in G0/G1-arrested 
cells (G0/1), compared to non-synchronized (NS) cells and mitosis-arrested cells (M; 
Fig. IV.1A). Moreover, opposite results were observed when cells were arrested in 
mitosis where significantly lower intracellular levels of both LAP1 isoforms were 
detected. The intracellular levels of LAP1 increased approximately 24% in G0/G1-
arrested cells and decreases by 36% in mitosis-arrested cells when compared to NS cells 
(Fig. IV.1A). The cell cycle arresting in prometaphase using nocodozale was confirmed 
by detection of histone H3 phosphorylated at Ser10 (Fig. IV.1A), which was previously 
shown elevated during mitosis (Hendzel et al., 1997). Ponceau S staining was used as 
loading control (data not shown). Further, non-synchronized and synchronized SH-
SY5Y cells were loaded on Phos-tag polyacrylamide gels in order to analyze the 
phosphorylation state of LAP1 proteins. In SDS-PAGE with polyacrylamide-bound 
Mn
2
-Phos-tag, phosphorylated proteins are trapped by the Phos-tag sites, thus delaying 
their migration (Hosokawa et al., 2010; Kinoshita et al., 2006). Therefore, in Phos-tag 
SDS-PAGE, LAP1 was separated into multiple bands in non-synchronized and 
synchronized cells, indicating as expected that LAP1 is a multiphosphorylated protein 
(Fig. IV.1B). In fact, our previous report indicated that LAP1 is multiphosphorylated in 
NS cells (Santos, 2014).  Moreover, an upward shift is visible in mitosis-arrested cells 
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(Fig. IV.1B). The two faster-migrating bands were barely detected in mitosis-arrested 
cells, while the other bands appear to have the same intensity of that seen in non-
synchronized cells (Fig. IV.1B). In addition one slower-migrating band was detected in 
mitosis-arrested cells. Thus, our results showed that LAP1 was phosphorylated during 
both interphase and mitosis, but seems to be highly phosphorylated during mitosis, in 
agreement with previous reports (Dephoure et al., 2008; Olsen et al., 2010). 
 
 
 
Figure IV.1. Detection of LAP1 proteins in cell cycle- synchronized cells. A- Quantification of LAP1B 
and LAP1C intracellular levels in NS cells, G0/1 and M-synchronized cells. Immunoblotting with histone 
H3 Ser10 antibody was performed to confirm mitosis arresting. Data are presented as mean ± SEM of at 
least three independent experiments. Statistically different from NS cells, * p < 0.05. B- Detection of 
phosphorylated LAP1 in non-synchronized (NS) cells, G0- and mitosis (M)- synchronized SH-SY5Y 
cells by the Phos-tag reagent. Proteins were separated in SDS-PAGE containing 50 µM Phos-tag and 100 
µM MnCl2 or containing only MnCl2 for comparative analysis. 
 
 
IV.3.2.  Localization of LAP1 during mitosis 
 
During mitosis, LAP1 is dispersed throughout ER membranes and is found in 
mitotic vesicles that associate transiently with the mitotic spindle (Maison et al., 1997; 
Yang et al., 1997). In this study, the distribution of human LAP1 during cell cycle was 
analyzed by immunofluorescence using a specific LAP1 antibody (Goodchild and 
Dauer, 2005) in the neuronal-like SH-SY5Y cells. Acetylated α-tubulin antibody was 
used to label the microtubules/mitotic spindle during mitosis. Our results showed that 
during interphase LAP1 localizes at the nuclear periphery in accordance with its known 
localization at the INM (Fig. IV.2). At metaphase, LAP1 is distributed throughout the 
cell in a punctuate pattern, excluding the chromosomal area, and this is also seen at 
anaphase and initial stages of telophase. In some points, LAP1 co-localized with 
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acetylated α-tubulin in the mitotic spindle and also in the mid-body (Fig. IV.2), in 
agreement with previous reports (Maison et al., 1997). At late telophase, LAP1 is 
clearly detected encircling the chromosomes (Fig. IV.2), even when chromosomes are 
still not decondensed. 
 
 
Figure IV.2. Immunolocalization of LAP1 during cell cycle in SH-SY5Y cells. Acetylated α-tubulin 
(α-tubulin acet.) labels the microtubules/mitotic spindles. Specific primary antibody for endogenous 
LAP1 was detected with Alexa Fluor 594-conjugated secondary antibody (red) and α-tubulin acetylated 
was detected with Alexa Fluor 488-conjugated secondary antibody (green). DNA was stained with DAPI 
(blue). The higher magnification view shows in more detail the co-localization of LAP1 and acetylated α-
tubulin in the mitotic spindle. Photographs were acquired using an Olympus epifluoresence microscope.  
Bars, 10 µm. 
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Additionally, we performed imunofluorescence analysis using an antibody against 
γ-tubulin, a marker for centrosomes. The results showed that a fraction of LAP1 co-
localize with γ-tubulin in centrosomes during metaphase and anaphase (Fig. IV.3). 
 
Figure IV.3. Co-localization of LAP1 and γ-tubulin during mitosis in SH-SY5Y cells. γ-tubulin labels 
the centrosomes. Specific primary antibody for endogenous LAP1 was detected with Alexa Fluor 594-
conjugated secondary antibody (red) and γ-tubulin was detected with Alexa Fluor 488-conjugated 
secondary antibody (green). DNA was stained with DAPI (blue). The higher magnification view shows in 
more detail the co-localization of LAP1 γ-tubulin in centrosomes. Photographs were acquired using an 
Olympus epifluoresence microscope. Bars, 10 µm. 
 
 
IV.3.3.  Effects of LAP1 knockdown 
 
During mitosis, LAP1 has been implicated in the assembly of the mitotic spindle 
(Neumann et al., 2010) and in the reassembly of the NE; the latter mainly due to the 
association with chromosomes at the end of mitosis (Gerace and Foisner, 1994; Martin 
et al., 1995). However, the specific role of LAP1 association with microtubules/mitotic 
spindle was not yet established. In order to determine the functional impact of LAP1 
and alpha-tubulin association, LAP1 was down regulated in SH-SY5Y cells using 
specific LAP1-shRNAs. Cells were transfected with two different LAP1-shRNAs 
(pSIREN-LAP1 plasmids) or with the negative control, the pSIREN-CMS plasmid. 
Then immunofluorescence analysis was performed using LAP1 and acetylated α-tubulin 
antibodies and DAPI (nuclear marker) to monitor cell cycle phases. Microscopic 
visualization of LAP1-negative and –positive labeled cells, leads us to confirm that 
LAP1 levels were reduced by 36%. Afterward, we analyzed and count mitotic cells in 
pSIREN-CMS and pSIREN-LAP1 transfected cells. The results showed that the 
percentage of mitotic figures in control cells is about 3.39% but this number decreases 
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to 2.37% in LAP1-deficient cells (Fig. IV.4A). This mean that the number of mitotic 
cells significantly decrease (around 30% less) after LAP1 knockdown. Moreover, the 
nucleus of LAP1-negative labeled interphase cells presented an abnormal morphology 
(Fig. IV.4B). The distribution of acetylated α-tubulin was also altered in those cells. 
Acetylated α-tubulin was either concentrated around the nucleus or barely detected (Fig. 
IV.4B), thus suggesting that the levels of acetylated α-tubulin decreased in LAP1-
depleted cells. In addition, the effects of LAP1 knockdown were analyzed by 
immunoblotting. Since the nuclei of LAP1-depleted cells have abnormal morphology, 
we performed immunoblotting with lamin B1 antibody to infer about nuclear lamina 
integrity. Our results showed that LAP1 knockdown lead to decrease levels of lamin B1 
(approximately 33%). In agreement with immunofluorescence observations, we also 
showed that LAP1-deficient cells presented lower levels of acetylated α-tubulin, thereby 
resulting in a decrease of approximately 27% in the ratio acetylated α-tubulin/total 
tubulin (Fig. IV.4C). Moreover, the levels of histone H3 phosphorylated at Ser10 were 
reduced approximately 41% in LAP1-deficient cells (Fig. IV.4C), in agreement with the 
lower number of mitotic cells detected by microscopic visualization (Fig. IV.4A). 
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Figure IV.4. Effects of shRNA knockdown of human LAP1. SH-SY5Y cells were transfected with two 
specific LAP1 shrnas (LAP1) or a control missense shRNA (CMS) A- Analysis of the number of cells in 
mitosis after LAP1 knockdown. The analysis of LAP1 expression (on the left) and % of mitotic cells (on 
the right) was performed by microscopic visualization. Representative microscopic images are also 
shown. The arrow indicates the presence of a mitotic figure. B- Microscopic visualization of shRNA-
LAP1 and CMS transfected cells. Specific primary antibody for endogenous LAP1 was detected with 
Alexa Fluor 594-conjugated secondary antibody (red) and α-tubulin acetylated was detected with Alexa 
Fluor 488-conjugated secondary antibody (green). DNA was stained with DAPI. Photographs were 
acquired using a LSM 510-Meta confocal microscope. Bars, 10 µm. C- Analysis of the expression of 
acetylated α-tubulin/total tubulin ratio, lamin B1 and histone H3 phosphorylated at Ser10 in LAP1-
deficient cells by immunoblotting.  Data are presented as mean ± SEM of at least three independent 
experiments. Statistically different from CMS transfected cells, *p < 0.05, 
**
p < 0.01.  
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IV.4. DISCUSSION 
 
LAP1 was one of the first lamin associated proteins identified (Senior and Gerace, 
1988), however its function remains poorly understood. Despite that, LAP1 has been 
implicated in the regulation of the NE reassembly (Gerace and Foisner, 1994; Martin et 
al., 1995) and assembly of the mitotic spindle (Neumann et al., 2010) during mitosis. In 
this study, we used the neuronal-like SH-SY5Y cells as a model to study the 
intracellular levels and potential role of human LAP1 during mitosis. Our results 
revealed that LAP1 is differentially expressed in SH-SY5Y cells during the cell cycle. 
LAP1 expression is reduced in mitosis-arrested cells, whereas is upregulated in G0/G1-
arrest cells after serum deprivation (Fig. IV.1A). Several genes are differentially 
expressed throughout cell cycle, thereby contributing to the regulation of specific 
processes (Cho et al., 2001; Shedden and Cooper, 2002). In agreement with our 
findings, genes encoding nuclear proteins, such as lamins, were found to be upregulated 
at the end of mitosis and beginning of G1 phase (van der Meijden et al., 2002). These 
facts underline the importance of LAP1 and other nuclear proteins for the regulation of 
NE synthesis at the end of mitosis. Furthermore, the association of LAP1 with 
chromosomes at late anaphase/telophase may contribute to the NE reassembly, possibly 
by targeting lamins and membrane vesicles to chromosomes surface and/or anchoring 
chromatin to the NE (Gerace and Foisner, 1994; Martin et al., 1995). Others INM 
proteins such as LBR, emerin and LAP2 were also found to accumulate on the surface 
of chromatin during anaphase/telophase in vivo (Foisner and Gerace, 1993; Haraguchi et 
al., 2000). Thus, the binding of INM proteins to chromatin accompanies NE assembly at 
the end of mitosis, while dissociation is required for NE breakdown. 
NE breakdown and reassembly are complex processes that require the action of 
several cellular activities such as reversible protein phosphorylation (Bollen et al., 2009; 
Guttinger et al., 2009). Our results also showed that LAP1 is regulated by 
phosphorylation during both interphase and mitosis, but seems to be highly 
phosphorylated during mitosis (Fig. IV.1B). Indeed, it was previously shown that 
several nuclear proteins are highly phosphorylated during mitosis (Dephoure et al., 
2008; Olsen et al., 2010). Nevertheless, LAP1 could be (de)phosphorylated in a cell 
cycle-dependent manner at specific residues, as it happens with lamins. Phosphorylation 
of lamins at different residues might play specific roles throughout the cell cycle. For 
example, phosphorylation of lamin B2 at Ser17 is specifically involved in lamin 
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depolymerization and NE disassembly (Kuga et al., 2010). Nevertheless, it has been 
accepted that phosphorylation of lamins is an important mechanism for lamin 
depolymerization when the NE is disassembled, whereas dephosphorylation leads to 
lamin polymerization and the end of mitosis (Thompson et al., 1997). Recently, we have 
reported that LAP1B is dephosphorylated by PP1 (Santos et al., 2013), a phosphatase 
that is responsible for the dephosphorylation of several proteins in association with cell 
cycle events (Bollen et al., 2009). Another interesting fact is that phosphorylation can 
abolish the binding of INM proteins, such as LBR and LAP2β, to chromatin (Foisner 
and Gerace, 1993; Pyrpasopoulou et al., 1996; Takano et al., 2004). Thus, the effects of 
LAP1 (de)phosphorylation on chromatin binding and its role on NE dynamics should be 
addressed.  
Furthermore, one report uncovered a potential function for LAP1 in the assembly 
of the mitotic spindle (Neumann et al., 2010). Downregulation of LAP1 led to the 
formation of defective mitotic spindles and thereby aberrant mitotic exit and cell death 
(Neumann et al., 2010). Defects in mitotic spindle integrity can affect the stability of 
microtubules and therefore the levels of microtubules acetylation. In this study, we were 
not able to identify defective mitotic spindles; however we observed a decrease in the 
number of mitotic figures after LAP1 knockdown (Fig. IV.4A), concomitant with 
decrease phosphorylation of histone H3 at Ser10. Histone H3 phosphorylation has been 
correlated with chromosome condensation during mitosis (Hendzel et al., 1997). 
Therefore, decrease number of mitotic figures could be result of the inhibition of cell 
cycle progression to the mitosis phase. Moreover, we showed that LAP1 co-localize 
with acetylated α-tubulin in the mitotic spindle and mid-body (Fig. IV.2), and also co-
localize with γ-tubulin at some points in centrosomes (Fig. IV. 3), the main microtubule 
organizing centre. Maison et al reported that LAP1C and lamin B colocalize in mitotic 
vesicles that associate transiently with the mitotic spindle (Maison et al., 1997), 
however the localization of LAP1 in centrosomes has never been shown. Interestingly, 
emerin and the novel INM protein SAMP1 are involved in centrosome positioning and 
connection to the NE (Buch et al., 2009; Salpingidou et al., 2007).  
Additionally, depletion of LAP1 also affected the levels of tubulin acetylation, 
lamin B1 and the morphology of the nucleus in interphase cells (Fig. IV.4B and C). 
Decrease levels of tubulin acetylation could be result of microtubules instability due to 
disruption of NE integrity. Cytoskeleton elements as tubulin are connected to the NE 
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through interaction with nesprins (proteins of the ONM), binding partners of SUN 
proteins in the INM, which is turn bind to lamins, thereby forming the LINC complex 
(Crisp et al., 2006; Haque et al., 2006). Depletion of LAP1 from the INM may cause 
disruption of protein interactions at the NE and loss of the LINC complex, and thereby 
lead to a deregulation of microtubules dynamics. In a similar manner, it was previously 
reported that lamin A/C depletion lead to the disturbance of actin, vimentin and tubulin 
organization (Broers et al., 2004). Interestingly, mutations in some genes encoding NE 
proteins cause different NE-related diseases, often associated with reduced expression 
levels of those proteins (reviewed in Dauer and Worman, 2009). Currently, disease 
associated-LAP1 mutations have not been reported. Nevertheless, Kim et al reported 
that various tissues and cultured neurons of TOR1AIP1 knockout mice embryos exhibit 
NE abnormalities and these mice usually dye on the last prenatal day or first postnatal 
day (Kim et al., 2010a). More recently, LAP1 was found to interact with the INM 
protein emerin. Emerin loss of function causes X-linked Emery-Dreifuss muscular 
dystrophy in humans. Similarly, conditional depletion of LAP1 from mouse striated 
muscle causes muscular dystrophy leading to early lethality (Shin et al., 2013). 
Furthermore, LAP1 has been associated with DYT1 dystonia due to its interaction with 
torsinA (Goodchild and Dauer, 2005). The NE of torsinA null fibroblasts is normal, but 
reducing LAP1 levels in those cell causes NE abnormalities, thus suggesting that these 
proteins are functionally related (Kim et al., 2010a). Therefore, several evidences 
suggest that LAP1 is a crucial protein for the maintenance of the NE structure and 
regulation of cell-cycle dynamics. 
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TorsinA is primarily located in the endoplasmic reticulum (ER) lumen and 
nuclear envelope (NE), while the DYT1 dystonia mutant (ΔE-torsinA) is abnormally 
concentrated in the NE (Gonzalez-Alegre and Paulson, 2004; Goodchild and Dauer, 
2004; Naismith et al., 2004), where it interacts with LAP1 (Goodchild and Dauer, 
2005). The accumulation of ΔE-torsinA causes NE abnormalities, presence of 
inclusions and seems to affect the cytoskeleton structure (Gonzalez-Alegre and Paulson, 
2004; Goodchild et al., 2005; Hewett et al., 2000; Nery et al., 2008). Therefore, the 
work described in chapter V was designed so as to provide novel insights into DYT1 
dystonia pathophysiology based on torsinA. 
Chapter V is subdivided in three sections. In section V.A., the distribution of wt-
torsinA and ΔE-torsinA in non-neuronal and neuronal cells was analyzed, with the 
intent of choosing an adequate DYT1 dystonia cellular model. The aim of section V.B. 
was to evaluate the effects of ΔE-torsinA overexpression in cytoskeleton dynamics. 
Finally, the aim of section V.C. was to validate and characterize the interaction between 
PP1, LAP1 and torsinA. Two of these sections (V.B and V.C) are being prepared as 
manuscripts for publication. 
 
Section V.A.:  
“Characterization of DYT1 dystonia cellular models” 
 
Section V.B. (Manuscript 4): 
“DYT1 dystonia-associated mutant affects cytoskeletal dynamics”, submitted for 
publication in the Microscopy and Mycroanalysis journal.  
 
Section V.C. (Manuscript 5): 
“Protein phosphorylation regulates a novel torsinA trimeric complex”, will be submitted 
for publication in the Frontiers in Cellular Neuroscience journal. 
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Abstract 
TorsinA is the central protein in DYT1 dystonia, since a mutation of one glutamic 
acid within the C-terminal of this protein (ΔE302/303, also referred to as ΔE) was found 
in most cases of DYT1 dystonia. Wt-torsinA protein is primarily located in the 
endoplasmic reticulum (ER) lumen and nuclear envelope (NE), while ΔE-torsinA 
protein is abnormally concentrated in the NE. However, the ΔE-torsinA cellular 
phenotype appears to be specific to neuronal cells. Therefore, in order to establish an 
adequate cellular model for the study of DYT1 dystonia, we analyzed the distribution of 
wt- and ΔE-torsinA in non-neuronal cells (COS-7) and neuronal-like cells (SH-SY5Y). 
Our results suggest that ΔE-torsinA is specifically enriched in the NE in neuronal cells, 
in agreement with previous reports. Thus, the SH-SY5Y cell line will be used as a 
DYT1 dystonia cellular model to study the molecular and cellular mechanisms 
associated with ΔE-torsinA mutation.   
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V.A.1. INTRODUCTION 
 
TorsinA and its related family members belong to the ATPases associated with a 
variety of cellular activities (AAA
+
) superfamily. TorsinA has been the most studied 
torsin family member because of its association with DYT1 dystonia. A mutation of a 
single glutamic acid within the C-terminal of torsinA (ΔE302/303, also referred to as 
ΔE) was found in most cases of DTY1 dystonia (Ozelius et al., 1997). TorsinA is 
primarily located in the ER lumen and NE, while ΔE-torsinA is abnormally 
concentrated in the NE (Gonzalez-Alegre and Paulson, 2004; Goodchild and Dauer, 
2004; Naismith et al., 2004). Neurons from ΔE-torsinA knockin mice present severe NE 
abnormalities and vesicles in the lumen of the NE, although non-neuronal cells appears 
to be normal (Goodchild et al., 2005). Indeed, Giles et al reported that the accumulation 
of ΔE-torsinA in the NE may be specific for neuronal cells (Giles et al., 2008). At the 
NE, torsinA was found to interact with LAP1 (Goodchild and Dauer, 2005), SUN1 
(Jungwirth et al., 2011) and nesprin-1, -2 and -3 proteins (Nery et al., 2008). The 
discovery that torsinA not only resides in the ER but also in the NE, suggested that 
torsinA plays a role in the NE. Therefore, we addressed the distribution of wt- and ΔE-
torsinA in non-neuronal cells (COS-7) and neuronal-like cells (SH-SY5Y) in order to 
test if both cell lines present the phenotypes previously reported. 
. 
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V.A.2. MATERIAL AND METHODS 
 
V.A.2.1. Antibodies  
 
The primary antibodies used were rabbit polyclonal LAP1 (Goodchild and Dauer, 
2005) and rabbit polyclonal calnexin (StressGen Bioreagents Corp.). The secondary 
antibody used was Alexa 594-conjugated anti-rabbit IgG (Molecular Probes). 
 
V.A.2.2. Expression vectors and DNA constructs 
 
GFP-tagged wt-torsinA and ΔE-torsinA constructs were kindly provided by Dr. 
William Dauer. Briefly, wt-torsinA and ΔE-torsinA cDNAs were cloned into 
pcDNA3.1 vector and GFP was introduced between residues 21 and 22 of torsinA 
(immediately following the N-terminal signal sequence cleavage), as previously 
described (Goodchild and Dauer, 2004). 
 
V.A.2.3. Cell culture and transfection 
 
COS-7 (ATCC CRL-1651) cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 100 U/ml 
penicillin, 100 mg/ml streptomycin and 3.7 g/l NaHCO3 (Complete DMEM). SH-SY5Y 
cells (ATCC CRL-2266) were grown in Minimal Essential Medium (MEM) 
supplemented with F-12 Nutrient Mixture (Gibco, Invitrogen), 10% fetal bovine serum 
(FBS, Gibco, Invitrogen), 1.5 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL 
streptomycin (Gibco, Invitrogen). Cells were seeded onto 6-well plates (area of 10 cm
2
 
per well) to be at 80-90 % confluency at the time of transfection. Rat hippocampal 
primary cultures were established from embryonic day 18 embryos as previously 
described (Henriques et al., 2007). Briefly, after dissociation with 0.75 mg/ml trypsin, 
cells were plated onto poly-D-lysine-coated dishes at a density of 1.0x10
5
 cells/cm
2
 in 
B27-supplemented Neurobasal medium (GIBCO) (Brewer et al., 1993). The medium 
was supplemented with glutamine (0.5 mM), gentamicin (60 µg/ml) and glutamate (25 
µM). Cultures were maintained in an atmosphere of 5% CO2 at 37ºC until 10 days in 
vitro (DIV) before transfection.  
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Transient transfections were performed using TurboFect (Thermo Scientific) 
according to the manufacturer’s protocols. After 24 hours of transfection, the cells were 
fixed using 4% paraformaldehyde and further subjected to immunocytochemical 
analysis. 
 
V.A.2.4. Immunocytochemistry 
 
Once fixed as described above, cells were permeabilized with triton X-100 for 10 
minutes and further incubated with the primary antibodies for 2 hours followed by 
incubation with Alexa 594-conjugated secondary antibody for 1 hour. GFP was directly 
visualized using the adequate filter settings. Preparations were washed with PBS, 
mounted using Vectashield mounting media with DAPI (Vector). Preparations were 
visualized using an Olympus IX81 epifluoresence microscope (Olympus, Optical Co. 
GmbH) as previously described in chapter IV. 
 
V.A.2.5. Statistical Analysis 
 
Data were expressed as mean ± SEM of at least three independent experiments. 
Statistical significance analysis was conducted by Student’s t-test, with the level of 
statistical significance being considered P < 0.05.  
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V.A.3. RESULTS 
 
Several studies reported that overexpression of ΔE-torsinA in cultured cells leads 
to the relocalization of torsinA from the ER to the NE, namely in cells expressing low 
ΔE-torsinA levels. However, in cells expressing high levels of ΔE-torsinA, the protein 
is also present in the ER and forms inclusions (Goodchild and Dauer, 2004, 2005; 
Naismith et al., 2004). Moreover, it seems that ΔE-torsinA abnormally accumulates in 
the NE in neuronal cells (Giles et al., 2008; Goodchild et al., 2005) rather than other cell 
types. Thus, before proceeding to further studies, we tested two cellular models for the 
study of DYT1 dystonia. Non-neuronal cells (COS-7) and neuronal-like cells (SH-
SY5Y cells) were transfected with different amounts (0.5, 1, 2 and 4 µg) of GFP-tagged 
wt-torsinA (GFP-wt-torsinA) or ΔE-torsinA (GFP-ΔE-torsinA) cDNAs. In COS-7 cells, 
wt- and ΔE-torsinA are both distributed throughout the ER in all cells analyzed (Fig. 
V.A.1A), and are also found in a perinuclear localization. Moreover, the localization of 
both proteins was not dependent on the amount of transfected cDNAs. We also 
observed that both wt- and ΔE-torsinA transfected cells present inclusions, some located 
in the ER/cytoplasm and others around the NE (Fig. V.A.1A). From the cells analyzed 
about 31-45 % and 29-39 % of wt- and ΔE-torsinA transfected cells presented 
inclusions, respectively (Fig. V.A.1B). Moreover the number of inclusions significantly 
increased with increasing amounts of transfected cDNAs (Fig. V.A.1B), being 
statistically significant when we compared cells transfected with 0.5 µg of torsinA 
cDNAs with cells transfected with 2 and 4 µg (Fig. V.A.1B). The localization of both 
wt- and ΔE-torsinA proteins was confirmed using an ER marker (calnexin). We were 
able to determine that, in fact, both wt- and ΔE-torsinA proteins co-localize with 
calnexin (Fig. V.A.2, upper panel), which is not only an ER marker but also a binding 
protein of torsinA (Naismith et al., 2009a; Zhao et al., 2013b). Further, we labeled cells 
with LAP1 antibody and showed that both wt- and ΔE-torsinA co-localize with LAP1 
(Fig. V.A.2, lower panel), thus demonstrating that torsinA proteins are also localized in 
the NE.    
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Figure V.A.1. Localization of wt- and ΔE-torsinA in non-neuronal cells (COS-7 cells). A- 
Localization of torsinA proteins in COS-7 cells upon transfection with 0.5, 1, 2 or 4 µg of GFP-wt-
torsinA or GFP-ΔE-torsinA cDNAs. GFP-tagged torsinA proteins were directly visualized. Presence of 
inclusions is marked by arrows. B- Percentage of wt- and ΔE-torsinA transfected cells that present 
inclusions. Values are mean ± SEM, n=3 (20 cells analyzed in each experiment). Statistically different 
from 0.5 µg wt-torsinA transfected cells, * p < 0.05, ** p < 0.01. Statistically different from 0.5 µg ΔE-
torsinA transfected cells, 
+
 p < 0.05. Photographs were acquired using an Olympus epifluoresence 
microscope. Bars, 10 µm. 
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Figure V.A.2. Co-localization of torsinA proteins with calnexin and LAP1 in COS-7 cells. COS-7 
cells were transfected with 0.5 µg of GFP-wt-torsinA or GFP-ΔE-torsinA cDNAs. Specific primary 
antibodies for endogenous calnexin (upper panel) and LAP1 (lower panel) were detected with Alexa 
Fluor 594-conjugated secondary antibody (red). DNA was stained with DAPI (blue). GFP-tagged torsinA 
proteins were directly visualized. Photographs were acquired using an Olympus epifluoresence 
microscope. Bars, 10 µm. 
 
 
In contrast, in SH-SY5Y cells, a considerable number of ΔE-torsinA transfected 
cells revealed concentrated perinuclear localization (NE localization), while wt-torsinA 
is found throughout the cell body and processes and in the NE (Fig. V.A.3). Further, we 
observed increased labeling of the cytoplasm (presumably ER) upon transfection with 
increasing amounts of ΔE-torsinA cDNA (Fig. V.A.3B). Indeed, the percentage of cells 
with specific NE immunoreactivity is about 43% upon transfection with 0.5 µg of ΔE-
torsinA cDNA, but this percentage decrease to 31%, 27% and 26 % after transfection 
with 1, 2 and 4 µg of ΔE-torsinA cDNA, respectively.  
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Figure V.A.3. Localization of wt- and ΔE-torsinA in SH-SY5Y cells. A- Localization of torsinA 
proteins in SH-SY5Y cells upon transfection with 0.5, 1, 2 or 4 µg of GFP-wt-torsinA or GFP-ΔE-
torsinA cDNAs. GFP-tagged torsinA proteins were directly visualized. B- Percentage of ΔE-torsinA 
transfected cells that present specific perinuclear labeling. Values are mean ± SEM, n=3 (20 cells 
analyzed in each experiment). Statistically different from 0.5 µg transfected cells, ** p < 0.01. 
Photographs were acquired using an Olympus epifluoresence microscope. Bars, 10 µm. 
 
 
Moreover, only a small percentage of cells (around 1-10 %) expressing either wt- 
or ΔE-torsinA present inclusions. Further, we labeled cells with calnexin and the results 
revealed that both wt-torsinA and ΔE-torsinA co-localizes with calnexin in the ER (Fig. 
V.A.4, upper panel). The localization of both torsinA proteins in the NE of SH-SY5Y 
cells was evidenced by the co-localization of those proteins with LAP1 (Fig. V.A.4, 
lower panel).  
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Figure V.A.4. Co-localization of torsinA proteins with calnexin and LAP1 in neuronal-like cells 
(SH-SY5Y cells). SH-SY5Y cells were transfected with 0.5 µg of GFP-wt-torsinA or GFP-ΔE-torsinA 
cDNAs. Specific primary antibodies for endogenous calnexin (upper panel) and LAP1 (lower panel) were 
detected with Alexa Fluor 594-conjugated secondary antibody (red). DNA was stained with DAPI (blue). 
GFP-tagged torsinA proteins were directly visualized. Photographs were acquired using an Olympus 
epifluoresence microscope. Bars, 10 µm. 
 
 
Additionally, rat hippocampal neurons were transfected with wt- or ΔE-torsinA 
cDNAs (0.5 µg). As expected, wt-torsinA localized throughout the cell body and 
extends to neuritis, while ΔE-torsinA appears to be specifically concentrated in the NE 
and co-localizes with LAP1 (Fig. V.A.5). However, due to low levels of transfection, 
we were not able to perform a quantitative analysis regarding specific localization of 
torsinA proteins as previously described. Nevertheless, these results confirmed that ΔE-
torsinA mutation induces relocalization of torsinA from the ER to the NE in neuronal 
cells but not in non-neuronal cells. 
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Figure V.A.5. Distribution of wt- and ΔE-torsinA in rat primary hippocampal neurons.A. 
Hippocampal neurons were transfected with 0.5 µg of GFP-wt-torsinA or GFP-ΔE-torsinA cDNAs. B. 
Co-localization of ΔE-torsinA with LAP1. Specific primary antibody for endogenous LAP1 was detected 
with Alexa Fluor 594-conjugated secondary antibody (red). DNA was stained with DAPI (blue). GFP-
tagged torsinA proteins were directly visualized. Photographs were acquired using an Olympus 
epifluoresence microscope. Bars, 10 µm. 
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V.A.4. DISCUSSION 
 
TorsinA is expressed in both neuronal and non-neuronal tissues (Ozelius et al., 
1997), however it is unclear why DYT1 dystonia-associated mutation leads to a 
neuronal phenotype. ΔE-torsinA mutation drives torsinA to relocalize to the NE, which 
may also result in inclusion formation, in different cell types (Gonzalez-Alegre and 
Paulson, 2004; Goodchild and Dauer, 2004; Hewett et al., 2000; Naismith et al., 2004). 
Nevertheless, a study which provides a quantitative analysis of the relative NE/ER 
distribution, reported that accumulation of ΔE-torsinA in the NE is specific of neuronal 
cells (Giles et al., 2008). Moreover, torsinA null mice and ΔE-torsinA knock-in mice 
present an abnormal NE, with blebs and herniations in the perinuclear space, in cultured 
neurons, but not in non-neuronal cells (Goodchild et al., 2005; Kim et al., 2010a). 
Despite the ubiquitous presence of torsinA, high expression levels of torsinA are found 
within the brain (Ozelius et al., 1997). In contrast, another torsin family member- 
torsinB, has high expression levels in non-neuronal tissues, which could explain why 
torsinA depletion specifically affects neuronal tissues (Jungwirth et al., 2010; Kim et 
al., 2010a). Indeed, depletion of torsinB in torsinA knock-in mouse embryonic 
fibroblasts also leads to NE abnormalities in non-neuronal cells (Kim et al., 2010a).  
Our results are in agreement with the hypothesis that ΔE-torsinA phenotype is 
quite different between neuronal and non-neuronal cells. Indeed, it seems that ΔE-
torsinA is specifically recruited to the NE in neuronal-like cells (SH-SY5Y cells) at 
moderate expression levels, but not in non-neuronal cells (COS-7). Abnormal 
accumulation of torsinA in the NE suggests that a NE dysfunction may contribute to 
DYT1 dystonia pathogenesis. At the NE, torsinA was found to interact with LAP1 
(Goodchild and Dauer, 2005) and SUN1 (Jungwirth et al., 2011), proteins of the INM, 
and nesprins (Nery et al., 2008) located in the ONM. The results also revealed that both 
wt- and ΔE-torsinA appears to accumulate in inclusions in COS-7 cells (Fig. V.A.1). In 
contrast, the presence of inclusions was rarely seen in SH-SY5Y cells. These inclusions 
were previously reported in cells expressing higher levels of ΔE-torsinA (Goodchild 
and Dauer, 2004, 2005; Naismith et al., 2004). This could mean that, under our 
experimental conditions, COS-7 cells are expressing high levels of torsinA proteins. 
Moreover, as the level of expression increased, the labeling of ΔE-torsinA in the ER of 
SH-SY5Y cells also increased (Fig. V.A.3), as is characteristic of highly expressed NE 
proteins (Schirmer et al., 2003). These findings underline the importance of choosing an 
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adequate DYT1 dystonia cellular model to study the molecular and cellular mechanisms 
associated with ΔE-torsinA mutation.   
From the results here presented, SH-SY5Y cells were used as the model system 
for the study of DYT1 dystonia in further experiments. Another important aspect is that 
the levels of torsinA proteins should not be extremely high, in order to preserve proper 
cellular distribution of those proteins. Hence, we decided to transfect SH-SY5Y cells 
with 0.5 µg of wt-torsinA or ΔE-torsinA cDNAs per well of a 6-well plate (area of 10 
cm
2
) in subsequent studies. 
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CHAPTER V.B – DYT1 DYSTONIA-ASSOCIATED MUTANT AFFECTS 
CYTOSKELETAL DYNAMICS 
 
The work described in chapter V.B was included in the following extended 
abstract, submitted for publication in the Microscopy and Mycroanalysis journal:  
 
“DYT1 dystonia-associated mutant affects cytoskeletal dynamics” 
 
Santos, M.
*
, Rebelo, S.
*
, da Cruz e Silva, E. F.
*
, da Cruz e Silva, O. A. B.
*
 
 
*
Center for Cell Biology, Health Sciences and Biology Department, University of Aveiro, Campus de 
Santiago, 3810-193 Aveiro, Portugal 
 
Extended abstract 
TorsinA and its related family members belong to the ATPases associated with a 
variety of cellular activities (AAA
+
) superfamily. TorsinA has been the most studied 
torsin family member due to its association with DYT1 dystonia. A mutation of a single 
glutamic acid within the C-terminal of torsinA (ΔE302/303, also referred to as ΔE) was 
found in most cases of DTY1 dystonia. TorsinA is primarily located in the endoplasmic 
reticulum (ER) lumen and nuclear envelope (NE), while ΔE-torsinA is abnormally 
concentrated in the NE. TorsinA has been implicated in cytoskeleton dynamics through 
interaction with different binding partners. However, it seems that the ΔE-torsinA 
mutation interferes with cytoskeleton dynamics. Therefore, we analyzed cytoskeleton 
alterations associated with the ΔE-torsinA mutation. In order to achieve this goal, we 
transfected SH-SY5Y cells with GFP-wt-torsinA or GFP-ΔE-torsinA and performed 
immunofluorescence analysis with β-tubulin and acetylated α-tubulin specific 
antibodies and with phalloidin that binds to F-actin. We showed that in wt-torsinA 
transfected cells, β-tubulin, acetylated α-tubulin and F-actin were distributed throughout 
the cytoplasm, in a manner similar to non-transfected cells. In contrast, in some ΔE-
torsinA transfected cells, the distribution of those markers is altered, being more 
restricted to the NE, and cells seem to be less intensely labeled. Moreover, in some 
cells, β-tubulin co-localized with ΔE-torsinA positive inclusions. Further, when we 
quantified the fluorescence intensity (FI) of β-tubulin, we detected a slight decrease of 
the FI in ΔE-torsinA transfected cells compared to wt-torsinA transfected cells. In the 
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same way, ΔE-torsinA transfected cells have lower levels of acetylated α-tubulin, which 
is a marker for microtubules stability, suggesting that microtubule dynamics may be 
compromised by the ΔE-torsinA mutation. Furthermore, we observed a loss of F-actin 
stress fibers in ΔE-torsinA transfected cells. Indeed, we showed that F-actin FI decrease 
from 1.03 to 0.83 (around 20%) in ΔE-torsinA transfected cells compared with wt-
torsinA transfected cells. Our results are in agreement with previous reports where it 
was reported that the expression of ΔE-torsinA altered the localization of vimentin to 
the NE, KLC to inclusions and nesprin-3 to the ER. Nesprins in the outer nuclear 
membrane bind to actin, microtubules and intermediate filaments, thus forming a 
complex that links the nucleoskeleton and cytoskeleton (the LINC complex). Therefore, 
torsinA and its binding partners may have a role in modulating the LINC complex. 
Disruption of the LINC complex may contribute to the development of muscular 
dystrophies and cardiomyopathies. 
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V.B.1. INTRODUCTION 
 
TorsinA has been shown to be involved in several cellular processes by 
interacting with different binding proteins (reviewed in Granata et al., 2009). 
Interestingly, torsinA has been implicated in cytoskeleton dynamics through interaction 
with nesprins, vimentin, KLC and tau. Nesprins in the ONM bind to actin filaments, 
microtubules and intermediate filaments, thus forming the LINC complex (Crisp et al., 
2006; Haque et al., 2006). When torsinA is depleted, nesprin-3 is redistributed to the 
ER, indicating that torsinA is important for the proper localization of nesprin-3 and 
participates in the LINC complex (Nery et al., 2008). Furthermore, immunoprecipitation 
of vimentin not only brings down torsinA, but also other cytoskeleton components such 
as α-tubulin, kinesin and actin and the NE protein LAP1 (Hewett et al., 2006). Further, 
overerexpression of ΔE-torsinA alters the localization of vimentin to the NE (Hewett et 
al., 2006) and KLC to inclusions (Kamm et al., 2004). Therefore, it is important to 
analyze not only the physiological function of torsinA in cytoskeleton dynamics, but 
also the alterations associated with the ΔE-torsinA mutation. In order to achieve this 
goal, we transfected SH-SY5Y cells with wt-torsinA or ΔE-torsinA and further 
analyzed it by immunofluorescence. The effects of ΔE-torsinA mutation in the 
distribution of cytoskeletal elements (β-tubulin, acetylated α-tubulin and F-actin) were 
determined.  
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V.B.2. Material and methods 
 
V.B.2.1. Antibodies and drugs 
 
The primary antibodies used were mouse monoclonal β-tubulin (Invitrogen) and 
mouse monoclonal acetylated α-tubulin (Sigma). The secondary antibody used was 
Alexa 594-conjugated anti-mouse IgG (Molecular Probes). Alexa Fluor 594-conjugated 
phalloidin (Molecular Probes) was used to label F-actin. 
 
V.B.2.2. Expression vectors and DNA constructs 
 
GFP-tagged wt-torsinA and ΔE-torsinA constructs were kindly provided by Dr. 
William Dauer (Goodchild and Dauer, 2004). 
 
V.B.2.3. Cell culture and transfection 
 
SH-SY5Y cells (ATCC CRL-2266) were grown in Minimal Essential Medium 
(MEM) supplemented with F-12 Nutrient Mixture (Gibco, Invitrogen), 10% fetal 
bovine serum (FBS, Gibco, Invitrogen), 1.5 mM L-glutamine, 100 U/mL penicillin and 
100 mg/mL streptomycin (Gibco, Invitrogen).  
Transient transfections were performed using TurboFect (Thermo Scientific) 
according to the manufacturer’s protocols. After 24 hours of transfection, the cells were 
fixed using 4% paraformaldehyde and further subjected to immunocytochemical 
analysis. 
 
V.B.2.4. Immunocytochemistry 
 
Once fixed as described above, cells were permeabilized with triton X-100 for 10 
minutes and further incubated with the primary antibodies for 2 hours followed by 
incubation with Alexa 594-conjugated secondary antibody for 1 hour. Cells were 
incubated with phalloidin for 30 minutes. Preparations were washed with PBS, mounted 
using Vectashield mounting media with DAPI (Vector) and visualized using an 
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LSM510-Meta confocal microscope (Zeiss) as previously described (Santos et al., 
2013). 
 
V.B.2.5. Statistical Analysis 
 
Statistical significance analysis was conducted by Student’s t-test, with the level 
of statistical significance being considered P < 0.05. Data were expressed as mean ± 
SEM   
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V.B.3. RESULTS 
 
There is significant evidence for a role of torsinA in cytoskeleton dynamics, 
mainly because of its interaction with different cytoskeletal proteins. Moreover 
depletion of endogenous torsinA or overerexpression of ΔE-torsinA alters the 
localization of some proteins such nesprin-3, vimentin and KLC (Hewett et al., 2006; 
Kamm et al., 2004; Nery et al., 2008). Therefore, we decided to analyze if the ΔE-
torsinA mutation alters the distribution/expression of other cytoskeletal elements. In 
order to achieve this goal, we transiently transfected SH-SY5Y cells with wt-torsinA or 
ΔE-torsinA and performed immunofluorescence with β-tubulin and acetylated α-tubulin 
specific antibodies and phalloidin that binds to F-actin. We showed that in cells 
overexpressing wt-torsinA, both β-tubulin and acetylated α-tubulin were distributed 
throughout the cytoplasm, in the same way as non-transfected (NT) cells (Fig. V.B.1A). 
In contrast, we noticed that some ΔE-torsinA transfected cells were weakly stained with 
β-tubulin and acetylated α-tubulin antibodies, and in some cells this proteins were found 
located around the NE (Fig. V.B.1A). In order to clearly establish if wt- and ΔE-torsinA 
transfected cells present different levels of β-tubulin and acetylated α-tubulin, we 
measure the fluorescence intensity (FI) of all cells and transfected cells, labeled with 
those antibodies, in various fields. Then we compared the ratio transfected cells FI/total 
cells FI of wt- and ΔE-torsinA transfected cells (Fig. V.B.1B). This analysis was 
performed using a specific software (Zeiss LSM 510 4.0 software). Thus, we showed 
that β-tubulin and acetylated α-tubulin FI was more intense in wt-torsinA transfected 
cells (1.05 and 0.98, respectively) than ΔE-torsinA transfected cells (0.99 and 0.89, 
respectively). Thus β-tubulin and acetylated α-tubulin FI in ΔE-torsinA transfected cells 
only decrease around 6.5% and 9.3%, respectively, when compared to wt-torsinA 
transfected cells. Moreover, we also observed that β-tubulin co-localized with ΔE-
torsinA positive inclusions (higher magnification view in Fig. V.B.1A). 
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Figure V.B.1. Distribution of β-tubulin and acetylated α-tubulin in wt- and ΔE-torsinA transfected 
cells. A- SH-SY5Y cells were transfected with GFP-wt-torsinA or GFP-ΔE-torsinA. Specific primary 
antibodies for endogenous β-tubulin and acetylated α-tubulin (acetyl. α-tubulin) were detected with Alexa 
Fluor 594-conjugated secondary antibody (red). The higher magnification view shows in more detail the 
co-localization of ΔE-torsinA and β-tubulin in inclusions. B- Quantification of β-tubulin and acetyl. α-
tubulin  fluorescence intensity (FI), which represents the ratio transfected cells FI/total cells FI, in wt- and 
ΔE-torsinA transfected cells. Values are mean ± SEM, n= 22 cells (for β-tubulin) and 30 cells (acetyl. α-
tubulin). Statistically different from wt-torsinA transfected cells, *p < 0.05. Photographs were acquired 
using a LSM 510-Meta confocal microscope. Bars, 10 µm. 
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Further, we observed that F-actin was distributed throughout the cytoplasm in wt-
torsinA transfected cells and NT cells. In contrast, ΔE-torsinA transfected cells seem to 
be less intensely labeled with phalloidin, thus showing a lost of F-actin stress fibers 
(Fig.V.B.2A). Indeed, F-actin FI was more intense in wt-torsinA transfected cells (1.03) 
than ΔE-torsinA transfected cells (0.83) (Fig. V.B.2B). Thus F-actin FI in ΔE-torsinA 
transfected cells decrease around 20% in comparison with wt-torsinA transfected cells. 
 
Figure V.B.2. Distribution of F-actin in wt- and ΔE-torsinA transfected cells. A- SH-SY5Y cells 
were transfected with GFP-wt-torsinA or GFP-ΔE-torsinA cDNAs and labeled with phalloidin (that binds 
to F-actin) conjugated with Alexa Fluor 594 (red). Two different focal planes are shown for each image. 
DNA was stained with DAPI (blue). B- Quantification of F-actin fluorescence intensity (FI), which 
represents the ratio transfected cells FI/total cells FI, in wt- and ΔE-torsinA transfected cells. Values are 
mean ± SEM, n= 20 cells. Statistically different from wt-torsinA transfected cells, **p < 0.01. 
Photographs were acquired using a LSM 510-Meta confocal microscope. Bars, 10 µm.  
 190 
 
V.B.4. DISCUSSION 
 
TorsinA has several potential functions and among them is cytoskeletal 
regulation. In this work we showed that ΔE-torsinA could potentially lead to a decrease 
in the intracellular levels and distribution of β-tubulin and acetylated α-tubulin (Fig. 
V.B.1). However, the effects of ΔE-torsinA mutation were more pronounced when we 
evaluated the intracellular levels of F-actin. Indeed, it seems that ΔE-torsinA mutation 
lead to a decrease in the intracellular levels of F-actin (Fig. V.B.2), possibly related with 
a loss of stress fibers. 
TorsinA was found to interact with different cytoskeleton elements such as 
vimentin, KLC and tau. Co-immunoprecipitation studies also showed that vimentin and 
torsinA are in a complex that includes other cytoskeleton components such as α-tubulin, 
kinesin and actin (Hewett et al., 2006). However, it seems that ΔE-torsinA mutation 
interferes with cytoskeleton dynamics. Expression of ΔE-torsinA altered the localization 
of vimentin to the NE (Hewett et al., 2006) and KLC to inclusions (Kamm et al., 2004). 
Moreover, fractioning studies suggested that ΔE-torsinA associates to a lesser degree 
with the cytoskeleton when compared with wt-torsinA (Hewett et al., 2006). However, 
no consistent alterations were seen in the distribution of actin and tubulin in DYT1 
fibroblasts compared to control fibroblasts. Nevertheless, when we quantified the FI of 
β-tubulin, we detected a slight decrease of the FI in ΔE-torsinA transfected cells 
compared to wt-torsinA transfected cells (Fig.V.B.1B). In the same way, ΔE-torsinA 
transfected cells seem to have lower intracellular levels of acetylated α-tubulin (Fig. 
V.B.1B), which is a marker for microtubules stability, suggesting that microtubule 
dynamics may be compromised by the ΔE-torsinA mutation. Furthermore, we observed 
a loss of F-actin stress in ΔE-torsinA transfected cells (Fig. V.B.2A). Indeed, we 
showed that F-actin FI decrease around 20% in ΔE-torsinA transfected cells compared 
with wt-torsinA transfected cells (Fig. V.B.2B). 
The localization of torsinA, and particularly ΔE-torsinA, at the NE suggests that a 
NE dysfunction may contribute to DYT1 dystonia pathogenesis. Moreover, the NE 
localization of torsinA and its binding to NE proteins make torsinA a candidate for 
establishing a link between the NE and cytoskeleton. At the NE, torsinA was found to 
interact with LAP1 (Goodchild and Dauer, 2005) and SUN1 (Jungwirth et al., 2011), 
proteins of the INM, and nesprins (Nery et al., 2008) located in the ONM. SUN proteins 
have a NE lumenal domain that interacts with nesprins, which form a functional link 
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with intermediate filaments, microtubules and actin, thereby forming the LINC complex 
(Crisp et al., 2006; Haque et al., 2006). SUN1 is required for torsinA localization in the 
NE (Jungwirth et al., 2011). Moreover, torsinA depletion appears to remove nesprin-3 
from the NE, suggesting that torsinA is important for the proper maintenance of the 
LINC complex (Nery et al., 2008). In other hand, overexpression of ΔE-torsinA altered 
the localization of vimentin to the NE (Hewett et al., 2006). Nesprin-3 binds to vimentin 
through plectin and all three proteins were found to co-immunoprecipitate with torsinA. 
Therefore, torsinA and its NE binding partners may have a role in modulating the LINC 
complex, enabling proper nuclei positioning. It was reported that disruption of the LINC 
complex results in the impairment of nuclear positioning and cell polarization and may 
contribute to the development of muscular dystrophies and cardiomyopathies (Lombardi 
et al., 2011). 
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CHAPTER V.C – IDENTIFICATION OF THE NOVEL LAP1/PP1/TORSINA 
COMPLEX 
 
The work described in chapter V.C was included in the following manuscript, 
which will be submitted for publication in the Frontiers in Cellular Neuroscience 
journal: 
 
“Protein phosphorylation regulates a novel torsinA trimeric complex” 
 
Mariana Santos
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Abstract 
DYT1 dystonia is the most common form of early onset isolated dystonia and is 
caused by a mutation in the DYT1 gene, resulting in the loss of a single glutamic acid 
(ΔE) within the torsinA protein. Several functions have been proposed for torsinA 
including nuclear envelope (NE) and endoplamic reticulum (ER) dynamics, secretory 
protein trafficking, transport of secretory vesicles and response to stress, possibly acting 
as a chaperone at several subcellular compartments through interaction with specific 
binding partners. TorsinA is localized in the contiguous lumen of the ER and NE, 
however the mutant form, ΔE torsinA, concentrates in the perinuclear space of the NE. 
At the NE, torsinA interacts with others proteins, including the lamina associated 
polypeptide 1 (LAP1). We have recently reported that LAP1 also interacts with protein 
phosphatase 1 (PP1). PP1 is a ser/thr phosphatase that dephosphorylates about a third of 
all proteins in eukaryotic cells. PP1 regulates several functions by associating with 
different binding partners. Like torsinA, PP1 is expressed virtually in all tissues but has 
higher expression levels in the brain. The work here presented confirms the occurrence 
of the trimeric complex PP1/LAP1/torsinA in rat brain and cellular models. Moreover, 
results from blot overlay assays, suggest that torsinA and PP1 do not bind directly but 
via LAP1. Significantly, results showed that torsinA proteins (wt- and ΔE-torsinA) can 
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be dephosphorylated by PP1, as well as LAP1. Furthermore, knockdown of the bridging 
protein LAP1 leads to reduced intracellular levels of both PP1 and torsinA proteins. 
Localization studies for LAP1 and PP1 in a cellular model of DYT1 dystonia were also 
conducted. The identification of this novel trimeric complex provides new insights for 
DYT1 dystonia, where protein phosphorylation may represent a pivotal regulatory 
mechanism.  
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V.C.1. INTRODUCTION  
 
Dystonia is a movement disorder characterized by sustained or intermittent 
muscle contractions causing abnormal, often repetitive, movements, postures, or both 
(Albanese et al., 2013). Several genes have been mapped for dystonia, though dystonia 
associated with the DYT1 gene, encoding torsinA protein, is the most common and 
severe form of hereditary isolated dystonia. DYT1 dystonia is an autosomal dominant 
disease with penetrance of around 30% and it is caused by a 3 bp (GAG) deletion in the 
coding region of the DYT1 (TOR1A) gene. This deletion results in the loss of a single 
glutamic acid in the C-terminal of torsinA protein (ΔE-torsinA) (Ozelius et al., 1997). 
Three other variations in torsinA have been found, but none has been unequivocally 
associated with the disease (Kabakci et al., 2004; Kock et al., 2006; Leung et al., 2001; 
Ozelius et al., 1997). TorsinA and its related family members belong to the ATPases 
associated with a variety of cellular activities (AAA
+
) superfamily (Ozelius et al., 
1997). These proteins typically act as chaperones and are involved in several functions, 
such as, protein folding and degradation, membrane trafficking, DNA replication and 
repair, cytoskeletal regulation and mitosis (reviewed in Ogura and Wilkinson, 2001; 
Vale, 2000). The predicted structure of torsinA contains a single AAA
+
 domain, which 
includes Walker A and Walker B nucleotide binding motifs, and the α-helical domains 
sensor-1 and sensor-2, which are important for the ATPase activity (Iyer et al., 2004; 
Neuwald et al., 1999; Ogura and Wilkinson, 2001).  
TorsinA resides in the endoplasmic reticulum (ER) lumen (Hewett et al., 2003; 
Kustedjo et al., 2000), but it is also located in the nuclear envelope (NE) (Goodchild 
and Dauer, 2004; Naismith et al., 2004). Additionally, the ΔE-torsinA mutation was 
found to be abnormally concentrated in the NE of cultured cells, neurons and DYT1 
patient-derived fibroblasts (Goodchild and Dauer, 2004). Furthermore, a mutation in the 
Walker B domain (E171Q-torsinA) inhibits ATP hydrolysis and results in an ATP-
bound state, causing high affinity substrate interactions. This mutation causes a 
redistribution of torsinA from the ER to the NE (Goodchild and Dauer, 2004; Naismith 
et al., 2004). Abnormal accumulation of ΔE-torsinA in the NE suggests that a NE 
dysfunction may, in turn, contribute to DYT1 dystonia pathogenesis. The accumulation 
of torsinA in the NE led to the discovery of lamina associated polypeptide 1 (LAP1) or 
torsinA interacting protein 1 (TOR1AIP1) as a binding partner of torsinA (Goodchild 
and Dauer, 2005). LAP1 is a type II transmembrane protein of the inner nuclear 
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membrane (INM), containing a nucleoplasmic N-terminal domain, a single 
transmembrane domain and a lumenal C-terminal domain located in the perinuclear 
space (Martin et al., 1995). The latter domain in conserved between LAP1 family 
members (LAP1A, B and C) (Martin et al., 1995) and mediates the interaction with 
torsinA (Goodchild and Dauer, 2005). Moreover, LAP1 was found to relocate torsinA 
to the NE in a perinuclear distribution (Goodchild and Dauer, 2005). Additionally, 
torsinA was found to interact with others NE proteins such as SUN1 and nesprin-1, -2 
and -3 (Jungwirth et al., 2011; Nery et al., 2008). Recent work from our laboratory, 
established that LAP1B interacts with protein phosphatase 1 (PP1) in the nucleoplasm 
and it is dephosphorylated in vitro by PP1γ1 (Santos et al., 2013). In mammalian cells 
three genes (PPP1CA, PPP1CB and PPP1CC) encode four PP1 isoforms: PP1alpha 
(PP1α), PP1beta/delta (PP1β/δ), PP1gamma1 (PP1γ1) and PP1gamma2 (PP1γ2) (da 
Cruz e Silva et al., 1995b; Sasaki et al., 1990). PP1 proteins are predicted to catalyze the 
majority of protein dephosphorylation events in eukaryotic cells (Bollen et al., 2010; 
Heroes et al., 2013). The versatility of PP1 is largely determined by the binding of its 
catalytic subunit to different specific regulatory subunits. Close to 200 PP1 interacting 
proteins have thus far been identified (Esteves et al., 2012a; Esteves et al., 2012b; 
Fardilha et al., 2011; Heroes et al., 2013).  
TorsinA, LAP1 and PP1 are ubiquitously expressed (da Cruz e Silva et al., 1995b; 
Goodchild and Dauer, 2005; Ozelius et al., 1997), but PP1 and torsinA both exhibit high 
levels of expression in the brain (Augood et al., 1999; da Cruz e Silva et al., 1995b; 
Ozelius et al., 1997). Moreover, within cells, torsinA interacts with LAP1 in the 
perinuclear space (Goodchild and Dauer, 2005), which in turn binds to PP1 in the 
nucleoplasm (Santos et al., 2013). Thereby it is plausible that these three proteins co-
exist in a complex. In fact, the data here presented show that both wt-torsinA and ΔE-
torsinA form a complex with LAP1 and PP1. Moreover, it is possible to infer that 
torsinA and PP1 do not bind directly but instead via LAP1. Nevertheless, torsinA was 
found to be dephosphorylated by PP1, as well as LAP1. Therefore, the functionally 
consequences of reversible protein phosphorylation on torsinA and its potential role in 
DYT1 dystonia pathogenesis is an avenue that should be explored in future studies. 
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V.C.2. MATERIALS AND METHODS 
 
V.C.2.1. Antibodies 
 
The primary antibodies used were rabbit polyclonal LAP1 (Goodchild and Dauer, 
2005); rabbit polyclonal CBC2C and CBC3C, that recognize the C-terminal of PP1α 
and PP1γ, respectively (da Cruz e Silva et al., 1995b); mouse monoclonal torsinA 
(Milipore); rabbit polyclonal torsinA (ab76133, Abcam); mouse monoclonal JL-8 
antibody (BD Biosciences) that recognizes GFP-fusion proteins and Myc-tag antibody 
(Cell Signaling) that recognizes Myc-fusion proteins. The secondary antibodies used 
were anti-mouse and anti-rabbit horseradish peroxidase-linked antibodies (GE 
Healthcare) for ECL detection, and Alexa 594-conjugated anti-rabbit IgG (Molecular 
Probes) and Alexa 350-conjugated anti-mouse for co-localization studies.  
 
V.C.2.2. Expression vectors and DNA constructs 
 
pcDNA3.1-GFP-wt-torsinA and pcDNA3.1-GFP-ΔE-torsinA constructs have 
been previously described (Goodchild and Dauer, 2004), as well as, pET-LAP1B and 
Myc-LAP1B (Santos et al., 2013). The pSIREN-RetroQ vector was kindly provided by 
Dr. Celso Cunha from the Instituto de Higiene e Medicina Tropical, Lisbon (Casaca et 
al., 2011) 
 
V.C.2.3. Cell culture and transfection 
 
SH-SY5Y cells (ATCC CRL-2266) were grown in Minimal Essential Medium 
(MEM) supplemented with F-12 Nutrient Mixture (Gibco, Invitrogen), 10% FBS 
(Gibco, Invitrogen), 1.5 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL 
streptomycin (Gibco, Invitrogen). Transient transfections were performed using 
TurboFect (Thermo Scientific) according to the manufacture’s protocol. After 24 hours 
of transfection, cells were harvested for subsequent immunoprecipitation experiments or 
fixed, using 4% paraformaldehyde for immunocytochemical analysis. 
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V.C.2.4. Brain dissection 
 
Winstar rats (9-12 weeks) were obtained from Harlan Interfaune Ibérica, SL. All 
experimental procedures observed the European legislation for animal experimentation 
(2010/63/EU). No specific ethics approval under EU guidelines was required for this 
project, since the rats were only euthanized, by cervical stretching followed by 
decapitation, for brain removal. This is within the European law (Council Directive 
86/609/EEC) and during this procedure all steps were taken to ameliorate animal 
suffering and the minimum number of possible animals were used. The procedures were 
approved and supervised by our Institutional Animal Care and Use Committee 
(IACUC): Comissão Responsável pela Experimentação e Bem-Estar Animal 
(CREBEA). 
Briefly, animals were euthanized by cervical stretching followed by decapitation 
and the cerebellum was dissected out on ice. The tissue was then homogenized on ice, 
in non-denaturing lysis buffer (50 mM Tris-HCl pH 8.0, 120 mM NaCl, 4% CHAPS) 
containing protease inhibitors (1 mM PMSF, 10 mM Benzamidine, 2 µM Leupeptin, 1.5 
µM Aprotinin, 5 µM Pepstatin A), with a Potter-Elvehjem tissue homogenizer with 10-
15 pulses at 650-750 rpm (Rebelo et al., 2013). Resulting tissue extracts were used for 
IP analysis using Dynabeads Protein G (Dynal, Invitrogen) as previously described 
(Santos et al., 2013). 
 
V.C.2.5. Co-immunoprecipitation 
 
SH-SY5Y cells were transfected with wt-torsinA or ΔE-torsinA were collected in 
lysis buffer (50 mM Tris-HCl pH 8, 120 mM NaCl, 4% CHAPS) containing protease 
inhibitors (1 mM PMSF, 10 mM Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin, 5 
µM Pepstatin A). Immunoprecipitations were carried using Dynabeads Protein G 
(Dynal, Invitrogen) as previously described (Santos et al., 2013). 
 
V.C.2.6. Blot overlay assay 
 
LAP1B, wt-torsinA and ΔE-torsinA proteins were generated by in vitro 
transcription/ translation (IVT) from pET-LAP1B, pcDNA3.1-GFP-wt-torsinA and 
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pcDNA3.1-GFP-ΔE-torsinA expression vectors, respectively, using the TnT-coupled 
transcription/translation kit (Promega), according to the manufactures’ instructions. For 
the overlay assays, four samples of 250 ng of purified recombinant PP11 protein 
(Watanabe et al., 2003) were separated on a 12% SDS-PAGE. All proteins were 
transferred onto a nitrocellulose membrane and overlaid with either LAP1B-IVT, wt-
torsinA-IVT, ΔE-torsinA-IVT or negative control of IVT. The bound proteins were 
detected by incubating the membrane with JL-8 (GFP) antibody and developed by ECL. 
 
V.C.2.7. Immunocytochemistry 
 
Once fixed as described above, SH-SY5Y cells were permeabilized with triton X-
100 for 10 min. Cells were first incubated with one of the primary antibodies for 2 
hours, followed by the secondary antibody for 1 hour. After washing with 1x PBS, cells 
were subsequently incubated with a second primary antibody for 2 hours, followed by 
the secondary antibody for 1 hour. GFP was visualized directly. Preparations were 
washed with PBS, mounted using Vectashield mounting media (Vector) or Vectashield 
mounting media with DAPI (Vector). Preparations were visualized using an Olympus 
IX81 epifluoresence microscope (Olympus, Optical Co. GmbH) equipped with the 
appropriate filter combinations and a 100×objective (Plan-Neofluar, 100x/1.35 oil 
objective). Images were acquired with an F-view II CCD camera (Soft Imaging System 
GmbH, Münster, Germany) driven by Soft Imaging software. 
 
V.C.2.8. Detection of protein phosphorylation 
 
SH-SY5Y cells were transfected with wt- or ΔE-torsinA cDNAs and treated with 
0.25 nM or 500 nM okadaic acid (OA) for 3 hours. Then, cells were collected in PP1 
buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 1 mM MnCl2 and 5 mM DTT) and 
lysates incubated at 30ºC for 1 hour with or without 100 ng of purified PP1γ1 protein. 
Proteins were resolved in 7.5% SDS-PAGE containing 50 µM Phos-tag (AAL-107, 
Wako) and 100 µM MnCl2. After electrophoresis, Phos-tag acrylamide gels were 
washed with transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol) 
containing 10 mM EDTA for 10 min to chelate MnCl2 and then with transfer buffer 
without EDTA for 10 min according to the manufacturer’s protocol. 
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V.C.2.9. LAP1 knockdown 
 
Knockdown of endogenous LAP1 in SH-SY5Y cells was achieved using a short 
hairpin RNA (shRNA) strategy as previously described (Santos, 2014). SH-SY5Y cells 
were transfected with both pSIREN-LAP1-C1 and pSIREN-LAP1-C2 plasmids or with 
the pSIREN-CMS (negative control). 
 
V.C.2.10. SDS-PAGE and immunoblotting 
 
Samples were separated on SDS-PAGE and electrophoretically transferred onto 
nitrocellulose. Nitrocellulose membranes were incubated in Ponceau S solution for 5 
minutes and then scanned in a GS-800 calibrated imaging densitometer (Bio-Rad), in 
order to assess equal gel loading. Membranes were washed in TBST 1x to remove 
Ponceau S staining, followed by immunological detection with specific antibodies as 
indicated. Membranes were saturated in 5% non-fat dry milk in TBS-T for 2 hours and 
further incubated with primary antibodies. The incubations with the CBC2C, CBC3C 
and torsinA were performed overnight while LAP1 and GFP antibodies were incubated 
for 3 hours. Detection was achieved using horseradish peroxidase-conjugated anti-rabbit 
or anti-mouse IgGs as secondary antibodies and proteins visualized by ECL (GE 
Healthcare). 
 
V.C.2.11. Quantification and Statistical Analysis 
 
Autoradiograms were scanned in a GS-800 calibrated imaging densitometer (Bio-
Rad) and protein bands quantified using the Quantity One densitometry software (Bio-
Rad). Data were expressed as mean ± SEM of at least three independent experiments. 
Statistical significance analysis was conducted by Student’s test, with the level of 
statistical significance being considered P < 0.05 
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V.C.3. RESULTS 
 
V.C.3.1. Identification of the novel LAP1/PP1/TorsinA complex 
 
Given that torsinA binds to the lumenal domain of LAP1 in the perinuclear space 
(Goodchild and Dauer, 2005), while PP1 binds to the nucleoplasmic domain of LAP1 
inside the nucleus (Santos et al., 2013), it is reasonable to deduce that these proteins 
could form a trimeric complex. Moreover, PP1 and torsinA are both particularly 
abundant within the brain (Augood et al., 1999; da Cruz e Silva et al., 1995b; Ozelius et 
al., 1997). Hence, co-immunoprecipitations of rat cerebellum extracts using LAP1, 
PP1α, PP1γ and torsinA specific antibodies were performed (Fig. V.C.1). Upon 
immunoprecipitation with LAP1 and torsinA antibodies, bands of approximately 37 
kDa corresponding to PP1α and PP1γ were identified (Fig. V.C.1). Further, when 
immunoprecipitations were carried out with PP1α, PP1γ or torsinA antibodies, a band 
below 75 kDa corresponding to the higher LAP1 isoform (LAP1B) was clearly 
indentified. The smaller LAP1 isoform (LAP1C) seems to be co-immunoprecipitated, 
but the band is obscured by the antibody’s IgG heavy chain (Fig. V.C.1). Using the 
same methodology, similar results were detected in other brain regions, namely striatum 
and cortex (data not shown) that are, in addition to the cerebellum, implicated in 
dystonia pathogenesis.   
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Figure V.C.1. Co-immunoprecipitation of the PP1/LAP1/TorsinA complex in rat cerebellum. Rat 
cerebellum extracts were immunoprecipitated with PP1α, PP1γ, LAP1 or torsinA antibibodies bound to 
protein G- Dynabeads. Negative controls were performed by incubating cell extracts with beads. IP, 
immunoprecipitation. IB, immunobloting. 
 
 
Having shown that endogenous torsinA (wt-torsinA) forms a complex with LAP1 
and PP1, we went on to test if the same happen with ΔE-torsinA mutant. Thus, SH-
SY5Y cells overexpressing GFP-wt-torsinA or GFP-ΔE-torsinA were 
immunoprecipitated using specific LAP1, PP1α or PP1γ antibodies (Fig. V.C.2A). 
Upon PP1α and PP1γ immunoprecipitation, immunoblotting with GFP antibody was 
performed in order to detect wt- and ΔE-torsinA in fusion with GFP-tag, and also with 
LAP1 antibody to detect endogenous LAP1. The results showed that PP1 antibodies 
immunoprecipitated both wt- and ΔE-torsinA and also LAP1. Moreover, when the 
immunoprecipitation was carried out with the LAP1 antibody, wt- and ΔE-torsinA and 
PP1γ could be decteted (Fig. V.C.2B). In addition, similar results were obtained in 
COS-7 cells using the same methodology (data not shown). 
 
 202 
 
 
Figure V.C.2. Wt-torsinA and ΔE-torsinA form a complex with LAP1 and PP1. A- SH-SY5Y cells 
were transfected with GFP-Wt-torsinA or GFP-ΔE-torsinA and immunoprecipitated with PP1α and PP1γ 
antibodies bound to protein G- Dynabeads. B- SH-SY5Y cells were transfected with GFP-wt-torsinA or 
GFP-ΔE-torsinA and immunoprecipitated with LAP1 antibody bound to protein G- Dynabeads. Negative 
controls were performed by incubating cell extracts with beads. IP, immunoprecipitation. IB, 
immunobloting. 
 
 
V.C.3.2. Localization of the trimeric complex 
 
Having established that PP1, LAP1 and torsinA form a trimeric complex of 
potential physiological relevance, it is important to unravel its subcellular localization. 
Thus, SH-SY5Y cells were transfected with GFP-wt-torsinA or GFP-ΔE-torsinA, 
followed by immunofluorescence analysis using LAP1 and PP1γ specific antibodies 
(Fig. V.3A and B). Individually, all proteins have the expected subcellular distribution. 
Namely, GFP-wt-torsinA was found throughout the ER and encircling the nucleus, 
while GFP-ΔE-torsinA was mainly found in a perinuclear distribution. LAP1 was 
located in the NE and PP1γ was predominantly found in the nucleus, including the 
nucleolus, and throughout the cytoplasm. As expected, both torsinA proteins (wt and 
ΔE) clearly co-localized with LAP1 in the NE, as is evident by the yellow color in the 
merge images (Fig. V.3A). PP1γ co-localized with wt-torsinA at some points in the 
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ER/cytoplasm and with both wt- and ΔE-torsinA near the NE (Fig. V.3B), probably at 
the outer membrane of the NE (cytoplasmic side). Furthermore, SH-SY5Y cells were 
transfected with Myc-LAP1B followed by immunofluorescence analysis using Myc-tag 
and PP1γ antibodies. As previously reported by us (Santos et al., 2013), LAP1B and 
PP1γ co-localize at specific points within the nucleus and near the inner side of the NE 
(nucleoplasmic side). These results indicate that the common location for PP1, LAP1 
and torsinA proteins is the NE, presumably the perinuclear space.   
Additionally, SH-SY5Y cells were co-transfected with GFP-wt-torsinA or GFP-
ΔE-torsinA plus Myc-LAP1B followed by immunofluorescence analysis using Myc-tag 
and PP1γ antibodies. The results show that the overexpression of LAP1B and one of the 
torsinA proteins caused nuclear abnormalities and invaginations of the NE (Fig. V.3C). 
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Figure V.C.3. Localization of the PP1/LAP1/TorsinA complex in SH-SY5Y cells. A- Co-localization 
of overexpressed GFP-wt-torsinA or GFP-ΔE-torsinA with endogenous LAP1 or PP1γ. B- 
Immunolocalization of Myc-LAP1B and endogenous PP1γ. The presence of the complexes is evidenced 
by the ROI (region of interest). C- Nuclear defects were observed in cells overexpressing GFP-wt-torsinA 
or GFP-ΔE-torsinA plus Myc-LAP1B. GFP was directly visualized. Specific primary antibodies for 
endogenous LAP1 and PP1γ were detected with Alexa Fluor 594 conjugated secondary antibody (red) 
and a specific primary antibody for the Myc-tag was detected with Alexa Fluor 350 conjugated secondary 
antibody (blue). DNA was stained with DAPI. Photographs were acquired using an Olympus 
epifluoresence microscope. Bars, 10 µm. 
 
 
V.C.3.3. LAP1 as a bridging protein between torsinA and PP1 
 
LAP1 binds directly to torsinA in the perinuclear space (Goodchild and Dauer, 
2005) and to PP1α and γ isoforms in the nucleoplasm (Santos et al., 2013). Thus, it is 
possible that LAP1 may be a bridging protein between PP1 (inside the nucleus) and 
torsinA (in the perinuclear space). Moreover, none of the documented PP1 binding 
motifs (Ayllon et al., 2002; Hendrickx et al., 2009; Meiselbach et al., 2006; Wakula et 
al., 2003) were identified in torsinA by in silico analysis. Nonetheless, in order to 
understand wheter wt- and ΔE-torsinA bind directly to PP1 or via LAP1, an in vitro blot 
overlay assay was performed. Firstly, human LAP1B, wt-torsinA and ΔE-torsinA 
proteins were generated by in vitro translation (IVT). Subsequently, membranes 
containing recombinant purified PP1γ1 protein were overlaid with the negative control 
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of IVT, wt-torsinA or ΔE-torsinA or with LAP1B and then with wt-torsinA or ΔE-
torsinA IVTs. Further, immunoblotting was performed using GFP antibody to detect wt- 
and ΔE-torsinA in fusion with GFP-tag. Upon incubation with LAP1B and subsequently 
with wt- or ΔE-torsinA, a band of approximately 37 kDa was clearly decteted, which 
corresponds to the molecular weight of PP1γ1 (Fig. V.C.4). This was not observed 
when PP1γ1 was directly overlaid with wt- and ΔE-torsinA (in the absence of LAP1B); 
however a very faint band was detected (Fig. V.C.4). Thus, one cannot indubitable 
confirm that wt- and ΔE-torsinA do not bind directly to PP1, but LAP1B clearly 
strengths the binding between these proteins. Moreover, LAP1B binds directly to both 
wt- and ΔE-torsinA in vitro and seems to link torsinA with PP1.  
 
 
Figure V.C.4. Blot overlay assay. Five samples of purified recombinant PP11 protein were separated 
by SDS-PAGE and the resulting blot was overlaid with the negative control of IVT [(-) control], wt-
torsinA-IVT, ΔE-torsinA-IVT or overlaid with LAP1B-IVT followed by a second overlay with wt-
torsinA-IVT or ΔE-torsinA-IVT. IB, immunobloting. 
 
 
V.C.3.4. TorsinA is dephosphorylated by PP1 
 
TorsinA has several potential phosphorylation sites and at least two residues (Thr 
215 and Ser 224) were found to be phosphorylated, as determined by mass spectrometry 
analysis (Oppermann et al., 2012). Given that torsinA interacts with PP1, it is plausible 
that this phosphatase is responsible for dephosphorylating torsinA. Hence, SH-SY5Y 
cells were transfected with GFP-wt-torsinA or GFP-ΔE-torsinA and then incubated with 
two different concentrations of OA: 0.25 nM or 500 nM that inhibit PP2A and 
PP2A/PP1, respectively. Cell lysates were further incubated with or without 100 ng of 
recombinant purified PP1γ1 protein. Proteins were resolved in MnCl2/Phos-tag SDS-
PAGE in order to analyze the phosphorylation state of torsinA proteins (Hosokawa et 
al., 2010; Kinoshita et al., 2006) and in MnCl2 SDS-PAGE for comparative analysis. In 
the Phos-tag SDS-PAGE, GFP-torsinA proteins apparently migrated as two bands (Fig. 
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V.C.5C, immunoblotting with GFP antibody). However, it is not clear in the images if 
the upper (slower migrating) band(s) detected after PP2A/PP1 inhibition (500 nM OA 
treatment) is a single diffuse band or a doublet. Nevertheless, PP2/PP1 inhibition 
considerable produces an upward shift of those bands (that are also more intense), 
which was not seen when PP2A alone was inhibited (0.25 nM OA treatment). 
Moreover, these effects were reversed upon PP1γ1 incubation in vitro; thus showing 
that the slower migrating bands are phosphorylated species and that PP1γ1 is involved 
in the dephosphorylation of GFP-wt-torsinA and GFP-ΔE-torsinA proteins. In addition, 
immunoblotting with torsinA antibody (Fig.V.C.5D) was performed, in order to analyze 
the phosphorylation state of endogenous torsinA. The results showed that endogenous 
torsinA migrated as three bands in Phos-tag SDS-PAGE. Moreover, the slower 
migrating band is only detectable after 500 nM OA treatment in both wt- and ΔE-
torsinA transfected cells, in agreement with our previous results. This band is still 
detectable upon PP1γ1 incubation in vitro, but the intensity of the band decreased (Fig. 
V.C.5D). These results showed that endogenous torsinA is also phosphorylated and is 
dephosphorylated to some extent by PP1γ1.  
Additionally, the phosphorylation state of LAP1 was also analyzed. In MnCl2 
SDS-PAGE (Fig. V.C.5B), a slight downward shift of LAP1 was detected in wt-torsinA 
transfected cells upon incubation with PP1γ1 in vitro, but this shift was not so evident in 
ΔE-torsinA transfected cells (Fig. V.C.5B). Nevertheless, in Phos-tag SDS-PAGE 
(V.C.5E), LAP1 was separated into several bands with large mobility differences. 
Interestingly, upon PP2A/PP1 inhibition (500 nM OA) a considerable upward shift of 
LAP1 was detected, which was not observed when PP2A alone was inhibited (0.25 nM 
OA). Moreover, this shift was reversed after PP1γ1 incubation in vitro, in agreement 
with our previous studies (Santos et al., 2013). The changes in the phosphorylation state 
of LAP1 were observed in both wt- and ΔE-torsinA transfected cells; thus showing that 
the pathogenic ΔE-torsinA mutation does not seem to affect the phosphatase activity of 
PP1 toward its substrates. 
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Figure V.C.5. Detection of phosphorylated torsinA proteins. SH-SY5Y cells were transfected with 
GFP-wt-torsinA or GFP-ΔE-torsinA. Transfected cells were left untreated (lane 1) or treated with 0.25 
nM OA (lane 2) or 500 nM OA (lanes 3 and 4) for 3 hours. Cell lysates were then incubated in vitro with 
(lane 4) or without (lanes 1, 2 and 3) purified PP1γ1. Proteins were resolved in SDS-PAGE containing 
MnCl2 (upper panel, A and B) or 50 µM Phos-tag plus 100 µM MnCl2 (lower panel, C, D and E) for 
comparative analysis. 1, without OA; 2, 0.25 nM OA; 3, 500 nM OA; 4, 500 nM OA plus PP1γ1 addition. 
IB, immunoblotting; NT, non-transfected cells. 
 
 
V.C.3.5. Effects of LAP1 knockdown 
 
To further investigate the physiological relevance of the trimeric complex, down 
regulation of the bridging protein, LAP1, was performed using specific LAP1-shRNAs. 
SH-SY5Y cells were transfected with two different pSIREN-LAP1 plasmids 
(previously described), in order to induce LAP1 knockdown, or with the pSIREN-CMS 
plasmid as the negative control. Interestingly, reducing the levels of LAP1 (decrease by 
42%) resulted in a significant decrease in the expression levels of both PP1γ and 
torsinA (31% and 40%, respectively) (Fig. V.C.6). Ponceau S staining was used as a 
loading control. 
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Figure V.C.6. Effects of LAP1 knockdown. SH-SY5Y cells were transfected with two specific LAP1- 
shRNAs (LAP1) or a control missense shRNA (CMS). Data are presented as mean ± SEM of at least 
three independent experiments. Statistically different from CMS transfected cells, *p < 0.05, 
**
p < 0.01. 
IB, immunoblotting. 
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V.C.4. DISCUSSION 
 
TorsinA is localized at different subcellular compartments (ER and NE and cell 
body and processes of neuronal cells), interacting with different proteins. Consequently, 
several potential functions have been attributed to torsinA, such as organization of the 
NE and ER, regulation of the cytoskeleton network, protein processing in the secretory 
pathway, synaptic vesicle recycling and response to stress (reviewed in Granata et al., 
2009). LAP1 was the first binding protein of torsinA identified in the NE (Goodchild 
and Dauer, 2005). Of note, overexpressed LAP1 was able to recruit wt-torsinA to the 
NE, while other NE proteins did not produce the same effect. We have recently reported 
that LAP1 binds to PP1 in the nucleoplasm (Santos et al., 2013).  
In this study, LAP1, torsinA and PP1 were shown to form a trimeric complex 
(Fig. V.C.1, V.C.2 and V.C4). Several immunoprecipitations using specific antibodies 
directed against these proteins were performed, thereby confirming that LAP1, torsinA 
and PP1γ and PP1α isoforms are all part of a complex in rat brain (Fig. V.C.1). In order 
to establish the potential relevance of the latter complex for DYT1 dystonia, the relative 
association of wt-torsinA and DYT1 dystonia mutant (ΔE-torsinA) in this complex was 
evaluated. Thus, both wt-torsinA and ΔE-torsinA were found to be in a complex with 
LAP1 and PP1 isoforms in SH-SY5Y cells (Fig. V.C.2). Conversely, ΔE-torsinA was 
previously reported to compromise the binding of torsinA ATP-hydrolysis mutant 
(E171Q-torsinA) with LAP1 (Naismith et al., 2009a; Zhao et al., 2013b). In the absence 
of ΔE-torsinA, E171Q-torsinA mutant showed high affinity for substrate binding and 
was found to strongly co-immunoprecipitate with LAP1 (Goodchild and Dauer, 2005). 
Nevertheless, the results showed that ΔE-torsinA mutant is able to interact with both 
LAP1 and PP1 (Fig. V.C.2 and V.C.3) in a manner similar to wt-torsinA. This is the 
first time that torsinA was reported to bind to a protein phosphatase. However, 
torsinA/PP1 interaction may be indirect and mediated by LAP1 (Fig. V.C.4). Indeed, 
torsinA does not have any of the canonical PP1 binding motifs previously described 
(Ayllon et al., 2002; Hendrickx et al., 2009; Meiselbach et al., 2006; Wakula et al., 
2003). Most PP1 binding proteins interact with the PP1 catalytic subunit through a 
conserved PP1 binding motif termed the RVxF motif (Meiselbach et al., 2006; Wakula 
et al., 2003). Additionally, other PP1 binding motifs have been reported, such as the 
SILK and the MyPhoNE motifs (Hendrickx et al., 2009) and the apoptotic signature F-
X-X-[KR]-X-[KR] (Ayllon et al., 2002). Nevertheless, some proteins bind to PP1 
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through additional docking motifs. For example, iASPP (inhibitory member of the 
apoptosis-stimulating proteins of the p53 family) lacks a canonical RVxF binding motif 
but binds to PP1 through a noncanonical motif (RNYF) (Llanos et al., 2011), and the 
leucine-rich repeats of sds22 protein are essential for binding to PP1 (Ceulemans et al., 
2002b). Thus, one can not exclude the possibility that torsinA interacts directly with 
PP1, but the overlay assay (Fig. V.C.4) strongly suggests that LAP1 is a bridging 
protein between PP1 and wt- and ΔE-torsinA proteins.  
Reversible protein phosphorylation is a crucial mechanism for signal transduction, 
regulating the biological activity of diverse proteins (Barford et al., 1998; Cohen, 1989). 
TorsinA has several potential sites for phosphorylation and two residues (Thr 215 and 
Ser 224) can be phosphorylated (Oppermann et al., 2012). In addition, another torsin 
family member, torsinB, seems to also be regulated by phosphorylation (Olsen et al., 
2010). However, the involvement of specific kinases and/or phosphatases had not 
previosuly been documented. The work here described established that torsinA 
associates with PP1, and is plausible that torsinA can be dephosphorylated by the latter. 
PP1 catalyzes the majority of protein dephosphorylation events in eukaryotic cells 
(Bollen et al., 2010; Heroes et al., 2013) and its action is largely determined by binding 
to different regulatory subunits. These regulatory subunits can be inhibitors of the 
catalytic activity, substrate-specifying subunits, targeting subunits or substrates of PP1 
(Bollen et al., 2009; Bollen et al., 2010). In order to determine if torsinA is a substrate 
of PP1, Phos-tag SDS-PAGE methodology was applied in order to analyze the 
phosphorylation state of torsinA. Results showed that the phosphorylated forms of 
torsinA were upregulated after PP1 inhibition in vivo and this effect was reversed upon 
PP1 addition in vitro (Fig. V.C.5). These results were similar for GFP-wt-torsinA, GFP-
ΔE-torsinA and endogenous torsinA; thus arguing that torsinA is a substrate of PP1. 
Moreover, it seems that the presence of ΔE-torsinA mutant does not affect the 
phosphatase activity of PP1 toward its substrates (torsinA and LAP1). Some PP1 
substrates can be either activated by dephosphorylation, as is the case of focal adhesion 
kinase and caspase 2 (Bollen et al., 2010) or inactivated, as it happens with NEK2 and 
Aurora-A (Mi et al., 2007). Thus, it will be interesting to understand the effects of PP1 
dephosphorylation on torsinA function.  
Protein phosphorylation regulates the enzymatic activities and modulates protein-
protein interactions (Barford et al., 1998), thereby it is plausible that LAP1 and torsinA 
(de)phosphorylation events can regulate the interaction between those proteins. 
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Interestingly, protein phosphorylation has been linked to the regulation of the 
interaction between NE components during mitosis (Bollen et al., 2009; Guttinger et al., 
2009). For example, phosphorylation of lamins is important for lamin depolymerization 
and NE breakdown (Kuga et al., 2010), while dephosphorylation of lamin B by PP1 
leads to lamin polymerization and accompanies NE reassembly (Thompson et al., 
1997). Moreover, protein phosphorylation can also regulate the interaction of NE 
proteins with chromatin (Foisner and Gerace, 1993; Pyrpasopoulou et al., 1996; Takano 
et al., 2004) and chromatin regulators such as BAF (Hirano et al., 2005). Therefore, 
LAP1 and torsinA dephosphorylation by PP1 may regulate LAP1 and torsinA 
interactions at the NE in order to preserve the NE integrity, which may be compromised 
in DYT1 dystonia. Additionally, aberrant protein phosphorylation of key proteins has 
been linked to many diseases and dysfunctional states (da Cruz e Silva et al., 1995a; 
Delobel et al., 2002b; Fardilha et al., 2010; Rebelo et al., 2013; Rebelo et al., 2007; 
Vieira et al., 2010). Regarding INM proteins, it was reported that mutated forms of 
emerin found in Emery-Dreifuss muscular dystrophy patients exhibited abnormal cell-
cycle dependent phosphorylation forms and altered nuclear lamina interaction (Ellis et 
al., 1998). Interestingly, emerin was recently found to bind to LAP1 and conditional 
depletion of LAP1 from mouse striated muscle caused muscular dystrophy (Shin et al., 
2013). In closing, given that LAP1 and torsinA are regulated by reversible protein 
phosphorylation, and that PP1 dephosphorylates both proteins, this provides novel 
insights into DYT1 dystonia and other NE-related diseases pathogenesis. 
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VI.1. LAP1B, A NOVEL PP1 BINDING PROTEIN 
 
Several clones encoding human LAP1B (NM_001267578) were identified in 
YTH screens of a human brain cDNA library using PP1 α, γ1 and γ2 isoforms as baits 
(Esteves et al., 2012a; Esteves et al., 2013a; Santos et al., 2013). The interaction 
between LAP1B and PP1 was validated using different techniques (yeast co-
transformation, blot overlay assay and co-immunoprecipitations). Moreover, the 
LAP1B/PP1 binding is direct as confirmed in vitro by blot overlay assay. LAP1B 
interacts with PP1 through a conserved RVxF-like motif (REVRF) located in the 
nucleoplasmic domain. Microscopic analysis confirmed the association between LAP1 
and PP1 in the nucleoplasm and near the INM. Furthermore, LAP1B is a substrate of 
PP1, since PP1 dephosphorylated LAP1B in vitro. From these results we were able to 
describe a novel PP1 regulatory protein. 
Interestingly, the majority of PP1 binding proteins are located in the nucleus, 
cytoplasm and plasma membrane (Esteves et al., 2013a; Heroes et al., 2013). However, 
LAP1B (Santos et al., 2013) and AKAP1-149 (Steen et al., 2000) are the only PP1 
binding proteins specifically located at the NE. AKAP-149 functions as a PP1 targeting 
protein by recruiting PP1 to the NE upon NE assembly and promoting lamin B 
dephosphorylation and polymerization (Steen and Collas, 2001; Steen et al., 2000; 
Thompson et al., 1997). LAP1B also binds to lamins, thereby it is plausible that LAP1B 
also function as a PP1 targeting protein in order to promote lamins or other NE proteins 
dephosphorylation. In addition, PP1-mediated dephosphorylation of LAP1B may also 
regulate the function of the latter or even the interaction between LAP1B and other NE 
proteins or chromatin. Dephosphorylation of NE proteins is an important mechanism 
that promotes NE reassembly at the end of mitosis (Bollen et al., 2009; Guttinger et al., 
2009). Thus, dephosphorylation of LAP1B by PP1 may present itself as an important 
regulatory mechanism for NE reassembly during mitosis. 
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VI.2. IDENTIFICATION OF A NOVEL HUMAN LAP1 ISOFORM (LAP1C)  
 
The complexity of the NE components and protein composition increased 
throughout evolution. Several INM proteins were first found in metazoans and some 
proteins such as LAP1 were found, thus far, only in vertebrates.  It would appear that 
the emergence of INM proteins such as LAP1 probably conferred a selective advantage 
to vertebrates (Cohen et al., 2001; Mans et al., 2004). In rat, the LAP1 gene 
(TOR1AIP1) undergoes alternative splicing to originate three LAP1 isoforms (LAP1A, 
B and C) (Martin et al., 1995; Senior and Gerace, 1988). In silico analysis of mouse 
LAP1 transcripts present in the GenBank database showed that, at least, three LAP1 
isoforms are originated by alternative splicing of mouse TOR1AIP1 gene. However, it 
remained unclear, until this work, if the same occurs with the human TOR1AIP1 gene. 
Previous results had identified only the LAP1B isoform in human cells (Kondo et al., 
2002). Moreover, all clones identified in our previous YTH screen (using PP1 isoforms 
as baits) corresponded to the LAP1B isoform (Esteves et al., 2012a; Esteves et al., 
2013a; Santos et al., 2013). Nevertheless, given the diversity of LAP1 isoforms 
identified in other species, we decided to further clarify the existence of additional 
human LAP1 family members. 
ShRNA-mediated knockdown of LAP1 in human cells resulted in specific 
reductions of the expression of two proteins: a higher molecular weight protein 
(approximately 68 kDa), which corresponds to the known LAP1B isoform, and a lower 
molecular weight protein (approximately 56 kDa). Mass spectrometry analysis of these 
proteins, revealed that the 56 kDa protein is N-terminally truncated compared to the 
LAP1B isoform. Given its molecular weight similarity with rat LAP1C, we designated 
the newly identified human LAP1 isoform as LAP1C. Moreover, LAP1B and LAP1C 
were shown to be products of different RNAs and thereby their generation must be 
regulated at the transcriptional level, possibly by alternative promoter usage. The 
existence of non-RefSeq mRNAs matching with the LAP1C sequence in GenBank 
corroborates this hypothesis.  
The newly identified human LAP1C has a shorter nucleoplasmic domain. 
Thereby, LAP1C was more easily solubilized after detergent/salt treatment, compared to 
LAP1B, in agreement with previous reports regarding rat LAP1 isoforms (Foisner and 
Gerace, 1993). Kondo et al reported that the entire nucleoplasmic domain of human 
LAP1B may be required for full retention at the INM (Kondo et al., 2002). Therefore, a 
CHAPTER VI - DISCUSSION AND CONCLUDING REMARKS 
 
 
Characterization of novel LAP1 complexes and their relevance in DYT1 dystonia  217 
 
fraction of LAP1C may reside in other subcellular compartments in addition to the 
INM. Moreover, the lost of the N-terminal nucleoplasmic domain may affect protein-
protein interactions; consequently LAP1C and LAP1B may have different binding 
partners. For example, LAP1C lacks the PP1 binding motif (REVRF) present in 
LAP1B. Nevertheless, PP1 was able to dephosphorylate LAP1C, as well as LAP1B, 
under our experimental conditions. This could happen due to an indirect interaction 
between LAP1C and PP1, probably via other nuclear proteins such as lamins, or even 
via LAP1B. Furthermore, functional characterization of both human LAP1 isoforms 
showed that they are differentially expressed across diverse human cell lines and 
tissues. LAP1C was the major isoform detected in different cultured cell lines in 
agreement with previous reports regarding rat LAP1C (Senior and Gerace, 1988). In 
contrast, the abundance of LAP1B/LAP1C in human tissues is dependent on the specific 
tissue. Interestingly, human LAP1B is more abundant in brain and is upregulated later 
during SH-SY5Y cells differentiation when compared to LAP1C. Moreover, the 
expression levels of rat LAP1B/LAP1C during maturation of rat cortical primary 
cultures correlate well with those observed for human LAP1B in differentiated SH-
SY5Y cells.  
 
 
VI.3. POTENTIAL ROLE OF LAP1 PROTEINS DURING CELL CYCLE 
 
The association of LAP1 proteins with lamins and chromatin (Foisner and Gerace, 
1993) suggests that LAP1 is involved in the positioning of lamins and chromatin in 
close proximity to the NE, thereby contributing to the maintenance of the NE structure 
(Gerace and Huber, 2012; Martin et al., 1995). Moreover, Kim et al reported that 
various tissues and cultured neurons of TOR1AIP1 knockout mice embryos exhibit NE 
abnormalities such as “blebs – vesicle-appearing structures” in the perinuclear space 
(Kim et al., 2010a), thus arguing that LAP1 is a key protein in the NE. In support of this 
role, we showed that downregulation of human LAP1 proteins (LAP1B and LAP1C) in 
SH-SY5Y cells cause nuclear abnormalities and decrease expression of lamins and 
acetylated α-tubulin. Decreased levels of tubulin acetylation could be the result of 
microtubule instability due to disruption of NE integrity and loss of connection between 
the nucleoplasm and the cytoskeleton (disruption of the LINC complex).  
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In addition, LAP1 co-localized with acetylated α-tubulin in the mitotic spindle 
and midbody microtubules, suggesting that LAP1 and microtubules are functionally 
associated during mitosis. In agreement wih this, Neumann et al reported that 
downregulation of LAP1 led to the formation of defective mitotic spindles and thereby 
aberrant mitotic exit (Neumann et al., 2010). Moreover, LAP1 also co-localized with γ-
tubulin in centrosomes. Other NE proteins, such as emerin and SAMP1, were found to 
be involved in centrosome positioning and connection to the NE (Buch et al., 2009; 
Salpingidou et al., 2007).  
Furthermore, cell cycle-dependent phosphorylation of LAP1 proteins could 
regulate LAP1 function and interactions. In agreement with mass spectrometry data 
(Dephoure et al., 2008; Olsen et al., 2010), we showed that LAP1 proteins are highly 
phosphorylated during mitosis using the Phos-tag SDS-PAGE method. Interestingly, the 
activity of PP1, which is responsible for the dephosphorylation of LAP1 proteins, seems 
to be repressed at early-mid mitosis (Kwon et al., 1997). 
 
 
VI.4. RELEVANCE OF PP1/LAP1/TORSINA COMPLEX IN DYT1 DYSTONIA 
 
The finding that PP1 interacts with LAP1, which in turn binds to torsinA, opens a 
new perspective in the study of DYT1 dystonia. PP1 interacts with the nucleoplasmic 
domain of LAP1B (Santos et al., 2013), while torsinA binds to the lumenal domain of 
LAP1 in the perinuclear space (Goodchild and Dauer, 2005). The lumenal domain of 
LAP1 is conserved between LAP1 isoforms, thus it is reasonable to deduce that torsinA 
interacts with all LAP1 isoforms. In this study, the interaction between PP1, LAP1 and 
torsinA proteins was confirmed by co-immunoprecipitation in rat brain and human SH-
SY5Y cells and by an in vitro blot overlay assay. Moreover, both wt-torsinA and DYT1 
dystonia mutant (ΔE-torsinA) were found to interact with PP1 and LAP1. Therefore, we 
identified a novel trimeric complex composed by PP1, LAP1 and torsinA. In this 
trimeric complex, LAP1 seems to function as a bridging protein to bring PP1 into close 
proximity with torsinA that lacks a canonical PP1 binding motif. Furthermore, torsinA 
was shown to be regulated by reversible protein phosphorylation and PP1 is able to 
dephosphorylate torsinA. 
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VI.4.1.  DYT1 dystonia, a nuclear envelope-related disease 
 
Mutations in genes encoding NE proteins have been associated with increasing 
number of diseases referred to as laminopathies or nuclear envelopathies. The molecular 
mechanisms underlying these diseases are still not clearly understood. However, some 
proposed mechanisms that explain how these mutations cause disease are loss of 
assembly or stability of protein complexes, disruption of lamin-cytoskeleton 
interactions, altered gene expression and cell cycle abnormalities (Dauer and Worman, 
2009; Dorner et al., 2007; Wilkie et al., 2011). These diseases result from mutations in 
genes encoding widely expressed proteins of the nuclear envelope and many have 
tissue-selective effects (Dauer and Worman, 2009). DYT1 dystonia is a CNS selective 
nuclear envelopathy caused by a mutation in the TOR1A gene encoding torsinA protein 
(Ozelius et al., 1997). Wt-torsinA has been localized in the ER and between the inner 
and outer nuclear membranes, while DYT1 dystonia mutant (ΔE-torsinA) abnormally 
concentrate between the NE membranes (Goodchild et al., 2005; Hewett et al., 2003; 
Kustedjo et al., 2000; Naismith et al., 2004). The accumulation of torsinA in the NE 
results in abnormal morphology of the NE and the presence of inclusions (Gonzalez-
Alegre and Paulson, 2004; Goodchild et al., 2005; Hewett et al., 2000). However this 
phenotype seems to be specific of neuronal cells. ΔE-torsinA knock-in mice exhibit 
abnormalities in the NE membranes specifically in neurons. Moreover, neurons from 
torsinA knockout mice display similar NE abnormalities, although non-neuronal cell 
types appear normal (Goodchild et al., 2005). However, reducing LAP1 levels in 
torsinA null fibroblasts causes NE abnormalities, thus suggesting that these proteins are 
functionally related (Kim et al., 2010a).  
 
 
VI.4.2.  Potential role of the PP1/LAP1/TorsinA complex in NE dynamics 
 
PP1 has several regulatory binding subunits in the nucleus; thereby PP1 can 
regulate different nuclear functions such as mRNA processing, transcription and cell 
cycle events (reviewed in Bollen and Beullens, 2002; Ceulemans and Bollen, 2004). 
During cell cycle, PP1 is particularly important in the reformation of the NE (Steen and 
Collas, 2001; Steen et al., 2000; Thompson et al., 1997). Indeed, NE breakdown and 
reassembly are complex processes that are regulated by reversible protein 
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phosphorylation (Bollen et al., 2009; Guttinger et al., 2009). LAP1 and torsinA 
dephosphorylation by PP1 may promote NE reformation and regulate LAP1 and torsinA 
interactions at the NE in order to preserve NE integrity. LAP1 and torsinA seem to be 
functionally related in the maintenance of the NE structure in neurons, since both 
TOR1AIP1 and TOR1A knockout mice display similar NE abnormalities (Kim et al., 
2010a). Interestingly, another AAA
+
 protein termed p97 was found to be involved in the 
final phases of NE reformation in order to form a sealed NE in vitro, presumably in 
association with a receptor protein in the NE (Burke and Ellenberg, 2002; Hetzer et al., 
2001).  
LAP1 and torsinA may participate in the regulation of the LINC complex which is 
required to maintain the structure and integrity of the NE as well as the nuclear size, 
shape and positioning of nuclei (reviewed in Rothballer and Kutay, 2013). LAP1 binds 
to lamins and may contribute to its positioning in close proximity with the NE. As 
previously described, downregulation of LAP1 in SH-SY5Y cells caused decreased 
expression levels of lamin B1 and acetylated α-tubulin (Chapter IV). In addition, 
downregulation of LAP1 caused a decrease in the expression levels of its binding 
partners torsinA and PP1. Moreover, LAP1 depletion in fibroblasts caused the 
mislocalization of emerin (Shin et al., 2013), which can bind directly to microtubules 
and actin (Holaska et al., 2004; Salpingidou et al., 2007). TorsinA interacts with the 
LINC components nesprins (Nery et al., 2008) and SUN proteins (Jungwirth et al., 
2011). Depletion of torsinA caused mislocalization of nesprin-3 to the ER and affects 
the positioning of the nucleus (Nery et al., 2008), while ΔE-torsinA overexpression lead 
to the accumulation of vimentin, which binds to nesprin-3 through plectin, around the 
nucleus (Hewett et al., 2006). In addition, our results provided evidence that ΔE-torsinA 
overexpression affects the expression/localization of tubulin and F-actin.  
Reversible protein phosphorylation is a mechanism capable of modulating 
protein-protein interactions (Barford et al., 1998), thereby it is plausible that LAP1 and 
torsinA (de)phosphorylation events contribute to the maintenance of the NE structure 
through regulation of protein-protein interactions at the NE. Moreover protein 
phosphorylation can regulate the interaction of NE proteins with chromatin (Foisner and 
Gerace, 1993; Pyrpasopoulou et al., 1996; Takano et al., 2004) and chromatin regulators 
such as BAF (Hirano et al., 2005). Additionally, aberrant protein phosphorylation on 
key proteins has been linked to many diseases and dysfunctional states (da Cruz e Silva 
et al., 1995a; Delobel et al., 2002a). For example, neurofibrillary tangles found in 
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Alzheimer's disease patients are composed of a hyperphosphorylated form of the 
microtubule-stabilizing protein tau. Inhibition of PP1 and PP2A could lead to the 
hiperphosphorylation of tau (Malchiodi-Albedi et al., 1997). Regarding INM proteins, it 
was reported that mutated forms of emerin found in Emery-Dreifuss muscular 
dystrophy patients exhibited abnormal cell-cycle dependent phosphorylation forms and 
altered nuclear lamina interaction (Ellis et al., 1998).  
 
 
 
Figure VI.1. Schematic illustration of LAP1, PP1 and torsinA interactions at the nuclear envelope. 
TorsinA can be found in both the endoplasmic reticulum (ER), where it interacts with LULL1, and lumen 
of the perinuclear space. In the nuclear envelope torsinA can bind to proteins of the inner nuclear 
membrane (INM) like LAP1 and SUN and to nesprins located in the outer nuclear membrane (ONM). 
SUN proteins bind to lamins and to nesprins, which in turn bind to cytoskeleton elements (F-actin, 
kinesin/microtubules and plectin/intermediate filaments). LAP1 is located in the INM where it binds to 
both torsinA (in the perinuclear space) and PP1 in the nucleoplasm. LAP1 can also bind to lamins, 
chromosomes and emerin. The latter can be localized in both the inner and outer nuclear membranes and 
interacts directly with lamins, SUN, nesprins and chromatin associated protein BAF. PP1 is highly 
abundant in the nucleus and is linked to the NE through interaction with AKAP-149, lamins and LAP1. 
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VI.4.3.  Abnormal dopamine signaling in DYT1 dystonia 
 
TorsinA, LAP1 and PP1 are ubiquitously expressed (da Cruz e Silva et al., 1995b; 
Goodchild and Dauer, 2005; Ozelius et al., 1997), but PP1 and torsinA are both present 
at high levels of expression in the brain (Augood et al., 1999; da Cruz e Silva et al., 
1995b; Ozelius et al., 1997). Moreover, ΔE-torsinA has a specific neurological 
phenotype (Giles et al., 2008; Goodchild et al., 2005), suggesting that torsinA plays a 
specific role in selected neuronal cells. In support of this, torsinA is expressed at high 
levels within dopaminergic neurons of the substantia nigra pars compacta. PP1α and 
PP1γ1 have the highest levels of expression in the striatum, where they were shown to 
be relatively enriched in the medium-sized spiny neurons (da Cruz e Silva et al., 1995b; 
Ouimet et al., 1995), which express DARPP-32 (Ouimet et al., 1984). DARPP-32 has a 
crucial role in dopaminergic transmission and is a potent inhibitor of PP1 when 
phosphorylated at Thr34. The state of (de)phosphorylation of DARPP-32 is modulated 
by dopamine and other neurotransmitters in the striatum. Dopamine, acting on D1 
receptors, causes activation of PKA and phosphorylation of DARPP-32 on Thr 34. 
Conversely, dopamine, acting on D2 receptors, causes the dephosphorylation of 
DARPP-32, through inhibition of PKA and activation of PP2B (Greengard et al., 1999). 
Several studies in mouse models have provided evidence that DYT1 dystonia is related 
with impaired dopaminergic and cholinergic signalling. Particularly, reduced D2 
receptor activity and function have been documented (Dang et al., 2012; 
Giannakopoulou et al., 2010; Napolitano et al., 2010; Pisani et al., 2006; Yokoi et al., 
2011). Therefore, D2-deficiency may alter the rate of phosphorylation of DARPP-32, 
resulting in reduced activity of PP1, which controls the state of phosphorylation and the 
physiological activity of several neuronal phosphoproteins. The hypothesis that PP1 
and/or abnormal protein phosphorylation may have a key role in DYT1 dystonia seems 
worthwhile exploring in the future. 
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VI.5. CONCLUDING REMARKS 
 
LAP1 was identified in 1988 but its function remains poorly understood. Later, 
LAP1 was found to interact with torsinA, which abnormally concentrates in the NE, 
indicating that LAP1 is involved in the pathogenesis of DYT1 dystonia. Nevertheless, 
the molecular mechanisms underlying the neuropathology of DYT1 dystonia are not 
clearly understood.The work included in this thesis provides important new insights into 
the biological properties of LAP1 proteins and LAP1 proteins complexes. 
 In conclusion this work resulted in: 
 the validation of LAP1B as a novel PP1 binding protein in the nuclear 
envelope; 
 the identification and characterization of the novel human LAP1C isoform; 
 the uncovering of the potential role of LAP1 proteins during cell cycle; 
 the identification of the novel PP1/LAP1/torsinA complex; 
 the identification of LAP1 and torsinA (wt- and ΔE-torsinA) as 
phosphoproteins and substrates of PP1. 
 
The fact that LAP1 and torsinA are regulated by reversible protein 
phosphorylation, and that PP1 dephosphorylates both proteins, opens a new perspective 
in the study of DYT1 dystonia. Altough the findings presented here do not provide a 
definitive role for protein phosphorylation/PP1 in DYT1 dystonia pathogenesis, they do 
provide a basis for futures studies. Moreover, our work suggests that the function of 
protein complexes in the nuclear envelope, particular LAP1 complexes, may underlie 
the pathology of nuclear envelope-related diseases such as DYT1 dystonia. Thereby, the 
functional relevance of these complexes should be pursued in the future.  
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APPENDIX I – CULTURE MEDIA AND SOLUTIONS 
 
Bacteria media 
 
LB (Luria-Bertani) Medium 
To 950 mL of deionised H2O add: 
LB 25 g 
Agar 15 g (for plates only) 
Shake until the solutes have dissolved. Adjust the volume of the solution to 1 L with 
deionised H2O. Sterilize by autoclaving. 
 
SOB Medium 
To 950 mL of deionised H2O add: 
SOB Broth 25.5 g 
Shake until the solutes have dissolved. Add 10 ml of a 250 mM KCl (prepared by 
dissolving 1.86 g of KCl in 100 mL of deionised H2O). Adjust the pH to 7.0 with 5 N 
NaOH. Sterilize by autoclaving. Just prior to use add 5 ml of a sterile solution of 2 M 
MgCl2 (prepared by dissolving 19 g of MgCl2 in 100 mL of deionised H2O and sterilize 
by autoclaving). 
 
SOC Medium 
SOC is identical to SOB except that it contains 20 mM glucose. After the SOB medium 
has been autoclaved, allow it to cool to 60ºC and add 20 mL of a sterile 1M glucose 
(this solution is made by dissolving 18 g of glucose in 90 mL of deionised H2O; after 
the sugar has dissolved, adjust the volume of the solution to 100 mL with deionised 
H2O and sterilize by filtration through a 0.22 µm filter). 
 
100 mg/ml antibiotics stock solution (Ampicilin or Kanamycin) 
Dissolve 1 g of the antibiotic in 10 mL of deionised H2O. Mix until de solutes have 
dissolved, filter through a 0.22 µm filter, aliquot and store at -20ºC. 
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Competent cell solutions 
Solution I (1L) 
MnCl2.4H2O 9.9 g 
CaCl2.2H2O 1.5 g 
Glycerol 150 g 
KHAc 1M  30 mL 
Adjust the volume of the solution to 1 L with deionised H2O. Adjust pH to 5.8, filter 
through a 0.2 μm filter and store at 4ºC. 
 
Solution II (1L) 
0.5 M MOPS (pH 6.8) 20 mL 
RbCl    1.2 g 
CaCl2.2H2O   11g 
Glycerol   150 g  
Adjust the volume of the solution to 1 L with deionised H2O. Filter through a 0.2 μm 
filter and store at 4ºC. 
 
 
Solutions for DNA manipulation 
 
50x TAE Buffer (1 L) 
Tris base   242 g 
Glacial acetic acid  57.1 ml 
0.5 M EDTA (pH 8.0) 100 ml 
 
TE Buffer (pH 7.5) 
10 mM Tris-HCl pH 7.5 
1 mM EDTA pH 8.0 
 
6x loading Buffer (LB) 
Bromophenol blue 0.25% 
Glycerol  30%  
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Miniprep solutions 
Cell resuspension solution 
50 mM glucose 
25 mM Tris-HCl pH 8.0 
10 mM EDTA 
 
Cell lysis solution  
0.2 N NaOH 
1% SDS 
 
Neutralization solution 
3 M potassium acetate 
2 M glacial acetic acid 
 
Maxiprep solutions 
Cell Resuspension Solution 
50 mM Tris-HCl (pH 7.5) 
10 mM EDTA 
100 µg/mL RNAase A  
 
Cell Lysis Solution  
0.2 M NaOH 
1% SDS 
 
Neutralization Solution 
1.32 M potassium acetate pH 4.8 
 
Column Wash Solution 
80 mM potassium acetate 
8.3 mM Tris-HCl (pH 7.5) 
0.04 mM EDTA 
55 % ethanol 
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Yeast Media 
 
YPD medium 
To 950 mL of deionised H2O add:  
YPD 50 g 
Agar 15 g (for plates only) 
Shake until the solutes have dissolved. Adjust the volume to 1 L with deionised H2O 
and sterilize by autoclaving. Allow medium to cool to 60ºC and add glucose to 2% (50 
ml of a sterile 40% stock solution).  
 
10x Dropout solution (DO 10x) 
This solution contains all but one or more of the following components: 
             10x concentration (mg/L)    SIGMA # 
L-Isoleucine     300       I-7383 
L-Valine     1500      V-0500 
L-Adenine hemisulfate salt   200      A-9126 
L-Arginine HCl    200      A-5131 
L-Histidine HCl monohydrate  200      H-9511 
L-Leucine     1000      L-1512 
L-Lysine HCl     300      L-1262 
L-Methionine     200      M-9625 
L-Phenylalanine    500      P-5030 
L-Threonine     2000      T-8625 
L-Tryptophan                200      T-0254 
L-Tyrosine     300      T-3754 
L-Uracil     200      U-0750 
 
10x dropout supplements may be autoclaved and stored for up to 1 year. 
 
Triple Drop Out: DO/-Leu/-Trp/-His 
Quadruple Drop Out: DO/-Leu/-Trp/-His/-Ade 
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SD synthetic medium 
To 800 mL of deionised H2O add:  
Yeast nitrogen base without amino acids (DIFCO) 6.7 g 
Agar (for plates only)     15 g 
Shake until the solutes have dissolved. Adjust the volume to 850 mL with deionised 
H2O and sterilize by autoclaving. Allow medium to cool to 60ºC and add glucose to 2% 
(50 mL of a sterile 40% stock solution) and 100 mL of the appropriate 10x dropout 
solution. 
 
 
Cell Culture Solutions and immunocytochemistry 
 
PBS 1x 
For a final volume of 500 mL, dissolve one pack of BupH Modified Dulbecco’s 
Phosphate Buffered Saline Pack (Pierce) in deionised H2O.  
Final composition: 
8 mM Sodium Phosphate   
2 mM Potassium Phosphate  
40 mM NaCl  
10 mM KCl  
Sterilize by filtering through a 0.2 m filter and store at 4ºC 
 
MEM + GLUTAMAX (HeLa cells) 
For a final of 500 mL add: 
Complete MEM + GLUTAMAX (Gibco, Invitrogen) 
Fetal Bovine Serum (FBS) (Gibco, Invitrogen) 50 mL (10% v/v) 
Non-Essential aminoacids (Gibco, Invitrogen)  5 mL (1% v/v) 
100x Antibiotic-antimycotic (Gibco, Invitrogen) 5 mL (1% v/v) 
Adjust the pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
FBS is heat-inactivated for 30 min at 56ºC.  
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MEM + GLUTAMAX (HeLa cells) 
For a final of 500 mL add: 
Complete MEM + GLUTAMAX 
Fetal Bovine Serum (FBS) (Gibco, Invitrogen) 50 mL (10% v/v) 
Non-Essential aminoacids (Gibco, Invitrogen)  5 mL (1% v/v) 
100x Antibiotic-antimycotic (Gibco, Invitrogen) 5 mL (1% v/v) 
Adjust the pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
FBS is heat-inactivated for 30 min at 56ºC.  
 
DMEM medium (COS-7 cells and HEK193) 
For a final volume of 1 L, dissolve one pack of DMEM powder (with L-glutamine and 
4500 mg glucose/L, Sigma Aldrich) in deionised H20 and add: 
NaHCO3 (Sigma)    3.7 g 
FBS (Gibco, Invitrogen) 100 ml (10% v/v) 
100x Antibiotic-antimycotic (Gibco, Invitrogen) 10 mL (1% v/v) 
Adjust the pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
FBS is heat-inactivated for 30 min at 56°C.  
 
MEM/F12 medium (SH-SY5Y cells) 
For a final volume of 1 L of deionized H2O add: 
MEM (Gibco, Invitrogen) 4.805 g 
Ham’s F12 (Gibco, Invitrogen) 5.315 g 
NaHCO3 (Sigma) 1.5 g 
L-glutamine (200 mM stock solution) 2.5 mL 
FBS (Gibco, Invitrogen) 100 mL (10% v/v) 
100x Antibiotic-antimycotic (Gibco, Invitrogen) 10 mL (1% v/v) 
Adjust the pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
FBS is heat-inactivated for 30 min at 56°C.  
 
RPMI medium (PC12 cells) 
For a final volume of 1 L dissolve one pack of RPMI 1640 powder (with L-glutamine 
and 4500 mg/L glucose, Gibco) in deionized H2O and add: 
NaHCO3 (Sigma) 0.85 g 
FBS (Gibco, Invitrogen) 50 mL (5% v/v) 
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Horse serum (HS) 100 mL (10% v/v) 
100x Antibiotic-antimycotic (Gibco, Invitrogen) 10 mL (1% v/v) 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
FBS is heat-inactivated for 30 min at 56ºC.  
 
Neurobasal medium (Cortical primary cultures) 
The serum-free medium (Neurobasal; Gibco, Invitrogen) is supplemented with: 
2% B27 Supplement (Gibco, Invitrogen) 
0.5 mM L-glutamine 
60 µg/ml Gentamicin (Gibco, Invitrogen) 
0.001% Phenol Red (Sigma)  
Sterilize by filtering through a 0.2 μm filter and store at 4°C 
 
Hank’s balanced salt solution (HBSS) 
137 mM NaCl 
5.36 mM KCl 
0.44 mM KH2PO4 
0.34 mM Na2HPO42H2O 
4.16 mM NaHCO3 
5 mM Glucose 
1 mM Sodium pyruvate 
10 mM HEPES 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
Borate buffer 
To a final volume of 1L, dissolve in deionised H2O 9.28 g of boric acid (Sigma). Adjust 
to pH 8.2, sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
1 mg/mL Poly-L-ornithine solution (10x) 
To a final volume of 100 mL, dissolve in deionised H2O 100 mg of poly-L-ornithine 
(Sigma-Aldrich).  
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10 mg/mL Poly-D-lysine solution (100x) 
To a final volume of 10 mL, dissolve in deionised H2O 100 mg of poly-D-lysine 
(Sigma-Aldrich).  
 
4% Paraformaldehyde  
For a final volume of 100 mL, add 4 g of paraformaldehyde to 25 mL deionised H2O. 
Dissolve by heating the mixture at 58ºC while stirring. Add 1-2 drops of 1 M NaOH to 
clarify the solution and filter (0.2 m filter). Add 50 mL of 2X PBS and adjust the 
volume to 100 mL with deionised H2O. 
 
 
Immunoprecipitation solutions 
 
Lysis Buffer + Protease inhibitors 
50 mM Tris-HCl (pH 8.0)   
120 mM NaCl    
4% CHAPS 
1 mM PMSF 
10 mM Benzamidine 
2 µM Leupeptin 
1.5 µM Aprotinin 
5 µM Pepstatin A 
 
 
SDS-PAGE and immunoblotting solutions  
 
4x LGB (Lower Gel Buffer) 
To 900 mL of deionised H2O add:  
Tris 181.65 g 
SDS  4 g  
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1 L 
with deionised H2O. 
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4x UGB (Upper Gel Buffer) 
To 900 mL of deionised H2O add:  
Tris 75.69 g 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L 
with deionised H2O. 
 
30% Acrylamide/0.8% Bisacrylamide 
To 70 mL of deionised H2O add: 
Acrylamide 29.2 g 
Bisacrylamide 0.8 g 
Mix until the solutes have dissolved. Adjust the volume to 100 mL with deionised H2O. 
Filter through a 0.2 μm filter and store at 4°C. 
 
10% APS  
In 10 mL of deonised H2O dissolve 1 g of APS.  
Prepare fresh before use. 
 
10% SDS  
In 10 mL of deonised H2O dissolve 1 g of SDS. 
 
4x Loading Gel Buffer  
1 M Tris solution pH 6.8 2.5 mL (250 mM) 
SDS    0.8 g (8%) 
Glycerol   4 mL (40%) 
β-Mercaptoethanol  2 mL (2%) 
Bromophenol blue  1 mg (0.01 %) 
Adjust the volume to 10 mL with deionised H2O. Store in darkness at room 
temperature. 
 
1 M Tris pH 6.8 solution 
To 150 mL of deonised H2O add: 
Tris base 30.3 g 
Adjust the pH to 6.8 and adjust the final volume to 250 mL. 
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10x Running Buffer  
To 800 mL of deionised H2O add:  
Tris  30.3 g (250 mM)  
Glycine 144.2 g (2.5 M) 
SDS  10 g (1%) 
Adjust the pH to 8.3 and the final volume to 1 L. 
 
1x Transfer buffer  
To 600 ml of deionised H2O add:  
Tris  3.03 g (25 mM) 
Glycine 14.41 g (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and the volume to 800 mL 
with deionised H2O. Just prior to use add 200 mL of methanol (20%). 
 
10x TBS (Tris buffered saline) 
To 800 mL of deionised H2O add:  
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM) 
Adjust the pH to 8.0 with HCl and the final volume to 1 L with deionised H2O.  
 
10x TBST (TBS + Tween) 
To 800 mL of deionised H2O add:  
Tris  12.11 g (10 mM) 
NaCl  87.66 g (150 mM) 
Tween 20 5 mL (0.05 %) 
Adjust the pH to 8.0 with HCl and the final volume to 1 L with deionised H2O.  
 
Stripping solution 
Tris    3.76 g (62.5 mM) 
SDS   10 g (2%)  
β-mercaptoethanol 3.5 mL (100 mM) 
Dissolve Tris and SDS in deionised H2O and adjust pH to 6.7. Add mercaptoethanol 
and ajust the volume to 500 ml.  
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Coomassie blue staining solutions 
Staining solution 
Coomassie Brilliant Blue 2 g 
Methanol   500 mL 
Acetic Acid   100 mL 
Adjust the volume to 1 L with deionised H2O. 
 
Destaining solution 
Methanol 250 mL 
Acetic Acid 50 mL 
Adjust the volume to 1 L with deionised H2O. 
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APPENDIX II – PRIMERS 
 
Oligo name Sequence (5’ - 3’) Target RE 
Gal4-AD FW TACCACTACAATGGATG pACT2  
Amplimer 3 RV ATCGTAGATACTGAAAAACCCCGCAAGTTCAC pACT2  
T7 promoter TAATACGACTCACTATAGGG T7 promoter  
LAP1B-BM1 FW GGAATTCATATGGCGGGCGACGGG LAP1B  EcoRI 
LAP1B-BM1 RV CCGCTCGAGTTAGACACTGGTGGCTTC LAP1B XhoI 
LAP1B-BM2 FW GGAATTCATATGGACGAGCCGCCAGAA LAP1B  EcoRI 
LAP1B-BM2 RV CCGCTCGAGTTAGGCTACATCTTTGAAGGC LAP1B XhoI 
LAP1B-BM1/2 FW GGAATTCATATGGCGGGCGACGGG LAP1B  EcoRI 
LAP1B-BM1/2 RV CCGCTCGAGTTAGACACTGGTGGCTTC LAP1B XhoI 
LAP1B-BM3 FW GGAATTCATATGGCCAGATCCAGGGAT LAP1B  EcoRI 
LAP1B-BM3 RV CCTCGAGTTATAAGCAGATGCCCCT LAP1B XhoI 
LAP1B-BM1/2+TM FW GGAATTCATATGGCGGGCGACGGG LAP1B EcoRI 
LAP1B-BM1/2+TM RV CCTCGAGTTAGAACTCTTGAACAG LAP1B  XhoI 
LAP1B-BM1/2-TM RV CCTCGAGTTACCGGTTCCTCTTGAC LAP1B XhoI 
LAP1B-BM3+TM FW GGAATTCATATGGTCAAGAGGACGG LAP1B EcoRI 
LAP1B-BM3-TM FW GGAATTCATATGGCTGTTCAAGTTC LAP1B EcoRI 
LAP1B (ΔA185) FW CATACAAGAGGCTCCAGTGAGTGAAGATCTTG LAP1B   
LAP1B (ΔA185) RV CAAGATCTTCACTCACTGGAGCCTCTTGTATG LAP1B  
E1FW CAGGAGAACCTAGGGTCCATAAAG LAP1B  
E2FW CATTCCTCTGAAGAGGATG LAP1B  
E5FW CTGAAGAAGATGATCAAGACAGCTC LAP1B  
E10FW CAAGGTCAAGATGAGAAGCTG LAP1B  
E10RV CTTGGCCTGACCTACTCTTAAGAC LAP1B   
E10BRV GTGAACAATTCTCAGAACTTGGGAC LAP1B  
E10CRV GTGAGCAGTAAGATAGCAGGCTG LAP1B  
AFW GCTCGTCGTCGACAACGGCTC β-sctin  
ARV CAAACATGATCTGGGTCATCTTCTC β-actin  
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APPENDIX III – BACTERIA AND YEAST STRAINS 
 
Bacteria strains: 
E. coli XL1-Blue: recA endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac[F’ proAB 
lacZDM15 Tn10(Tetr)] 
E. coli Rosetta (DE3) F
–
ompT hsdSB(rB
–
mB
–
) gal dcm (DE3) pRARE
2
 (Cam
R
) 
 
Yeast strains:  
S. cerevisiae AH109: MATa, trp1-901, leu2-3, 112 ura3-52, his3-200, gal4Δ, gal 80Δ, 
LYS2:: GAL1UAS- GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2, URA3::MEL1UAS-
MEL1TATA-lacZ, MEL1 
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APPENDIX IV – PLASMIDS  
 
 
 
 
pACT2 (Clontech) map and multiple cloning sites. Unique sites are in bold. pACT2 is used to generate 
a hybrid containing the GAL4 AD, an epitope tag and a protein encoded by a cDNA in a fusion library. 
The hybrid protein is expressed at medium levels in yeast host cells from an enhanced, truncated ADH1 
promoter and is targeted to the nucleus by the SV40 T-antigen nuclear localization sequence. pACT2 
contains the LEU2 gene for selection in Leu
-
 auxotrophic yeast strains. 
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pAS2-1 (Clontech) map and multiple cloning sites. Unique restriction  sites are coloured blue. pAS2-1 
is a cloning vector used to generate fusions of a bait protein with the GAL4 DNA-BD. The hybrid protein 
is expressed at high levels in yeast host cells from the full-length ADH1 promoter. The hybrid protein is 
targeted to the yeast nucleus by nuclear localization sequences. pAS2-1 contains the TRP1 gene for 
selection in Trp
-
 auxotrophic yeast strains. 
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pET-28a-c(+) (Novagen) restriction map and multiple cloning sites. Unique sites are indicated on the 
circular map. pET-28a-c(+) is a E. coli expression vector with an N-terminal His tag/thrombin/T7 tag. 
This vector possesses the Kanamycin resistance gene.  
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pCMV-Myc (Clontech) restriction map and multiple cloning sites. Unique restriction sites are in bold. 
pCMV-Myc is a mammalian expression vector with an N-terminal c-Myc epitope tag. This vector 
possesses the ampicillin resistance gene for selection in E. coli. 
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pcDNA3.1(Invitrogen) map and multiple cloning site. pcDNA3.1 is a mammalian expression vector. 
This vector possesses the ampicillin resistance gene for selection in E. coli. 
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pNZYY28 (Nzytech) restriction map and multiple cloning region. The pNZY28 vector is provided 
linearized at the EcoRV site and allows the direct cloning of PCR products with blunt ends. This vector 
possesses the ampicillin resistance gene for selection in E. coli. 
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RNAi-Ready pSIREN-RetroQ (Clontech) map and cloning site. RNAi-Ready pSIREN-RetroQ is a 
self-inactivating retroviral expression vector designed to express a short hairpin RNA (shRNA) using the 
human U6 promoter. It is used for targeted gene silencing when an oligonuceotide encoding an 
appropriate shRNA is ligated into the vector. This vector possesses the ampicillin resistance gene for 
selection in E. Coli and the puromycin resistance gene for the selection of stable transfectants. 
